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ABSTRACT
Inflammation plays a crucial role in atherosclerotic plaque 
generation/progression. Dendritic cells (DCs), cellular immune-response components 
linking innate and adaptive immune systems, have been found in atherosclerotic 
plaques. In this study, DCs were examined as a possible therapeutic tool to modulate 
the inflammatory immune response underlying plaque formation.
Apolipoprotein (apo) B-lOO derived antigens are believed to modulate 
humoral immune responses to achieve atheroprotection, but their role in cellular 
immunity remains unclear. Therefore, one objective was to characterise the 
immunomodulatory effect of apoB-lOO-derived peptides (P2, P45, P210) on 
immature DCs (iDCs) and naïve T lymphocytes in vitro. iDCs were generated from 
bone-marrow progenitor-cells of male apoE' '^ mice. Peptide up-take and processing 
was studied by confocal microscopy after 6h, 24h and 48h. Peptide P45 was found in 
the endolysosomal compartments, co-localising with MHC-I and MHC-II antigen- 
presenting complexes. The phenotypic and differentiation characteristics of P2, P45 
and P210-loaded DCs were studied by flow cytometry, and cytokine and matrix 
metalloproteinase production by PCR/ELISA after 48h. Proliferation and 
differentiation of T lymphocytes driven by peptide-loaded DCs was also studied. 
Peptide-loaded DCs displayed a tolerogenic phenotype similar to that of unloaded, 
iDCs, and inhibited CD4^ proliferation induced by mature DCs when co-cultured. 
My results suggest that the protective effect of the peptides could be mediated by 
DCs presenting them to T cells.
A second objective was to examine the effect of vaccination with tolerogenic 
DCs (tolDCs), generated in vitro through incubation with IL-10 and TGF-p for 6 
days, on atherosclerotic progression in apoE' '^ mice. This showed that immunisation 
with tolDCs increased the number of CD8^CD25ToxP3’*' T regulatory cells as well 
as secretion of IL-10 within the spleen of immunised mice. IL-10 levels were also 
elevated in the serum, while cholesterol levels were reduced, although plaque size 
remained unchanged. These results provide new insights for treatment and 
prevention of atherosclerosis through vaccination.
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CHAPTER 1 GENERAL INTRODUCTION
1.1 Cardiovascular Disease
Cardiovascular disease is the leading cause of death and a major cause of 
disability in developed countries and its morbidity rate is progressively increasing in 
the developing countries as well [1]. In 2008, CVD provoked 17.3 million deaths 
which represented a percentage of 30% over the number of global mortalities [2]. 
Most of the cases of CVD are caused by atherosclerotic vascular disease which 
includes coronary heart disease, cerebrovascular disease and peripheral arterial 
disease. Coronary heart disease and stroke are the two types of CVD provoking the 
highest percentages of mortality [3]. The number of these deaths for 2004 was 
recorded to be 7.3 million from coronary heart disease and 6.2 million from stroke.
1.2 Risk Factors
There are many risk factors ([3],[4],[5, 6]) including hypertension (high blood 
pressure), high low density lipoprotein (LDL) levels, smoking, physical inactivity, 
obesity, unhealthy diet (low fruit and vegetable intake and/or a diet high in saturated 
fats), type 2 diabetes, psychological stress levels, alcoholism, lipoprotein (a), left 
ventricular hypertrophy, ageing, genetic predisposition, infection agents 
(Cytomegalovirus, C. pneumonia, H. pylori, Herpes simplex virus [7]), inflammatory 
mediators (such as C-reactive protein (CRP), interleukins (such as IL-6), serum 
amyloid A, vascular and cellular adhesion molecules, soluble CD40 ligands 
(sCD40L) [7]), being male and ethnicity. Recently, novel risk factors have been
21
identified including high homocysteine blood levels, and abnormal blood coagulation
m.
1.3 Atherosclerosis
The main underlying cause of CVD is atherosclerosis. Atherosclerosis is a 
multi-factorial inflammatory process occuring in the arterial wall characterised by 
the development of lesions in the arterial wall. An important stimuli for the immune 
reposnse that takes place is lipid accumulation which triggers inflammation, cell 
recruitment, cell death and fibrosis [8], [9]. The thickening of the arterial wall due to 
the accumulation of lipid and connective tissue narrows the lumen of the artery 
(stenosis. Figure 1.1) and therefore may obstruct the blood flow [10].
Haemodynamic factors influence the location of atherosclerotic lesions along 
the arterial tree [11, 12]. Local injury in the arterial wall sometimes results in 
pathological remodelling that will lead to atherosclerotic plaque formation through a 
cascade of cellular and molecular events [6]. Repair and inflammation factors 
contribute to the thickening of the arterial wall and the plaque progression (Figure
1.1) through inflammatory mediators: cytokines (interleukin-1 (IL-1), interleukin-6 
(IL-6), tumor necrosis factor alpha (TNF-a)), chemokines (monocyte chemotactic 
protein (MCP-1)), and growth factors (platelet-derived growth factor (PDGF), 
vascular endothelial growth factor (VEGF) [6, 13, 14]. In addition to the narrowing 
of the lumen, the rupture of the plaque can cause severe acute events as the pro- 
thrombotic agents contained in the plaque are released in the circulating blood 
causing thrombosis at that site of injury [8].
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Figure 1.1: The progression of atherosclerotic plaques over the years. The first sign of 
atherogenesis is the accumulation of foam cells within the intima, the innermost layer of the 
arterial wall. The excessive accumulation of foam cells, their death and the subsequent 
release of cholesterol will then cause the formation of fatty streaks and later on intermediate 
lesions. The bigger mature plaques (atheromas) will form a fibrous cap and their rupture can 
cause severe events as it will release the pro-thrombotic agents they contain. (Adapted from 
Stary et al [15]).
1.4 Innate and adaptive immunity in atherosclerosis.
Atherosclerosis belongs to the group of chronic inflammatory diseases in 
which the cellular components of the immune system play a key role in its 
development and complications. The chronic accumulation of 
monocytes/macrophages, smooth muscle cells, and T cells in response to the 
accumulation and release of proinflammatory molecules within the arterial wall 
constitutes the hallmark of a developing atherosclerotic plaque [8, 9]. Although most 
of the antigenic stimuli that occur within atherosclerotic plaques come from modified 
self-molecules, the immune response triggered is remarkably similar to inflammatory 
reactions mounted against microbial organisms[16-19]. The list of atherosclerosis- 
related antigens range from oxidised LDL (oxLDL), heat shock proteins (HSP) to 
protein components of the extracellular matrix such as collagen and fibrinogen 
(Table LI) [20, 21]. On the other hand, the disputed role of foreign antigens, such as
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viruses and bacteria, in atherogenesis as causative or bystander participants in its 
development introduces another level of complexity to the analysis. Here I 
summarise the most important scientific findings published within the last two 
decades on the importance of antigens, antigen stimulation, and adaptive immune 
responses in the development of atherosclerotic plaques.
Many antigens, both endogenous autoantigens and exogenous bacterial ones, 
have been identified to be involved in atherogenesis. Some of the most discussed in 
the current literature can be found in [21].
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Figure 1.2: The LDL particle and its constituents. The particle has a large size (around 
2x10®KD) and therefore provides the immune system with many various epitopes, either 
apoB-100-derived or lipids, all of which have an important role in atherogenesis.
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Antigen Reference
Autoantigens Oxidised low-density lipoprotein (LDL) [22-24]
Beta2glycoprotein1 (beta2GP1) [25-27]
Lipoprotein a (LP(a)) [28]
Lipoprotein-lipase (LPL) [29]
Advanced glycation-end products (AGEs) [30]
Heat-shock proteins [31,32]
Collagen [33-35]
Fibrinogen [36]
Microbial antigens Porphyromonas gingivalis [37, 38]
Chlamydia pneumoniae [39-50]
Bacteroides forsynthus [37]
Streptococcus mutans [37, 38, 51]
Helicobacter pylori [52-65]
Echerichia coli [66, 67]
Enterovirus [68-70]
Cytomegalovirus [22, 71-79]
Vipérin [80]
1.5 oxLDL
OxLDL remains one of the most studied antigens in atherogenesis (Figure
1.2). LDL does not normally trigger immune responses in its native state; however 
when it gets oxidised, it can initiate inflammation-leading to atherosclerosis. OxLDL 
is considered a neoantigen, a term used to describe modified self-antigens for which
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normally the immune system is tolerant but which upon modification have the 
potential to excert autoreactive immune responses. Modified lipoprotein particles 
have the capacity to interact with the endothelium, triggering their accumulation and 
retention in the subendothelial space. Scientists have shown that oxidation of LDL in 
the arterial wall causes aldehyde-modification of surrounding extracellular matrix 
proteins. These modifications alter macrophage function and lead to activation of 
pathophysiological autoimmune responses that initiate atherosclerosis development 
[81]. The retained oxLDL particles induce macrophage foam cell formation, smooth 
muscle cell migration and proliferation [82, 83] and, in addition, stimulate the 
secretion of inflammatory cytokines [84]. OxLDL also induces the expression of 
adhesion molecules promoting endothelial cell dysfiinction and leukocyte 
extravasation [85].
Recently a number of studies underline the role of oxLDL in atherosclerosis. 
More specifically, the C-reactive protein/oxidised low-density lipoprotein/p2- 
glycoprotein I (CRP/oxLDL/p2GPI) complex has been shown to enhance lipid 
uptake in atherosclerotic plaques and thus promote atherosclerosis development in 
diabetic BALB/c mice possibly through the p38MAPK pathway [86]. Furthermore, 
oxLDL has been shown to lead in increased platelet-dependent neutrophil 
transmigration through the endothelium into the tissue [87].
In atherosclerosis, increased levels of oxLDL have been found in the serum 
of patients admitted with acute myocardial infarction, and immunohistochemical 
studies revealed the presence of oxLDL within atherosclerotic plaques [88-91]. 
Proteoglycans, contained within the extracellular matrix of the arterial wall, interact 
with oxLDL via their carbohydrate groups, glycosamynoglycans (GAGs) as it has 
been described in vitro and in immunohistochemical studies using defective LDL
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unable to bind to GAGs [89]. The initial interaction of LDL with the proteoglycans 
leads to structural changes that expose the GAG-binding sites contributing to LDL 
retention. This interaction is mediated by apolipoprotein B-lOO (apoB-100), which is 
the main protein component of LDL particles [82, 92]. According to recent studies, 
the apoBDS-1 peptide in apoB-100 is a peptide that had not been recognized until 
now with strong proinflammatory activity and promotes the characteristics of low- 
density lipoprotein that lead to the pathogenesis of atherosclerosis [93]. At least two 
proteoglycan-binding sequences within apoB-100 have been identified and shown to 
be necessary for retaining LDL particles within the intimai layer [92, 94]. The 
interaction between the apoB-100 and the GAGs also facilitates LDL oxidation by 
oxygen-reactive species released by vascular cells or as a result of enzymatic 
modifications driven by endothelial cells, smooth muscle cells, or macrophages 
present within the atherosclerotic plaques [95]. Cholesterol molecules also have a 
high affinity for GAGs. The accumulation of oxLDL within atherosclerotic plaques 
has been demonstrated, amongst other methods, by using monoclonal antibodies 
such as DLH3 that bind specifically to oxLDL but non to native LDL (nLDL) [88]. 
DLH3 binds to the oxidised phosphatidylcholine groups (oxPC) and to the 
phosphatidylcholine (PC)-apoB-lOO adducts formed when LDL is oxidised. PC- 
apoB-100 adducts are considered to be the principal antibody targeted epitopes on 
the surface of the particles. Furthermore, oxPC also promotes endothelial-monocyte 
adhesion by inducing the secretion of MCP-1 by endothelial cells [24], and can also 
be recognized by scavenger receptors such as CD36 which are involved in the 
oxLDL uptake by macrophages [90, 96-99].
The initial interaction of proteoglycans with the LDL within the arterial wall 
leads to lipid modifications that expose GAG binding sites. Cholesterol, cholesteryl
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esters and phospholipids are the main targets for lipid modifications and their role in 
the development of the disease has been extensively evaluated. These modifications 
play an important role, as stated above, in LDL retention within the arterial wall 
which is also facilitated by interactions with surface molecules such as 
apolipoprotein E (apoB) and lipoprotein lipase expressed on macrophages [98, 100].
However, most studies have focused on the role of oxidised phospholipids 
(oxPLs) [24, 101, 102]. Peroxidation of the phospholipids starts in the fatty acids. 
The decomposition of fatty acids generates a spectrum of reactive species such as 
malondialdehyde (MDA), 4-hydroxynonenal, and the 1 -palmitoyl-2-(5-oxovaleroyl)- 
glycero-3-phosphocholine molecule (POVPC) that can oxidise apoB-100 as well as 
other lipids, resulting in ox-PLs and oxidised protein-lipid adducts [96, 99].
It has also been established that oxLDL acts as a chemoattractant for 
monocytes allowing them to infiltrate the lesion site. OxLDL has been shown to 
induce monocyte adhesion to the endothelium by up-regulating the expression of 
adhesion molecules on their surface, by inducing macrophage major 
histocompatibility class II (MHC-II) & LeuM3 cell surface expression and by 
accelerating monocyte differentiation in to macrophages [22]. Endothelial cells are 
also capable of oxidising LDL, contributing to a continuous generation of oxLDL 
within the lesion site, and to attract more monocytes. Other inflammatory mediators 
such as IL-ip, TNF-a and monocyte colony stimulating factor (M-CSF) can induce 
the expression of the oxLDL receptor (oxLDL-R) on the surface of endothelial cells, 
thus further contributing to oxLDL accumulation [22, 103].
Scavenger receptors expressed by macrophages play a pivotal role in LDL 
accumulation; such receptors include CD36 (a membrane glycoprotein), CD68, 
CXCL16, the scavenger receptors A & B1 (SR-A & SR-Bl), and the lectin-type
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oxidised low-density lipoprotein receptor 1 (LOXl) [103-105]. It is believed that the 
high expression of the scavenger receptors on macrophages mediates lipid 
accumulation and foam cell formation [106]. Following proteolytic processing inside 
the cell, fragments of the oxidised-modifred apoB-100 protein are displayed on the 
surface of macrophages bound on MHC-II molecules. This process also leads to the 
up-regulation of important molecules such as toll-like receptors TLR2 and TLR4 that 
induce proatherogenic immune responses [37, 107]. There is also evidence that 
products of the inflammatory process such as endogenous HSP60 and LDL oxidation 
derivatives bind TLR4-CD14 complexes on monocytes and macrophages eliciting 
proinflammatory responses [31]. This has been associated with an enhanced 
production of cytokines, an enhancement of oxLDL uptake, and an increase adhesion 
of these cells to the endothelium mediated by IL-8 and NFkB synthesis [108, 109]. 
Furthermore, more recent studies have demonstrated that high glucose elevates the 
expression of SR-A, CD36 and LOX-1 scavenger receptors, which in turn, result in 
enhanced oxLDL-uptake by DCs [110].
The large size of the LDL molecule (2><10^kDa) favours the exposure of 
many epitopes recognised by the antibodies generated, mainly IgM. OxLDL is 
known to be a very potent immunogen and the antibodies generated in response to its 
modifications are able to bind to many other similarly modified endogenous proteins 
[111]. It has been demonstrated that there is a molecular mimicry between the head 
of the PC groups of oxLDL and the PC groups expressed on the surface of many 
pathogens such as Streptococcus pneumoniae [112], which indicates that during an 
infection, more autoantibodies against oxLDL might be generated. Studies using 
experimental animal models have shown that epitopes generated during LDL 
oxidation, such as oxPC, are also generated on the surface of bacteria and on the
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surface of endothelial cells [111]. These epitopes bind to antibodies that will mediate 
removal of oxLDL and apoptotic cells [113, 114]. Some of the oxidation-specific 
epitopes present on oxLDL are also presented on the surface of apoptotic cells in the 
lesion site, and play a role in the clearance of the damaged oxidised lipid molecules 
and of apoptotic cells generated during the inflammatory response within plaques 
[23].
1.6 Other atherosclerosis-related antigens
Many other antigens have been reported to be related to atherosclerosis and I 
will be mentioning them briefly in this and the two following sections.
p2-glycoprotein I (P2GpI) is a positively charged plasma protein circulating 
in the blood and also present in platelets and endothelial cells in atherosclerotic 
plaques [25]. It is a cofactor involved in anti-phospholipid binding. Binding to the 
anti-phospholipid antibodies (aPL) requires a structural change in p2GpI which 
occurs when the protein binds to negatively charged phospholipids present in the 
atherosclerotic plaques. When transgenic animals are immunised with p2GpI, the 
atherosclerosis process is accelerated [27].
Lp(a) is another antigen of relevance to atherosclerosis development [28],
[115]. Lp(a) is present in the atherosclerotic plaques bound to fibrin. Furthermore, it 
may be internalised by macrophages within the plaques and induce the expression 
and secretion of chemoattractants from endothelial cells, thus triggering the attraction 
of monocytes in to atherosclerotic plaques [28].
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A further self-antigen involved in lupus-related atherosclerosis is LPL [29],
[116]. It is a member of the lipase family that hydrolyses triglyceride molecules on 
lipoprotein molecules. LPL activity is significantly decreased with the progression of 
the disease due to the generation of anti-LPL antibodies [117, 118]. The hypothesis 
that has been formulated is that these antibodies might bind to LPL molecules on the 
surface of endothelial cells and obstruct lipid degradation by LPL, thus promoting 
lipid accumulation in the atherosclerotic plaques [118].
A recent study suggests a possible role of Advanced Glycation End Products 
(AGE) as facilitators of antigenic stimulation in atherosclerosis by promoting the 
maturation of dendritic cells (DCs) [30], [119]. AGE products stimulate the up- 
regulation of co-stimulatory and antigen presenting molecules on DCs which in turn 
causes T cell proliferation through the secretion of pro-inflammatory cytokines. This 
activation is mediated, at least in part by the up-regulation of the receptors for AGE 
(RAGE) and the scavenger receptor A (SR-A), which is responsible for regulating 
cholesterol accumulation on DCs through the Jnk signaling pathway [30].
Heat shock proteins (HSPs) are released from stressed endothelial cells and 
can act as chaperones in the process of dénaturation of other proteins. In 
atherosclerosis HSPs are thought to act as autoantigens that activate both cell- and 
antibody-mediated immune responses [120]. They can induce the production of 
specific antibodies which usually accelerate atherosclerotic plaque development 
when used to immunise experimental animals [27].
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1.7 Bacteria-Derived Antigens
The potential relationship between bacterial infections and the induction of 
atherosclerosis has been studied in different groups of cardiovascular patients 
including those who develop the disease but that lack the conventional risk factors 
associated with it such as hypercholesterolaemia, high blood pressure, smoking and 
diabetes [57, 121, 122]. It has been speculated that bacterial infection may have a 
direct cytopathic effect on the vascular wall or that could act indirectly through the 
induction of an autoimmune inflammatory response involving mechanisms such as 
molecular mimicry and epitope spreading to generate atherosclerosis [18]. Several 
microbial components known to ligate pattern recognition receptors or heat shock 
proteins and unmethylated CpG DNA have been reported as ligands for toll-like 
receptors (TLRs), and therefore, have the potential to induce atherosclerosis by 
triggering the expression of maturation markers and the secretion of pro- 
inflammatory cytokines on/by macrophages and dendritic cells [36]. TLRs are part of 
the sensing mechanisms in response to infections but it has been suggested that they 
may also play a role in inflammation leading to atherosclerosis. There is evidence 
showing that endothelial cells and macrophages in atherosclerotic lesions can 
upregulate TLR expression in response to microbial antigens [39]. It is known that 
autoantibodies such as those binding to endogenous human HSP60 and oxLDL can 
also activate TLR4 and induce proatherogenic immune responses. The response 
involves the secretion of proinflammatory cytokines, matrix metalloproteinases 
(MMPs), and other inflammatory mediators (nitric oxide, endothelin-1) [123, 124]. 
Such mechanisms have been described for Porphyromonas gingivalis [38], 
Chlamydophila pneumoniae (C. pneumoniae) [39], Helicobacter pylori [55, 59].
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More recent studies have showed that Aggregatibacter actinomycetemcomitans (Aa) 
enhanced innate immune signaling and LDL oxidation and therefore probably confer 
a role in atherosclerosis development [125].
1.8 Virus-Derived Antigens
Viruses have also been postulated as promoters of atherosclerosis. One of the 
most closely linked to this disease is cytomegalovirus. This virus infects the majority 
of the human population by targeting smooth muscle cells (SMCs) and endothelial 
cells producing a latent type of infection [126-130]. US28, one of the viral proteins 
expressed on the cell surface of the cytomegalovirus after infection, is a 
chemoattractant for SMCs. US28 and UL122 proteins were found to have an 11 
amino acid (aa) sequence homologous to human HSP60, and it is thought that 
antibodies against these viral proteins can bind to human HSP60 expressed on 
stressed endothelial cells [131]. The proteins also share some homology with non­
stressed endothelial cell markers such as CD 151, CD49f and connexin 45 (Cx45). It 
is believed that during cytomegalovirus infection, antibodies generated against these 
proteins can bind, by molecular mimicry, to the surface markers on both non-stressed 
and already-stressed endothelial cells causing apoptosis of endothelial cells, which is 
considered to be one of the key early events in atherosclerotic plaque formation.
Another pathogen associated with atherosclerosis is enterovirus, especially 
the enterovirus group coxsackie B virus [70, 132]. High levels of enterovirus 
antibodies have been detected in patients with myocardial infarction but it has not yet 
been fully established whether the virus contributes to the pathogenesis of the disease 
[70, 133, 134]. Other infectious organisms that have been implicated in the
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pathogenesis of atherosclerosis involve a member of the herpes virus family that is 
known to induce atherosclerosis in chickens [135]. The virus alters cellular 
metabolism resulting in cholesterol accumulation which is a common mechanism 
proposed for all virally-induced atherosclerosis. There is also evidence that the virus 
promotes smooth muscle cells (SMCs) proliferation [136-139].
1.9 Stages in atherosclerotic plaque formation
It is difficult to identify the factors responsible for the initiation of the 
atheroma lesion and/or the order in which these factors contribute to plaque 
formation. Nevertheless, it is known that endothelial dysfunction and high levels of 
circulating cholesterol, such as oxLDL, play a key role in the pro-inflammatory 
process that triggers the first steps in the development of atherosclerotic plaques 
[140, 141]. Whatever the cause, these steps are characterised by an initially 
reversible accumulation of lipid-laden macrophages in the subendothelial space as a 
consequence of the increasing migration of blood-derived monocytes. These cells 
accumulate at focal points within the vascular wall of medium and small size arteries 
driven by chemokines and adhesion molecules produced by the damaged 
endothelium [142-145]. Monocytes differentiate in situ into macrophages which 
express membrane receptors such as Toll-like receptors and scavenger receptors that 
participate in the clearance of oxLDL [146, 147]. Lymphocytes can also transmigrate 
and accumulate within the arterial wall from the very earliest stages (Figure 1.3) 
[148].
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As the inflammatory process becomes chronic, smooth muscle cells also start 
to migrate from the media into the intima layer of the vessel, in response to 
chemokines and aided by the release of membrane MMPs that enable them to break 
through the elastic lamina into the subendothelial space (Figure 1.3) [149, 150].
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Figure 1.3 Cellular mechanisms involved in the formation of atherosclerotic plaques. 
Circulating LDL is retained within the arterial wall through binding to proteoglycans present in 
the matrix and then oxidized by free radicals within the intima. Monocytes that infiltrate the 
intima differentiate into macrophages and engulf the oxLDL to form foam cells. Inflammation 
factors activated by lipid accumulation cause the activation of smooth muscle cells (SMC) 
that start secreting MMPs to degrade the elastic lamina between the media and the intima. 
When they arrive in the intima, SMC can also undergo the same events to form foam cells. 
When foam cells die, they release cholesterol contributing to the formation of a lipid core. 
The secretion of collagen from activated smooth muscle cells in the site will form the fibrous 
cap of the plaque which is a protective mechanism to wall off the inflammation developing in 
the plaques. The accumulation of foam cells and the formation of the fibrous cap cause the 
formation of a new layer in the arterial wall, the neo-intima. Reproduced from Runge et al. 
Matter’s cardiology, 2011 [151]
Persistence of inflammation ereates a vicious circle of cell migration, 
differentiation of smooth muscle cells, production of chcmotactic and pro-
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inflammatory mediators, and cell death leading to vascular wall remodelling and 
formation of a new layer called the neointima [152, 153].
Neointima formation is a complex phenomenon that occurs in response to 
vessel wall damage in which repair and injury mechanisms give birth to areas rich in 
proinflammatory cells and collagen deposition [152, 153]. It is within these areas 
where a close contact between macrophages, DCs, and lymphocytes has been 
reported. It has been speculated that the interaction between lymphocytes and DCs 
within the neointima is responsible for the development of local immune responses 
against exogenous and endogenous atherogenic antigens. These immune responses 
may contribute to cell death by apoptosis and accumulation of nondegradable 
cholesterol, contributing to the formation of the lipid core of the atherosclerotic 
plaque [8, 154-156]. However, the precise mechanisms involved are not yet clear.
In the next sections I will look more closely to the stages of formation of the 
atherosclerotic plaques and what is known for the mechanisms involved in each one 
of them.
1.10 Development of the fatty streak.
The initial event in atherosclerosis is the accumulation of LDL in the 
subendothelial matrix, especially when its levels in blood circulation are increased. 
There, LDL seems to be retained through interactions between the LDL molecule of 
apoB-100 and matrix proteoglycans [157]. Besides LDL, other lipoproteins which 
contain apoB-100 molecules, such as lipoprotein (a), enter and accumulate in the 
tunica intima leading to atherosclerosis formation.
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During the very early stages of atherosclerosis, monocytes migrate from 
peripheral blood circulation into the subendothelial layer of the arterial tunica. 
Adhesion molecules expressed on the surface of vascular endothelial cells, such as 
seleetins (E(endothelial)-Selectin, P(platelet)-seleetin, CD34 and murine glycation- 
dependent cell adhesion molecule 1 (GlyCAM-1)), integrins (intercellular cell 
adhesion molecule 1 (ICAM-1), intercellular cell adhesion molecule 2 (ICAM-2), 
vascular cell adhesion molecule 1 (VCAM-1)), frbroneetin and platelet-endothelial 
cell adhesion molecule 1 (PECAM-1), mediate leucocyte adhesion [158, 159]. 
Monocyte transmigration follows due to chcmotactic factors, cytokines and 
macrophage growth factors secreted mainly by vascular endothelial cells, smooth 
muscle cells and infiltrated cells [83]. Oxidatively modified lipoproteins may 
enhance the expression of adhesion molecules and cytokines that take part in 
atherogenic development.
In the intima, monocytes differentiate into macrophages or DCs. Most 
macrophages commence to phagocytose native and modified lipoproteins mainly 
through scavenger receptor pathways. Scavenger receptors are cell surface molecules 
that have the ability to bind the modified lipoproteins [160]. Important scavenger 
receptors in atherosclerosis are the scavenger receptor A family [161], macrosialin or 
CD68 [162, 163], and a putative HDL receptor, SRB-1 [164-166]. Normal 
cholesterol metabolism of those monocyte cells is disrupted due to deregulations in 
the cholesterol homeostatic mechanisms [13]. As a result, macrophages transform 
into foam cells. These rich in cholesterol foam cells accumulate and create fatty 
streaks which compose basic units of the atheromatic centres. [106, 167].
Fatty streaks are a normal phenomenon in young people and can lead to 
mature atherosclerotic plaque formation or disappear without causing any symptoms
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[15]. Fatty stteak lesions are usually found in the aorta during the first decade, the 
coronary arteries during the second decade, and the cerebral arteries during the third 
or fourth decades of life [168].
1.11 Plaque development
Atheromas or mature plaques are considered advanced lesions due to their 
lipid core, deregulated organization of their intima and arterial deformation. More 
specifically, foam cells and extracellular lipid droplets form a core area in the central 
region of the plaque. This core area consists of lipids and dead cell debris. A matrix 
rich in collagen fibres and smooth muscle cells, which migrate from the medial layer, 
surround this core region forming a fibrous cap [148].
Besides foam cells, a large number of other cell types are observed in mature 
plaques. Those include DCs [169], mast cells [170], some B cells [148] and possibly 
natural killer T (NKT) cells. Large numbers of T cells and macrophages characterise 
the shoulder area (the area where the plaque grows) and the area in between the 
fibrous cap and the core region of the plaque. Many of these immune cells are 
activated and secrete proinflammatory cytokines like interferon-gamma (IFN-y) and 
TNF-a [171], proteases, prothrombotie molecules and vasoactive substances which 
play an important role in plaque inflammation and vascular function [8].
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1.12 Progression to complex plaque
As time passes, the atheromatie plaque becomes more complex with 
calcification, ulceration at the luminal surface, and neovascularization. Calcification 
of the intima is a procedure believed to be controlled by oxysterols and cytokines 
[172]. During the process, osteoblast-like vascular cells secrete a matrix scaffold that 
becomes calcified. Furthermore, studies have shown that smooth muscle cells 
express proteins which are involved in bone formation and mineralization [173]. 
Smooth muscle cells have been shown to express osteopontin [174-176]. Bone 
morphogenetic proteins are also possibly able to act upon walls of vascular cells and 
promote plaque mineralization [177]. Atheroma mineralization is regulated by both 
synthetic and degradative procedures. Macrophages probably have osteoclast- 
properies in advancing plaques [178]. Furthermore, the growth of small vessels from 
the media of the blood vessel wall into the lesion provides a way for inflammatory 
cells to enter into the region. The core region of the atherosclerotic plaque in this 
stage consists of a small number of cells and cholesterol deposits. The fibrous cap 
that surrounds the core is characterised by varying thickness and does not allow 
contact between the pro-thrombotic factors of the lesion and blood circulation [8].
1.13 Plaque rupture
Vulnerable plaques are characterised by lean and fragile fibrous caps and a 
large number of inflammatory cells. The state of the fibrous cap is based on the 
opposing procedures of matrix production and matrix degradation. Cells of
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inflammation play a major role in both procedures: T cells produce IFN-y and block 
the production of matrix by smooth muscle cells, and macrophages produce 
proteases, like interstitial collagenase, gelatinases and stromolysinS, that cause the 
degradation of the extracellular matrix. Whether a plaque adopts a more or less stable 
state may also be influenced by the levels of calcification and neovascularization of 
the advanced lesions [168].
Plaque rupture often takes place at the rich in foam eells-edges of lesions and 
disruption of the fibrous cap may lead to atherosclerosis- associated complications 
[168]. The most important of these is blood vessel blockage because of the formation 
of a thrombus (thrombosis) or a blood clot, leading in myocardial infarction or 
stroke.
1.14 Plaque healing and plaque regression
The majority of plaque ruptures do not lead to death and most of them do not 
show clinical symptoms [179]. In those cases, smooth muscle cells accumulate at the 
region of the plaque rupture and produce extracellular matrix enriched in 
glycosaminoglyeans and type III collagen [180]. Through this procedure, plaque 
integrity is restored but it may also lead to rapid plaque progression and abnormal 
remodeling of the arterial wall [181].
Mechanisms behind plaque healing are not yet clearly understood. The classic 
theory considers local plaque smooth muscle cells, that are activated by growth 
factors and mitogens which are produced during thrombosis, to be responsible for 
plaque healing [182]. On the other hand, local smooth muscle cells in ruptured
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human atherosclerotic plaques seem to have limited proliferative capacity [183]. 
Moreover, smooth muscle cells in atheromas show characteristics of senescence in 
culture and in vivo [184].
According to more recent theories, activated platelets bind to sites of injury 
and recruite neointimal smooth muscle cells as well as endothelial cells that originate 
from circulating bone marrow-derived progenitor cells. The recruitment is made 
possible through P-selectin and stromal cell- derived factor 1 (SDF-1) mechanisms 
[185-187]. Activated platelets express P selectin which is involved in the adherence 
of progenitor cells to them and secrete SDF-1 which promotes further adhesion and 
migration of bone marrow cells The above theory is consistent with signs of bone 
marrow-derived smooth muscle cells in human coronary atherosclerosis where 
plaque ruptures occur [188].
Plaque regression as a therapeutic strategy for atherosclerosis is still under 
investigation. Plaque regression has been shown in animals but scientists are unsure 
if plaque regression has an effect on humans or whether the results of plaque 
regression in animal models can be applied with satisfactory results in humans. 
According to studies, the usage of lipid lowering agents leads to plaque stabilization 
and reduced cardiovascular events [189]. Furthermore, it has been shown that 
stabilization of atheromatous plaques could also promote plaque regression [190]. 
Risk factor modification and lipid lowering agents like statins, reduce the size of the 
lipid pool, weaken the inflammation and reduce thrombogenicity [191].
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1.15 Cell-mediated immunological mechanisms involved in 
atherosclerotic plaque formation
Atherosclerotic plaques contain different types of cells including 
macrophages, T cells, DCs, B cells, mast cells andNK cells [85]. Other components 
of the immune system have been also found present within the plaques such as 
antibodies and proteins from the complement system [85]. The accumulation of all 
these starts progressively when the LDL in circulation enters the arterial intima, is 
retained within the artery wall and then gets oxidized by free redicals (oxLDL) 
causing the activation of arterial wall cells (Figure 1.3) which in turn secrete 
cytokines and express adhesion molecules promoting endothelial cell dysfunction 
and leukocyte extravasation to the subendothelial space [85].
OxLDL acts as a chemoattractant for monocytes infiltrating the lesion site 
[73]. More specifically, PC-apoBlOO adducts induce the secretion of MCP-1 
promoting endothelial cell-monocyte adhesion [22]. It has been reported that other 
inflammatory mediators such as IL-ip, TNF-a and M-CSF (Macrophage Colony 
Stimulating Factor) induce the expression of the oxLDL-R on the surface of 
endothelial cells, therefore increasing the binding and contributing to promote 
oxLDL accumulation [22].
Monocytes infiltrate the plaque and differentiate into macrophages through 
interactions with the extracellular matrix and cytokines [103]. These macrophages 
contribute to the inflammation occurring within the vessel wall as they up-regulate 
important molecules such as Toll-like receptors TLR2 and TLR4 inducing a pro­
atherogenic immune response [37]. Other studies have shown the presence of 
autoantibodies against oxLDL which can increase the expression of TLR4 that in
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turn promote the secretion of pro-inflammatory cytokines and induce atherogenic 
immune responses [192]. Other ligands of TLRs that may induce atherosclerosis are 
microbial components, heat shock proteins and unmethylated CpG DNA [36]. The 
response involves the secretion of proinflammatory cytokines, MMPs and other 
inflammatory mediators (i.e. nitric oxide, endothelin-1) by antigen presenting cells 
(APCs) [8].Oxidation of lipoproteins also enables the macrophages to uptake the 
lipoprotein particles via the scavenger receptors, especially CD36, CXCL16 and SR- 
A, and to develop into foam cells [103, 193, 194]. Accumulation of foam cells within 
the arterial wall promotes the formation of lipid fatty streaks [73] which are then 
surrounded by populations of smooth muscle cells. Smooth cells will proliferate and 
differentiate to myofibroblasts that secrete collagen and contribute to the formation 
of the fibrous cap [85].
Apart from macrophages, other APCs such as DCs also engulf the oxLDL 
particles and process them into fragments that will be subsequently displayed on the 
surface of the cells bound in the context of MHC-II molecules or lipid fi-agments in 
the case of CDl molecules [195]. This presentation results in the activation of cell- 
mediated immune responses [88].
Most of the T cells present within atherosclerotic plaques are CD4^ and just a 
small proportion of the population consists of CD8  ^T cells. CD4^ cells isolated fi*om 
human plaques have been found to express the ap TCR [148], [196], which 
recognizes antigens presented on HLA-DR, a MHC-II molecule on the surface of 
APCs. The antigens presented included oxLDL components, [196] heat shock 
proteins and microbial antigens [197]. Therefore, lymphocytes seem to be involved 
in antigen recognition because they are located proximal to macrophages and DCs 
expressing MHC-II molecules in the shoulder regions of murine atherosclerotic
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lesions [85]. T cells are believed to be activated first in the regional lymph nodes by 
DCs and then they continue to be activated by macrophages in the plaque expressing 
MHC-II molecules [8]. These cells will then initiate adaptive cell mediated immune 
responses such as the activation of cytotoxic T cells and B cells for the production of 
antibodies to enhance the innate responses [198].
B cells have also an important role in atherosclerosis because of their abilities 
to secrete antibodies, present antigens and secrete cytokines [85]. It has been found 
that B cells from the spleen of adult apoE-defieient (apoE' '^) mice can up-regulate the 
expression of co-stimulatory molecules such as CD80 and CD86 needed during 
antigen presentation compared to younger apoE' '^ mice that have not developed 
significant atherosclerotic lesions, suggesting that B cells might present 
atherosclerosis-related antigens to T cells [199]. In the humoral responses, IgM 
antibodies secreted by B cells have been found to recognize atherosclerotic antigens 
[9] such as the oxidised phospholipids on oxLDL, the phosphorylcholine in the wall 
of Streptococcus pneumoniae and human as well as bacterial heat-shoek proteins 
[200]. Epitopes on oxLDL can also be recognized by IgM and these seem to cross- 
reaet with phosphorylcholine groups present on many pathogens such as 
Streptococcus pneumoniae [6], [201], indicating that during an infection, more 
autoantibodies against oxLDL might be generated. These epitopes bind to antibodies 
that will mediate removal of oxLDL and apoptotic cells generated during the 
inflammatory response in the plaques [114].
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1.16 apoE' '^ mice
The apoE knockout mice are created by gene targeting that disrupts the apoE 
gene [202]. The glycoprotein apoE is a structural component of very low density 
lipoproteins (VLDL) and chylomicrons and it mediates the high affinity of these 
particles to the LDL-R. In this way it mediates their specific uptake by the liver and 
prevents cholesterol accumulation in the blood. apoE is also a component of HDLs 
involved in cholesterol transport among cells.
Therefore, the apoE knockouts have five times more elevated plasma 
cholesterol levels, increased triglyceride levels and develop atherosclerotic lesions 
[203]. Lesions are already present at 3 months of age in the proximal aorta and they 
increase with age. In a study that investigated the immune responses to oxLDL 
during ageing in apoE' '^ mice, measurements of lipid, macrophage, and collagen 
content in plaques were taken in aortic sinus lesions. The results indicated that 
ageing was linked with a marked increase in size and collagen content but also with a 
decrease in macrophage and lipid content of the plaques. Furthermore, lesions were 
reported to be less cellular and the presence of a fibrous cap was observed [204].
ApoE knockout mice have many research applications including diabetes and 
obesity, neurobiology and cardiovascular research where they are used to study 
atherosclerosis and hypercholesterolemia.
1.17 Immune regulation; Focus on DCs
An important cell population present in the plaques which is very potent in 
inducing T cell activation and proliferation by antigen presentation is the DC. This
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project is based on the potential use of DCs for the treatment of atherosclerosis, 
therefore, I will first describe the characteristics and functions of these cells and then 
talk about their involvement in atherosclerosis.
Dendritic cells are believed to originate from a different hemapoietic lineage 
from other leukocytes through early committed myeloid and lymphoid progenitors 
(CMPs and CLPs) [205]. The potential that these progenitors have to generate DCs, 
is linked to frns-like tyrosine kinase 3 (Flt3) expression and their ability to respond 
to Flt3 ligand (Flt3L) [206]. The contribution of blood monocytes to the generation 
of specific DC subsets will be described in the paragraphs that follow. Differentiation 
to DCs occurs under the influence of various inflammatory stimuli [207-209].
It must be noted that there is a distinct type of DCs, the Langerhan cells that 
are found in the skin [210] and that exhibit unique differentiation features than the 
other DC subsets. In steady-state conditions the Langerhan cells are self-renewed by 
precursors that take residence in the skin prior to birth [211]. They are not therefore 
dependent on the bone marrow or Flt-3 for their generation. In inflammatory 
conditions though that disturb the epidermal-dermal basal membrane, the skin can be 
repopulated by blood-bome monocytes [212].
Two large subtypes of DCs have been identified: classical DCs and 
plasmatoid DCs. The abbreviation cDCs used in many papers for classical DCs 
should not be mistaken with the abbreviation cDCs used in this thesis for control 
DCs in the experiments presented. Plasmatoid DCs are smaller than classical DCs 
and resemble to lymphocytes when they are immature [213, 214]. They are more 
specialised in producing type 1 interferon [214] but they are not as potent as classical 
DCs in micropinocytosing antigens from their environment [215]. They express 
CD4, CD 123 and the blood DC antigens 2 and 4 (BDCA-2 and BDCA-4) [216,
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217].They have been linked with the delivery of tolerogenic signals [216] unless if 
they are infected with a virus in which case they induce an immunogenic response 
[218, 219]. Classical DCs have been found to be able to deliver both tolerogenic and 
immunogenic signals [220].
Classical DCs have been found in lymphoid as well non-lymphoid tissues 
where they encounter antigens, pick them up and travel to the lymph nodes 
controlled by the ehemokine CCR7 (C-C chemokine receptor type 7) to present them 
to T cells [221]. In the lymphoid tisues (spleen, lymph nodes and thymus), DCs have 
been identified divided in two important subsets: the CD8^CDllb' and the CD8" 
CDl lb'*' subset [222]. The CD8^CDllb' population is the dominant DC population 
in the thymus [223] while in the spleen and lymph nodes it accounts for 20-40% of 
the total DC population. CD8^CDllb' DCs are phenotypically immature in their 
steady-state [222]. The CD8'CDllb^ subset prevail in all other lymphoid tissues 
apart from the thymus. Thymic CD8'CDllb^ express a more mature phenotype 
compared to CD8^CDllb", also express CD 172a, also known as signal regulatory 
protein alpha-positive (SIRPa^) and secrete higher levels of the CCL17 and CCL22 
chemokines (which attract CD4^T cells) [224]. They are believed to originate from 
blood-bome Ly6C expressing monocytes [225]. Splenic CD8 CD1 Ib^ consist of the 
ESAM^^^ and the ESAM^°^ population (ESAM: endothelial cell-speeific adhesion 
molecule). The former are thought to be derived by DC-speeific precursors while the 
latter is thought to originate from circulating monocytes [226]. All lymphoid DCs 
express high-levels of Flt-3 [227]. The following subpopulations of DCs in lymphoid 
organs have attracted a lot of research attention in relation to their function: 
CDllc^CD4'*'CD8'CDllb^ CDl lc^CD4'CD8^CDl lb" (also present in thymus).
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CDllc*CD4'CD8'CDllb* and CDllc+CDdCDSCDllb' populations (Table I II)
These DC populations are going to be further analysed in Chapter 4, section 4.3.6.
Type of DC
Lymphoid 
Ofqan resident 
DCs
Migratory or Langerhans cells 
non lymphoid ,
organ resident 
DCs
DC subset Phenotype
CD8-DCs C D llc-C D llb'C D 8-C D 4 (also
C0103-CD207- subset)
CD4- DCs CDl Ic'C D l lb*CD8CD4'
CDS CD4- CDl Ic'CDS CD4 (CDllb* and
double negative DCs CDl lb  subsets)
CD1ÎC-CD207-CD103*
C D llc*C D llb ‘CDl03-
non lymphoid 
organ resident cells
C D llc 'C D llb  CD103-
CDl Ic-CDl lbCDl03-CD207*
C D llc ‘C D llb C D l0 3 -
C D llc*C D llbC D l03*
Location
Spleen, lymph nodes and 
thymus
Spleen and lymph nodes 
Spleen and lymph nodes
Skin (epidermis)
Skin (deimis), lung, liver, 
kidney, pancreas arrd 
intestine
L iver, kidney, pancreas and 
intestine
Skin (dermis) and lung 
Skin (dermis)
Intestinal lamina propria
SlRPa* DCs 
Plasmacytoid DCs
Inflammatory TIP DCs and
DCs monocyte IXIs
CDl lc*CDllb"'CD8""CD4*'SIRPa* Thymus
CDl Ic^ C D l 1 b CD8 ^^ CD4 GRl ' Spleen, lymph nodes and
(produce type I ItNs) thymus
C D llc ‘CDllb*Ly6C*(produceTNF Inflammatory lesions
and express iNOS)
DC. dendritic  cell; If N. in terferon: iN O S,inducible nitiic oxide svfttltase; StRP. signal regu la to rs  p io ie in ; UP DCs. TNf ■ and  
iNOS produt trig DCs; TNF, tum our necrosis factor.
Table I.II: DC subsets, reproduced from Turley et a!., 2010 [228].
In the non-lymphoid tissues, the CD8^ counterparts are identified by the 
expression of CD 103 [229], The CD103^CDllb’ subset is similar to the lymphoid 
CD8^ subset, in terms of origin and function [230], They populate most connective 
tissues and express higher levels of Flt-3 than CDllb^ non-lymphoid DCs [231], 
CD 103 expression is regulated by the cytokine colony-stimulating factor 2 (Csf-2) 
present in the local tissue environment [232]. The CDllb^ subset usually lacks the 
expression of the integrin CD 103 and also consists of two subpopulations, similar to 
lymphoid CDl lb \  the one that arises from DC-restricted precursors and the other 
one that originates from circulating monocytes [233], The markers used to
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differentiate between the two subpopulations differ according to the tissue where the 
DCs reside.
It has been reported that under inflammatory and infectious processes 
monocytes show remarkable developmental plasticity giving another DC subset: Tip 
DCs. The name Tip comes from the TNF-a and the iNOS (inducible nitric oxid 
synthase) that theses DCs produce [234]. Tip DCs have been found localized in the 
spleen and in peripheral lymph nodes, fighting microbes and helping B cells to 
produce antibodies via the iNOS.
DCs are cells with irregular shaped nuclei and long membrane extensions 
[235] that in their mature state resemble dendrites in nerve cells (Figure 1.4). 
Ultrastructural studies have shown that vascular DCs contain a tubulovesicular 
system and granular structures very similar to the Birbeck granules in Langerhans 
cells [236]. It has been suggested these structures might also be involved in cell 
contacts between DCs and endothelial cells [11]. The cytoplasm of immature DCs 
that have not encountered any inflammatory signals consists of a lot of lysosomes 
that contain MHC-II molecules that are going to be degraded. Mature DCs on the 
other hand, when interacting with T cells to present an antigen, contain 
multivesicular bodies with MHC-peptide complexes as well as luminal vesicles 
which carry CD9. These vesicles release exosomes when they fuse with the cell 
membrane [237].
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Figure 1.4
extensions 
et al.[238])
; The dendritic cell. DC has an irregular shaped nuclei and long membrane 
that extend away from the cell body in every direction. (Reproduced from Inaba
DCs are professional APCs involved in the development of both innate and 
adaptive immune responses. As part of the innate response they can secrete cytokines 
and as part of the adaptive response they present antigens to T cells and modulate the 
immune response depending on the nature of the antigen [213]. They can activate 
naïve, memory or effector T cells as well as NK cells [239] [240].
When an inflammation or infection occurs, immature DCs (iDCs) receive 
signals (GM-CSF, IL-4) that activate them to acquire antigens by phagocytosis, 
process them in endosomes, load them onto MHC class I (MHC-I) or MHC-II 
molecules (depending on the nature of the peptide antigen) and present them on the 
cell surface to T cells [241],[242]. Antigens presented by the MHC-I complex are 
presented to CD8^ cells while antigens presented on the MHC-II complex are 
presented to CD4^ cells [213]. Endogenous antigens are presented on MHC-I in 
most cell types while exogenous antigens are presented on MHC-II only by 
professional APCs (macrophages, DCs, B lymphocytes) [243]. Presentation of
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exogenous antigens via MHC-I is a distinct process termed cross-presentation and it 
occurs in specific DC subsets (CD8^) in vivo but can be replicated in other cell types 
in vitro [243]. Cross-presentation is crucial as the different cell types in the body 
expressing antigen-loaded MHC-I molecules on their surface cannot initiate an 
immune response. In cases of infection therefore, DCs are needed to pick up antigens 
from infected or allogeneic cells and present them on their own MHC-I in order to 
trigger a T cell response. Cross-presentation is crucial for priming CD8^ cytotoxic T 
cells that can fight tumors, viruses and allogeneic transplants but also for maintaining 
self-tolerance [244]. Towards the same direction, to enhance immunity, cross­
presentation can also occur with the presentation of endogenous antigens by MHC-II 
molecules to CD4^ T cells[245]. The epitopes presented may originate from the 
hydrolised proteins present in the mitochondria, the cytoskeleton, the nuclei or from 
metabolic proteins and chaperones [246, 247].
Along with their maturation, DCs quickly migrate into the local draining 
lymph nodes where they are trapped and they present the antigen to T cells [207]. 
Up-regulation of adhesion factors such as the intercellular adhesion molecule 3 
(ICAM-3), co-stimulatory molecules (CD80, CD86, CD54, CD58) and the MHC-I & 
II occurs to enable the formation of what is called the immunological synapse. This 
multimeric structure allows, among other mechanisms, the activation of T cells and 
occurs in two main steps: 1) MHC molecules loaded with antigens on DCs interact 
with the TCR complex which is formed by the CD3 molecules (the y, 5 and e chains 
of Ig superfamily) and the disulphide-linked homodimer of a protein called the Ç 
chain [248] 2) Co-stimulatory molecules such as CD80 (B7-1) and CD86 (B7-2) 
amplify the signaling provided by the engagement of this complex and induces T cell 
proliferation and maturation. In the second step, the CD40 ligand molecule (CD 154)
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that has been expressed on the surface of T cells interacts with the CD40 expressed 
on the DCs. As a consequence cytokines are released by both T cells and DCs. The 
prevalent pattern of cytokines released will determine the outcome of the immune 
responses and the polarization of the CD4^ cells into T-helper-1 (Thl) or Th2. 
Recent studies report that there is bi-directional activation between DCs and T cells 
that also determines the polarization of the T cell response [239, 249]. There are T 
cells with the ability to produce cytokines when antigen presentation is initiated and 
through them activate and differentiate iDCs into mature DCs (mDCs) [250].
Studies of cytokine secretion by DCs have shown that two main cytokines 
play a special role in DCs differentiation and maturation: High secretion of the anti­
inflammatory cytokine interleukin 10 (XL-10) has been identified as an autocrine- 
paracrine inhibitor of DCs differentiation [235] as well as an important antagonist of 
the pro-inflammatory cytokine interleukin 12 (IL-12). It is thought that high IL-10 
secretion down-regulates the expression of the MHC-II molecules, preventing them 
fi*om presenting antigens to T cells [251]. In contrast, IL-12 secretion is responsible 
for DC maturation and proliferation in response to pathogenic stimuli. IL-12 secreted 
by DCs also induces triggers T cell expansion upon antigen presentation and 
predisposes Thl differentiation. Furthermore, IL-12 induces adhesion molecules 
such as ligands for P- and E- selectin on Thl cells in order to promote their migration 
at sites of infection [252].
For in vitro studies, a widely used way of obtaining DCs are usually by using 
CD 14  ^monocytic cells incubated in the presence of granulocyte macrophage colony 
stimulating factor (GM-CSF) or IL-4 [249]. The addition of bacterial liposaccharide 
(LPS), a component of the cell wall of Gram-negative bacteria, activates iDCs which 
under the influence of complementary stimuli will be able to activate T cells.
52
Examples of DCs surface markers that can be up regulated by LPS are CD83, CD80, 
CD86, CD la and MHC-I or MHC-II, they all play a key role in antigen presentation 
[253].
It is worth mentioning that in the absence of the appropriate co-stimulatory 
signals, DCs develop a tolerogenic phenotype with the capacity of providing anergy 
or T cell apoptosis [248]. This particular phenotype can be antigen-specific [254] and 
they can also promote the proliferation of regulatory T cells (Tregs) which will in 
turn down-regulate T cell mediated immune activation. I will look more closely at 
tolerogenic DCs (tolDCs) in the next section as in the second part of this thesis, I will 
examine if they can be used as vaccines to offer atheroprotection in apoE' ' mice.
1.18 TolDCs
In order for our immune system to prevent autoimmune reactions, T cells that 
recognize self-antigens have to be destroyed or become tolerant. This procedure 
takes place in the thymus through positive and negative selection of T cells. Thymic 
DCs have been shown to play an important role in the regulation of negative 
selection of thymocytes [255]. Peripheral DCs also contribute to the procedure of 
negative selection by migrating to the thymus [256]. In order to prevent tissue 
damage by self-reactive T cells that managed to escape firom thymus selection, the 
immune system has adopted peripheral tolerance mechanisms [254]. DCs, primarily 
of the spleen and lymph nodes, seem to take part in the induction of such peripheral 
tolerance mechanisms by producing soluble factors like IL-10, transforming growth 
factor beta (TGF-p) or indoleamine 2,3-dioxygenase [257, 258], inducing Tregs
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[259, 260] and commencing abortive T cell proliferation which leads in the 
destruction of autoreactive T cells [261, 262]. Furthermore, it seems that, under 
steady-state conditions, DCs are necessary for the protection against spontaneous 
onset of autoimmunity [263].
1.19 DCs in atherosclerosis
Atherosclerosis is associated with the pathological inflammatory development 
of the vascular-associated lymphoid tissue (VALT). VALT is present in the 
subendothelium of arteries and consists of clusters of immunocompetent cells [11]. 
Waltner et al [264] have suggested that VALT-associated cells get activated by 
autoantigens and initiate immune responses leading to atherosclerotic plaque 
formation. Clusters of DCs have been found within atherosclerotic lesions by using 
immunohistochemical analysis and electron microscopy. However, they were absent 
or poorly present in the normal intima [265]. Most of the DCs within plaques are 
probably invading the plaques from the VALT in the artery wall but they can also be 
derived from blood-borne monocytes attracted to the vessel by inflammatory 
mediators [266]. It has been shown that endothelial cells in the artery wall up- 
regulate DC adhesion and migration molecules when they are presented with stimuli 
that are known to favour atherosclerosis development, such as hypoxia, oxLDL, 
TNF-a or when the nitric oxid (NO) synthase that they contain is inhibited [267]. DC 
aggregation in regions of atherosclerotic plaques is probably associated with 
decreased expression of specific chemokines and their ligands, which modulate DC 
migration. oxLDL was recently shown to promote down-regulation of DC homing-
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receptor CCR7 and endothelial-ligand CCL21 in vitro. These two molecules may be 
implicated in the observed decreased migration of DCs from the plaques [268].
DCs seem to be very low in numbers within atherosclerotic lesions as 
compared with their presence in other body tissues such as blood, lymphoid tissues, 
spleen [269]. It is known that they function as APCs in atherosclerosis [270] since 
they express the MHC-II and CDl molecules. Furthermore, they express adhesion 
molecules such as VCAM-1 and ICAM-1 which are necessary during the interaction 
between endothelial cells and lymphocytes. It has to be noted that CD Id, a molecule 
recognised to be responsible for the presentation of both exogenous and endogenous 
lipid and glycolipid antigens [271] is expressed on DCs in atherosclerotic plaques 
[266]. CDl molecules are also expressed on foam cells, T cells andNKT cells [272] 
in the atheroselerotic plaques which have been suggested to act to present lipid 
antigens through this receptor as well [273].
Around 70% of the intraplaque DCs have been found to express the 
activation markers CD83 and CD-LAMP [274] and to form clusters with T cells and 
NK cells [265]. Others travel to lymphoid tissues to activate naïve T cells [270]. 
They are endocytic cells but do not form foam cells; instead they are found located 
amongst them [265]. Recent studies have shown that DCs that present LDL 
components can promote specific immunity to their antigen, increase inflammation 
on the lesion site and speed up atherosclerosis [275].
Recently, it has been suggested that vascular DCs also have a role in plaque 
destabilisation as 90% of the DC population in atherosclerotic plaques is found in the 
shoulder regions of the plaques which are the rupture prone regions [265], [274], 
[276]. They can be seen in higher numbers in lesions from patients with acute 
ischaemic events but they appear to be less in those treated with statins, a class of
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drugs that inhibit the rate-limiting enzyme (3-hydroxy-3-methylglutarylcoenzyme A 
reductase) in the pathway of cholesterol biosynthesis [274]. Statins have also been 
shown to inhibit in vitro DC maturation [8, 277].
Pivotal remains the role of plasmacytoid DCs (pDCs) in atherosclerosis 
development. Studies on apoE' '^ mice showed that absence of pDCs in the aorta and 
spleen led in decreased atherosclerosis in the aortic sinus, more stable atherosclerotic 
plaques as well as decreased T cell activation in the spleen among others [278]. 
Blood myeloid DCs seem to bear the capacity to keep and distribute oral mucosa 
pathogens to plaques, which may result in myeloid DC differentiation [279].
More recent studies have shed some light in the biology of DCs in 
atherosclerosis. One of them demonstrated the role of myeloid differentiation 
primary response gene 88 (MYD88) in atherosclerosis. MYD88 comprises a TLR 
adaptor which is important for DC maturation. Lack of MYD88 decreases the ability 
of DCs to activate T cells. In this paper, its role was assessed in CDllc+ DC cells 
where MYD88 was shown to be important for the development of atheroprotective 
Tregs. Deficiency of this adaptor decreased the number of Tregs and increased the 
size of atherosclerotic lesions [280]. TGFpRII signalling also seems to be of 
importance in atheroprotection since absence of TGFpRII signalling in CDllc(+) 
cells results in specific alterations in DC subsets, which, in turn, lead to enhanced T 
cell activation and maturation and thus in increased atherosclerosis [281]. In another 
study, DCs were found to be able to produce IL-27 after oxLDL stimulation. IL-27 
may play an important role in modulating immunity and inflammation signalling in 
the development of atherosclerosis [282].
Another study investigated the effects of thymic stromal lymphopoietin 
(TSLP) on DCs. TSLP has the capacity to activate DCs and promote adaptive
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immune responses. Angiotensin II- induced TSLP was found to activate DCs and 
through this activation to promote Thl7 differentiation and thus enhance Thl7- 
dependent immune response in atherosclerosis [283]. Additionally, the effects of 
fibronectin in monocyte-derived iDCs were recently studied. This study found that 
fibronectin promoted intracrine and paracrine properties in monocyte-derived iDCs 
which potentially function as a protective vascular homeostasis mechanism [284].
Since DCs apparently have an important role in plaque formation and 
destabilisation, this study aimed to examine their potential use as immunomodulators 
in the T cell mediated immune responses involved in atherogenesis.
1.20 T cells
T cells are a category of lymphocytes that mature in the thymus. There are 
different categories of T cells, each with separate functions: T helper cells or CD4^ T 
cells, T cytotoxic cells or CD8^ T cells, T memory cells, Tregs, NK T cells and yô T 
cells.
1.21 T cell mediated immune responses in atherosclerosis 
development
T cells are present in atherosclerotic plaques at all stages of its development 
[8]. Most T cells within atherosclerotic plaques are CD4+ and a small fraction of the 
population consists of CD8+ T cells. CD4+ cells isolated from human plaques have 
been found to express the ap TCR [148, 196] that recognises antigens presented in 
the context of HLA-DR in the surface of APCs. The close proximity between T cells
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and APCs within atherosclerotic plaques supports the view that these lymphocytes 
are involved in antigen recognition and antigen-specific proliferation in the shoulder 
regions of atherosclerotic lesions [85]. They are attracted to the tissues by 
chemokines and adhesion molecules expressed on the surface of endothelial cells. 
Although the production of IgM, also called natural auto-antibodies, seems to be 
predominant in atherosclerosis, the presence in the serum of IgG antibodies specific 
to oxLDL epitopes is indicative of the involvement of CD4+ T cells in the process of 
affinity maturation and isotype class switching of B-cell clones specific to 
atherogenic antigens [23].
Recent studies have shown that CD8  ^ T cells confer the ability to lead 
macrophages, smooth muscle cells and endothelial cells in perforin- and granzyme 
B-dependent apoptosis, resulting in vulnerable plaque development. This, in turn, 
leads to necrotic core development and inflammation enhancement through TNF-a 
production [285].
The imbalance between pro- and anti-inflammatory immune responses 
appears to be responsible for the development of atherosclerosis. The activation of 
naïve CD4+ T cells generates one of the two major types of functionally different 
effector T cells, the T-helperl (Thl) or the Th2. The response of the former cells is 
considered to be proinflammatory in the context of atherosclerosis and is 
characterized by the secretion of IFN-y, IL-12 and TNF-a which are all involved in 
macrophage activation. IFN-y also drives Thl cell differentiation that can be 
inhibited by IL-10 [29, 286]. It has been suggested that plaque size correlates with 
the number of Thl cells present within the lesions [287]. Th2 response is considered 
to be anti-inflammatory due to the secretion and action of IL-10 and other cytokines 
such as IL-4, IL-5, and IL-13, all linked to B cell activation and differentiation. Th2
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differentiation is favored by IL-4 and it can be inhibited by IFN-y. Thl is the 
predominant T cell subset found in atherosclerotic lesions (Figure 1.5)[73, 288, 
289].The type of antibody produced, driven by Thl or Th2 immune responses, also 
plays a key role in atherogenesis [23]. The synthesis of IgG 1 antibodies indicates a 
predominant Th2 response while lg02a is indicative of Thl responses [23].
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Figure 1.5: The Thl-mediated cell immune responses involved in atherogenesis. 
Lymphocytes migrate into the lesion site attracted by chemokines and here they encounter 
APCs already activated by various atherogenic antigens. Antigen presentation takes place 
and T cells differentiate to Th1 type cells that will signal a cascade of pro-inflammatory 
responses (including the activation of smooth muscle cells). These responses can be down- 
regulated or inhibited in the presence of Tregs which have also been activated by APCs. It 
has to be noted though that there are T cells that have already been activated by trafficking 
DCs in the lymph nodes and have been attracted to the lesion site to act through the 
cytokines they secrete. (Reproduced from Hansson GK N Engl J Med 2005; 352:1685).
It is acknowledged that there is probably a balance between Thl and Th2 
responses, which cross-regulate each other, involved in atherosclerosis. The
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dominance of one against the other deeply affects the progress of the disease [27], 
[290]. It is important therefore to identify which of the immune responses that are 
produced are protective and which are promoting the disease in order to be able to 
take advantage of them for therapeutic purposes.
The regulation of the balance between Thl and Th2 immune responses 
appears to be controlled by another T cell subset referred to as Tregs (Figure 1.5), 
(reviewed in [291], [292]). Herbin et al. tried to determine the role of Tregs in the 
inhibition of vascular inflammation. By administrating adjuvant-free apoB-100- 
derived peptides to apoE' '^ mice they managed to induce a specific Treg cell response 
and reduce atherosclerosis [293].
Th2 activation and proliferation appears to be triggered by epitope-specific 
stimulation [147, 294-298] or by the induction of natural antibodies involved in the 
clearance of lipoprotein particles [101]. Auto-antibodies against oxLDL have been 
found circulating in the plasma and there is a correlation between the concentrations 
of these antibodies in plasma and lesion size [299]. Recent experimental evidence 
shows that pneumococcal vaccination using an animal model of atherosclerosis 
induces the production of anti-oxLDL IgM antibodies, which inversely correlates 
with the development of atherosclerotic plaques [201]. It has been also proposed that 
IgM antibodies may bind to oxLDL preventing its binding and degradation by 
macrophages, or even preventing the uptake of apoptotic cells by macrophages [300, 
301]. However, the mechanisms involved in the production of these antibodies or 
their precise role in atherogenesis have not yet been addressed.
Th2 responses are also recognised in advanced stages of atherosclerosis, 
when hypercholesterolemia is prominent and there seems to be a shift of the immune 
response towards a Th2 type, indicating that in late stages the immune system is
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trying to overcome the pro-inflammatory damage [297, 302]. Noticeably, the 
therapeutic correction of the balance between these two types of responses has been 
pivotal for the development of novel interventions, such as vaccines against the 
development of the disease.
Experiments carried out using inbred stains of mice show that C57BL/6 mice 
are more prone to develop Thl responses and more atherosclerosis than BALB/c 
mice which are prone to develop Th2 responses and consequently atheroresistant
[303]. It has also been noted that deletion of STAT6 , a transcription factor required 
for the activation of Th2 responses, prone these mice to develop atherosclerosis
[304]. Treatment of hypercholesterolaemic mice with recombinant IFN-y also 
accelerates atherosclerotic plaque development [305], an effect that is reversed when 
mice receive the drug pentoxyfyllin, a potent Thl blocker [287].
Switching the immune response to a Th2 type can be achieved by the 
expression of the anti-inflammatory cytokine IL-10 which suppresses the effect of 
proinflammatory cytokines such as IL-12 and IFN-y [306, 307]. The athero­
protective effect of IL-10 was noted even in mice fed a high-fat diet. However, the 
treatment failed to influence plasma cholesterol levels indicating that the EL-10 
effects are due to modulation of the immune response involved in intraplaque 
inflammation mechanisms [307].
Deficiency of T-bet, a transcription factor required for Thl differentiation, in 
experimental animals significantly reduced atherosclerotic lesions. This effect was 
linked to a reduction in number of proliferating smooth muscle cells in the intima 
layer [308]. T-bet deficient mice have also shown a skewed immune response 
towards the Th2-type when HSPs were administered to these mice [308]. These
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findings suggest that transcriptional regulation in T cell differentiation can represent 
a good target to immunomodulate atherosclerosis.
The first report on the possible role of Thl7 cells in cardiovascular disease 
appeared in 2008 [309-311]. Thl7 cells are characterised by IL-17 (or IL-17A), IL- 
17F, IL-6 , TNF-a, and IL-22 expressions. Their discovery has contributed to explain 
crucial regulatory mechanisms which until now the classic control by Thl and Th2 or 
Treg cell-mediated mechanisms could not explain. Thl7 cells have been suggested to 
play a key role in inflammation and autoimmunity. They have also been involved in 
the pathogenesis of hypersensitivity reactions. The study of their role in host defence 
mechanisms has just recently started and promises to be another area of high interest 
in cardiovascular biology research (see the following articles for a comprehensive 
review of the recently published literature on Thl7 [309, 311-316]). Cheng et al. 
have suggested that Thl7/Treg balance may play a key role in controlling 
inflammation, plaque destabilization, and the onset of acute coronary syndrome. 
They investigated this hypothesis by assessing Thl7/Treg functions through the 
analysis of T cell frequencies, secretion of specific cytokines, and production of key 
transcription factors in patients with acute myocardial infarction, unstable angina and 
stable angina. They found that Thl7 cell numbers as well as their cytokines (IL-17, 
lL-6, and IL-23) and transcription factor (RORgammat) levels were significantly 
higher in patients with acute coronary syndrome as compared to controls. The study 
also showed a significant decrease in Treg number, Treg-related cytokines (IL-10 
and TGF-P 1), and forkhead box P3 (FoxP3) levels in these patients as compared to 
stable angina and controls suggesting a potential role for Thl7/Treg imbalance in 
plaque destabilization and the onset of acute coronary syndrome (ACS) [309].
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1.22 Immunisation Using oxLDL Confers Atheroprotection
A series of studies have shown the benefits of using oxLDL to create 
protective immunity against atherosclerosis. These studies have demonstrated that 
immune responses against this lipoprotein may protect against the development of 
the disease [71, 317-322]. One of the first reports came from Palinski et al. who 
immunised LDL-R -deficient (LDLR"") rabbits using homologous MDA-modified 
LDL (MDA-LDL). This treatment induced high titres of antibodies displaying equal 
specificity as those risen by the native particle and reduced the extent of the 
atherosclerotic lesions in the aortic tree fi*om 68% (placebo group) to 48% 
(experimental group) [318]. Studies from other laboratories confirmed these results 
and showed that immunisation of hypercholesterolemic rabbits reduced T cell and 
oxLDL immunoreactivity within the neointima of immunized animals [319].
The effect of LDL immunisation on atheroprotection has also been assessed 
using mouse models of the disease. George et al. was the first to report the effect of 
MDA-LDL immunisation in apoE~^ ~ mice. Immunised mice developed high titres of 
anti-MDA-LDL antibodies and the treatment significantly reduced lesion size at the 
aortic sinus by more than half when compared with their control littermates 
immunised with PBS. However, they did not find differences between the groups 
with respect to cellular composition of the atherosclerotic plaques [320]. Later on, 
Freigang et al. showed that LDLR"" immunised with homologous MDA-LDL 
induced the synthesis of antibodies of different classes against distinctive epitopes on 
oxLDL and that this antibody response is significantly correlated with a reduction by 
approximately 40% of lesion size. However, they also showed that immunisation
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with MDA-LDL raised equivalent amounts of both T helper 1 (Thl)-related IgG2a 
and Th2-dependent IgGl antibodies [321]. On the other hand, an elegant study 
carried out by Zhou et al. provided evidence of the involvement and control of the 
production of oxLDL-induced antibodies by T cells. They immunised apoE~^ ~ mice 
with homologous plaque homogenates or homologous MDA-LDL. They found that 
both antigen preparations reduced lesion development. The protective effect was 
associated with a specific raise of T cell-dependent IgG antibodies against MDA- 
LDL and oxidised phospholipids which were correlated with the reduction in plaque 
size and circulating cholesterol levels [322].
According to similar studies, immunization of apoE'^'mice with MDA- 
fibronectin reduces the formation of atherosclerosis. This result suggests that the 
triggered immune response could have a protective effect in humans and that MDA- 
fibronectin could be a potent target for immunomodulatory therapy in atherosclerosis 
[323].
Recent studies from the same team, showed that immune responses against 
MDA-laminin could also play an important role in the development of 
atherosclerosis in humans. Aldehyde-modified laminin was observed in 
atherosclerotic lesions in mice and induction of an immune response against MDA- 
laminin correlates with Thl7 cell activation, reduced number of Tregs and an 
induced atherosclerosis formation [324].
Recent studies suggest that CD4^LAP^ Tregs and CD4^CD2 5^FoxP3 ^  Tregs 
induced after oxLDL nasal delivery have the ability to prevent oxLDL-specific T cell 
response and improve the atherosclerosis state [325].
64
Despite these demonstrations, the protective role of oxLDL during 
physiological conditions remains unknown and the immunological mechanisms 
related with it have not yet been fully studied.
1.23 Antigen-specific immunomodulation: apoB-lOO-derived
peptides in atheroprotection
In order to be able to manipulate the atheroprotective immune responses 
therapeutically, there is the need to study which antigens provoke them. Especially 
for LDL which is such a complex molecule it is important to detect which epitopes 
have an atheroprotective role [288], [288].To achieve this, Jan Nilsson and Prediman 
Shah have been working with MDA-modified apoB-100-derived peptides [326]. 
Fredrickson et al. [297] made a peptide library of 302 polypeptides, each of them 20 
a.a. long, with a 5a.a. overlap between adjacent peptides covering the whole 
sequence of human apoB-100 protein. They used this library to identify antibodies 
against these peptides, both in their native state and after MDA modification, by 
testing human serum ftom healthy donors and patients with coronary heart disease 
using an Enzyme-Linked ImmunoSorbent Assay (ELISA) [297]. Only 102 peptides 
cross-reacted with the serum samples. From these, Nilsson chose the peptides that 
presented the highest binding affinity to antibodies. The reason for this selection was 
that at the beginning of atherosclerosis, there is a repair mechanism to protect the 
arterial wall from atherosclerosis and antibodies are generated against certain oxLDL 
epitopes. The peptide-epitopes, therefore, that give the highest binding to antibodies 
could be the most potent in generating an atheroprotective response. The binding was 
more significant for the MDA-modified peptides but it followed the same pattern that
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was observed for the native peptides [297]. In subsequent clinical trials healthy 
individuals and CHD patients were immunized with the peptides and an increase in 
the levels of apoB-100-specific IgM antibodies in parallel with a decrease in 
circulating oxLDL was noted suggesting that these antibodies might function by 
clearing oxLDL jfrom the circulation [297].
The same but to a lesser extent was observed for IgG antibodies. The 
immunizations with the apoB-100 peptide P210 (Table Till) in apoE" ' mice resulted 
in a 60% decrease in atherosclerosis and an increase in the collagen content of the 
plaques as well in specific IgG levels, the former suggesting that specific IgG 
responses are also involved in atheroprotection in mice [327]. Subsequently, they 
found that recombinant IgG antibodies were generated against the MDA-modified 
apoB-100-derived peptides P45 and P210 (Table l.lll) used in the previous study and 
they were used to vaccinate apoE' '^ mice. The plaque size and the macrophage 
content were reduced significantly suggesting that generation of Th2 related apoB- 
100-specific IgGl plays an important role in atheroprotection in mice [328].
Table l.lll: The three human apoB-100-derived peptides, provided by Prof Jan Nilsson, 
which were used in my project.
peptide aa sequence aa no. % homology to 
mouse
P2 ATRFK HLRKY TYNYE AESSS 16-35 95
P45 lEIGL EGKGF ERTLE ALFGK 661-680 95
P210 KTTKQ SFDLS VKAQY KKNKH 3136-3155 90
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Studies that have been published after the experiments for this thesis were 
conducted, have confirmed the atheroprotective properties of the apoB-100 peptides 
and the belief that their effect involves T cell mediated responses. More specifically, 
Nilsson’s group has shown that nasal administration of the peptide P210, which was 
fused to the B subunit of cholera toxin (CTB), reduced atherosclerosis while 
inducing regulatory Trl cells [329]. A more recent study from the Mallat group has 
also shown that subcutaneous injection of adjuvant-free apoB-100-derived peptides 
to apoE-/- mice induced a specific Treg cell response and thus resulted in reduced 
atherosclerosis [293]. These and other recent studies will be discussed further in the 
General Discussion.
Based on the findings of the Nilsson group on the possible crucial 
involvement of T cell mediated responses in atheroprotection, the first part of this 
study focused on DCs, which are the cell population that initiates T cell-mediated 
responses, in order to examine if they can drive the immune response to an 
atheroprotective phenotype when loaded with three of the apoB-100-derived peptides 
already mentioned (Table l.lll).
1.24 Hypothesis
The hypothesis of my project was that DCs can be used to immunomodulate 
the inflammation related to atherosclerosis.
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1.25 Aims and objectives
This project aimed to investigate the cell-mediated immune mechanisms 
involved in atherosclerotic plaque formation & development in order to examine the 
potential use of DCs to attenuate atherosclerosis.
The first part focused on the effect that the apoB-100-derived peptides P2, 
P45 & P210 have on the phenotype, activation and function of iDCs.
-I examined peptide up-take by DCs, cell processing and presentation.
-1 studied the cell shape, the phenotypic and activation markers, the cytokine and 
metalloproteinase mRNA expression and the cytokine secretion by the peptide- 
loaded DCs.
-I looked at the expression of activation markers on T cells as well as T cell 
proliferation and T cell cytokine secretion induced by peptide-loaded DCs.
The second part focused on the in vivo immune response generated in apoE' '^ mice 
when these were immunised subcutaneously with tolDCs generated in vitro and the 
effect that it has on the progress of atherosclerosis in these mice.
-1 examined the levels of cytokines in the serum of immunised animals, the 
percentage of Tregs in their spleens as well as the cytokine secretion levels from the 
splenocytes.
-1 studied the progress of atherosclerosis in the immunised mice by measuring plaque 
size in the aortic sinus. I also looked at their plasma lipid profile.
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CHAPTER 2 GENERAL MATERIALS AND METHODS
2.1 Laboratory reagents
2.1.1 Peptides
2.1.1.1 apoB-lOO-derived peptides
The peptides used in these studies were kindly provided by Prof J. Nilsson, 
Department of Clinical Sciences, Malmo University Hospital, 20502 Malmo, 
Sweden. Their sequence, position in the apoB-100 polypeptide sequence and their 
homology to mouse is provided in Chapter 1 (Section 1.23, Table 1.111). They were 
supplied as a lyophilised powder and then reconstituted in sterile phosphate buffer 
saline (PBS) buffer (see section 2.1.4 for buffer composition) to prepare stock 
solutions at a concentration of 1.5mg/ml each. In the case of P2, dimethyl sulfoxide 
(DMSO, Sigma) was added (50pl) to allow full solubilisation of the peptide in the 
PBS buffer. The peptide solutions were stored at -20°C until use.
2.1.1.2 Fluorescent peptide P45
For confocal microscopy studies, an Alexa-488-labelled P45 was synthesized 
by Innovagen AB, Sweden at a purity >70%. It was reconstituted in sterile PBS to a 
concentration of 1 mg/ml to be used in the experiments.
69
2.1.2 Cell culture reagents
All cell culture reagents were purchased from Gibco (Invitrogen UK) unless 
otherwise stated. Roswell Park Memorial Institute (RPM1)-1640 media (simple for T 
cells and Advanced for DCs) that was used was certified to be mycoplasma-fi*ee and 
it was heated at 37°C before it was added to the cells. Simple RPMl was 
supplemented with 10% foetal calf plasma (PCS), IX penicillin-streptomycin- 
glutamine (lOOU/ml, lOOpg/ml & 2mM respectively). Advanced RPMI was 
supplemented with 5% PCS, IX Penicillin-Streptomycin-Glutamine (lOOU/ml, 
lOOfig/ml & 2mM respectively), P-mercaptoethanol (P-ME) (50pM) and (4-(2- 
hydroxyethyl)-1 -piperazineethanesulfbnic acid (HEPES, 25mM). The media was 
also supplemented with murine recombinant (mr) GM-CSF (lOng/ml) and mrIL-4 
(2ng/ml) that induce the differentiatin of the cells into immature DCs. PBS used for 
washes was calcium and magnesium fi-ee. Disposable plasticware were obtained 
from BD plasticpac, UK (syringes), Sterilin, Barloworld Scientific Ltd, UK (tubes), 
Termuno Europe, Belgium (needles), Fisher Scientific, UK (scrapers) and NUNC, 
UK (cell culture plates). Tissue culture (TC) hood surfaces were always wiped with a 
solution of 70% (v/v) ethanol before use and regularly cleaned with Vircon (Antec 
international, UK) as well as being exposed to UV light overnight. Incubators 
(Heraeus, Thermo Scientific, UK) were set to 37°C and 5% CO2, 80% humidity.
2.1.3 Cytokines and growth factors
The following murine cytokines, IL-2, lL-4, IL-10 and granulocyte monocyte 
colony stimulating factor (GM-CSF) were obtained from R&D Systemsm, UK or 
Peprotech, UK as lyophilised powders and then reconstituted in sterile PBS
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containing 0.1% BSA (bovine serum albumin) to prepare stock solutions of lOpg/ml 
and stored at -20°C until use. Recombinant human transforming growth factor beta 
(TGF-P) (Peprotech, UK) was first reconstituted in citric acid (lOmM solution) at a 
concentration of 50pg/ml and then further diluted in sterile PBS containing 2mg/ml 
albumin at a concentration of lOpg/ml.
Lipopolysaccharide from Escherichia coli 055:B5 (LPS, 5pg/ml, SIGMA, 
UK) was used as a polyclonal stimulator and activation factor in DC studies, 
reconstituted in sterile PBS at a concentration of Img/ml.
2.1.4 Composition of general buffers and solutions
-All chemicals were from Sigma-Aldrich, UK unless otherwise stated
Acetic alcohol 
Agarose gel
Agarose gel with nucleic acid stain
Ammonium persulphate (APS, 10%)
BSA/PBS/NaNs buffer
3% v/v acetic acid, 95% v/v methanol 
2% w/v agarose, IxTris-acetate-EDTA 
(TAE) buffer (see below for TAE buffer 
composition) and 0 .1% v/v ethidium 
bromide
1% w/v agarose, Ix Tris buffered saline 
(TBS) buffer (see below for TBS buffer 
composition), GelRed Nucleic acid gel 
stain (10  ^x in DMSO, Biotium, USA) 
10% w/v ammonium persulphate in 
distilled water (dH2 0 )
0.5% w/v BSA, 10 X PBS, milli-Q (mQ) 
H2O, 0.1% v/v of sodium azide (IM)
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Coomassie blue
ELISA Peprotech kit wash buffer 
ELISA Peprotech kit blocking buffer 
ELISA Peprotech kit dilution buffer
50% v/v methanol, 10% v/v acetic acid, 
0.25% w/v Coomassie Brilliant Blue R- 
250 (filtered solution)
0.05% v/v Tween-20 in PBS
1% BSA w/v in PBS
0.05% Tween-20, 0.1% BSA in PBS
Flow cytometry antibody incubation buffer 1% w/v BSA (Fluca, Biochemica,
Switzerland) in PBS, 0.05% v/v NaNg 
Flow cytometry washing buffer: 0.5% w/v BSA in PBS
Formalin (10% neutral phosphate buffered) 10% v/v formalin, 0.45% w/v
NaH2P0 4 .2H2 0 , 0.65% w/v Na2HP04
Phosphate Saline buffer (PBS)
Permeabilisation buffer:
Phosphate-citrate buffer (0.05M, pH 5.0)
TAE (5 Ox) buffer
in dH20
0.8% w/v NaCl, 0.02% w/v KCl, 
0.144% w/v Na2HP0 4 , 0.024% w/v 
KH2PO4 in dH2 0 , HCl to adjust pH to 
7.4
5% v/v of 10% w/v saponin solution in 
PBS and 95% v/v PBS/BSA/ NaNg 
buffer
one phosphate-citrate buffer tablet in 
every 100ml dH20
24.2% w/v Tris base, 5.71 % v/v glacial 
acetic acid, 10% v/v of 0.5 M Na2 
EDTA solution (pH 8.0) in dH20
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TBS (lOx) buffer
Zymography renaturation buffer: 
Zymography development buffer:
Zymography destaining buffer:
8.766% w/v NaCl, 1.211% w/v Tris, 
0.4% v/v HCl to adjust pH to 8.0 
2.5% v/v Triton X-100 in H2O 
1.7M HCl, 2M NaCl, 0.05M CaCh, 
0.2% Brij35 in dH2O,10x)
10% v/v MeOH, 5% v/v HAc
2.1.5 Mice
apoE' '^ mice (B6.129P2-Apoe^'”^ ^"7J) and CDl® mice were purchased from 
Charles River, UK. The mice were bred at the Faculty of Health and Medical 
Sciences (FHMS) Experimental Biology Unit (EBU) animal facility, holding a 
Certificate of Designation under the Animals (Scientific Procedures) Act of 1986. 
They were housed under the standard conditions approved by the UK Home Office. 
Animals were kept at room temperature (RT) in an environment with 55% humidity 
and 15-20 changes of conditioned air per hour (h) and a light-dark cycle of 12:12 
with the light intensity of 350-400 lux. Mice were 8-10 weeks old when they were 
used for in vitro experiments (bone marrow or spleen extraction) and 7 weeks old 
when they were used for in vivo experiments (vaccination with tolDCs).
T cells extracted from CDl® mice were used in the mixed lymphocyte 
reactions (MLR) presented in this thesis along with DCs extracted from apoE' '^ mice 
because the two strains have a different genetic background. CDl® mice have a white 
(albino) coat color and the original mice that were used as the progenitors of this 
stock were non-inbred Swiss albino mice from the laboratory of Dr. de Coulon, 
Switzerland. Mice from this strain are used as a general multipurpose model in fields
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such as toxicology (safety and efficacy testing), aging, pseudopregnancy and 
oncology.
2.2 General Methods
2.2.1 Statistical analysis
Experiments were performed in triplicate for most of the in vitro studies. For 
the in vivo ones, 8 animals were used per treatment group. Values in the figures are 
presented as mean ± SD. For my statistical analysis, I first ran a Shapiro-Wilk test to 
determine if the data were normally distributed or not in order to decide between a 
parametric or a non-parametric statistical test. When the data were not normally 
distributed, a non-parametric test was required and levels of significance were 
determined by the Kruskal-Wallis test (that was chosen due to the small number of 
samples per group and to the number of groups that I wished to compare). In the 
cases where the data were normally distributed, a parametric test was most 
appropriate and more specifically a univariate analysis of variance, also called a 
univariate ANOVA (as 1 wished to examine the differences between more than two 
experimental groups in one dependent continuous variable). Levene’s test was used 
to determine if the variance of the dependent variable was equal or not across the 
experimental groups to then decide which post hoc test to perform to make multiple 
comparisons between groups. The Bonferroni-Dunn post-hoc test was used where 
variance across groups was equal while the Tamhane post-hoc test was used in the 
cases where variance was not equal. The analysis was performed using the SPSS 
software (IBM, USA) version 17.0. Significance was determined at a 95%
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confidence level (p<0.05). I made a special note of the data that were significant at a 
99% significance level (p<0.01).
2.2.2 Computer Software and instruments
For flow cytometry analysis, data were collected using a FACScan analyser 
(Becton Dickinson, San Hose, CA) and processed using the WinMDI software, 
version 2.8 (WinMDI, USA) or collected using the BD FACSCanto analyser (BD 
Biosciences, UK) and controlled by the BD FACSDiva software, version 5.0.3 (BD 
Biosciences, UK).
Total RNA was quantified using the Nanodrop System (Agilent Technologies 
Ltd, UK) by examining just Ipl of the samples. RNA concentration was measured in 
ng/pl by the Nanodrop technologies software, version 3.0.0.
Image acquisition of polymerase chain reaction (PGR) products on agarose 
gels was carried out using a Gene Genious bioimaging system (Gene Snap, Version 
4.01.00, Syngene, UK). Densitometric analysis of the bands was performed using the 
Gene Tools software by Syngene, version 3.00.22.
ELISA assay plates were read either using a Perkin Elmer microplate reader 
(Wallac by Edenglen Ltd, UK) equipped with a 450nm filter and analysed using the 
Wallac 1420 software, version 3.2 or a ELxSOO microplate reader (BioTek, USA) 
with a 45Onanometers(nm) filter and the KC4™ software, version 5.1.2600.2180 
(BioTek, USA).
Confocal microscopy images were captured using a Zeiss LSM confocal laser 
microscope (Carl Zeiss Ltd, UK) with 40x and 63x magnification and bright field
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and fluorescence microscopy. The Zeiss LSM 510 software, version 3.2 SP2 was 
used to process the digital images.
Images from slide/tissue samples were captured at 4x magniflcation with a 
Leica microscope (Leica, Switzerland) equipped with a 3-CCD C-Mount digital 
processing colour camera using the Leica QWin Software, version 3.4.0. The Image 
J software (Wayne Rasband, National Institute of Health, USA, version 1.41) was 
used for morphometric analysis of the digitally acquired images.
Incubations at 37°C were carried out using a Heraeus Dry incubator (Fisher 
Scientiflc Inc, UK).
2.2.3 Generation and maintenance of cell cultures
2.2.3.1 Isolation of murine bone marrow progenitor cells and generation of DCs
Isolation of bone marrow progenitor cells was carried using a modifled 
version of the original protocol published by Inaba et al [238]. Male mice aged 8-10 
weeks old were used in my experiments. Bone marrow was extracted from the femur 
and tibia of the animals by flushing it out with a syringe containing RPMI-1640 
media. Contaminant erythrocytes were eliminated using a Mouse Erythrocyte Lysing 
kit (R&D Systems, UK). Cells were incubated in lysis buffer (1 ml/animal, Ix) for 10 
minutes (min) and then washed by centrifugation at 200  x g once with washing 
buffer and once with media.
Progenitor cells were then obtained by negative selection using BioMag® 
Goat anti-Rat IgG 1 mg/ml (Qiagen, UK) and a cocktail of rat anti-mouse antibodies 
against CD8, CD4 and CD 19 surface markers (Serotec, UK). First the cells were
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incubated with the cocktail of antibodies (each at O.lpg/ml) for 30min on ice and a 
solution of Goat anti-Rat IgG beads in media (lmg/10^ cells) was added and 
incubated for 20min at 4°C. Tubes were then placed in a magnetic separator and the 
supernatant containing the unbound cells was carefiilly collected. Cells were washed 
and cultured.
Bone marrow derived cells (BMDCs) were cultured for 7-10 days in 24-well 
plates at an initial concentration of IxlO^cells/well in advanced RPMI 1640, 
supplemented with FCS, penicillin-streptomycin-glutamine, P-ME, HEPES, mrGM- 
CSF and mrIL-4, as described in section 2.1.2. Cultures were supplied with fresh 
media every 2 days. On day 6 or 7, mononuclear cells were further purified 
(enrichment) by a density gradient as follows. Cells in culture were laid on 
Histopaque-1077® (SIGMA) in a 2.6:1 Histopaque to cells ratio and centrifuged for 
30min at 200 x g. This step allowed the removal of contaminants carried from 
previous steps such as dead cells. Purified cells were cultured in 24-well plates at an 
initial concentration of 0.5x1 O^cells/well for 48 hours. This step allowed cells to 
settle and adhere on to the TC plate.
2.23.1 Isolation and purification of naïve T cells.
Spleens were extracted from male apoE' "^ mice and the tissue was dissociated 
using the back of a syringe plunger to generate a cell suspension. Contaminant 
erythrocytes were removed using a Mouse Erythrocyte Lysing kit (R&D Systems, 
UK) as described in section 2.2.3.1. The cell suspension was cleared from 
macrophages, monocytes and other tissue adherent cells by incubating the TC flasks
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(25cm^) at 37°C, 5% CO2, 80% humidity for 2hrs. Floating cells were then obtained 
by collecting the supernatant with a pipette without disturbing the cells that were 
adhering to the surface. CD4^ T cells in the collected cells were obtained by negative 
selection using the BioMag® Goat anti-Rat IgG 1 mg/ml (Qiagen, UK) and a cocktail 
of rat anti-mouse antibodies against the CD8 , GDI lb and CD 19 markers (Serotec, 
UK) as described in section 2.2.3.1.
2.2.3.3 Cell counting
Viable cell numbers were determined by staining with the Trypan blue 
solution. The cell pellet was resuspended in 1ml of media and Ipl of the cell 
suspension were added to 9pl of the Trypan blue solution (0.2% w/v in PBS, Sigma, 
UK). The mix was then loaded on a hemocytometer chamber to count the cells in the 
four comer squares of the chamber. Each square represents a volume of IC^cm^. In 
order to estimate the average number of cells per ml, the average number of cells per 
square was multiplied by the dilution factor (which in my case was 10) and by 10"^ 
(lml=lcm^) the procedure was repeated at least twice per sample.
2.2.3.4 In vitro loading of DCs with apoB-lOO-derived peptide
For the in vitro peptide studies, cells were incubated with each of the peptides 
[P2, P45 & P210] alone with increasing concentrations ranging from 2.5pg, 5pg, 
25pg up to 50|xg or in combination with EPS from Escherichia coli 055:B5, 5pg/ml 
(Sigma-Aldrich, UK) for 48h. EPS was used as a positive control for DC activation.
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2.2.3.S In vitro treatment of DCs with TGF-p and IL-10
In order to carry out my in vivo experiments, I needed to generate tolDCs in 
vitro, which would then be used to immunise apoE' '^ mice to examine if tolDCs can 
be used to immunomodulate atherosclerosis. TolDCs have been described to be 
generated in vitro by culturing iDCs with TGF-p and IL-10 for 6 days [330]. I 
followed the same protocol, immediately after my usual 7-day procedure of iDCs’ 
generation (section 2.2.3.1). I tried several combinations of various TGF-p and IL-10 
doses, ranging from lOng/ml to lOOng/ml for each cytokine to incubate them with 
10^  cells/ml, in order to generate tolDCs. I then incubated these tolDCs with 
allogeneic (CDl®) T cells (1 million/well) and following incubation, I used a T cell 
proliferation assay to determine which dose combination was the most effective to 
generate the tolDCs that would be used to immunise apoE' '^ mice. (Table II.I)
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Table II.I: Diagram of the cell culture plates that were used tc test a series cf ccmbinaticn cf 
doses cf IL-10 and TGF-p in order tc generate tclDCs. iDCs from apcE^ mice were cultured 
with each ccmbinaticn cf cytokine doses in duplicate, for 6 days. Allogeneic (CDl®) T cells 
were then added tc the plates for 72h, after which a I  cell proliferation assay was performed 
to determine which combination of cytokines resulted in the most prominent inhibition of 
proliferation.
lOng/m
1
lOng/m
1
2 0 ng/m
1
2 0 ng/m
1
50ng/m
1
50ng/m
1
lOng/ml
2 0 ng/ml
50ng/ml
lOOng/ml
B
"■ % G F - P
lOOng/ml 1 OOng/ml
lOng/ml Control DCs
2 0 ng/ml Control DCs
50 ng/ml Control DCs
1 0 0  ng/ml Control DCs
2.2.3.6 OxLDL treatment of DCs and T cells
2.2.3.6.1 LDL purification and oxidation
LDL purification from fresh human plasma was carried out by Mrs Sama 
Attiyah in our laboratory. Briefly, human blood (50ml) was collected from healthy 
volunteers and centrifuged for 30min at 13000 x g. The plasma was collected and 
stored at 4°C. Optiprep™ (60% v/v, Axis-Shield Pic, UK) was mixed with the 
plasma in a 1:5 ratio and added to a 6% solution of Optiprep™ in PBS in a 5:6 ratio. 
LDL isolation was carried out by centrifugation at 40000 x g for 4hrs at 16°C in an 
ultracentrifuge (Beckman Coulter Inc, UK). Following centrifugation, the LDL can
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be identified as an orange color band in the middle of the tube. It was removed using 
a syringe, placed in a dialysis membrane (Size 2, pore diameter 14.3 mm, cut-off 12- 
14000 daltons (Da), Medicell International UK) and left to dialyse against PBS for 
48h in the dark at 4°C, while renewing the PBS after the first 24h. Care was taken to 
avoid exposure to light to prevent the oxidation of the particle. The LDL was then 
collected and half of it was oxidised by overnight incubation with 5pM CUSO4 at RT. 
The oxidized product was then filtered through a 0.22 pm filter (Millipore, UK) and 
dialysed again as described above and then stored at 4°C.
The protein concentration of the LDL was determined again by Mrs Sama 
Attiyah using the Pierce Micro BCA”^^ protein assay kit (Thermo Fisher Scientific, 
USA) following the manufacturer’s instructions. Briefly, a series of dilutions for 
BCA"^  ^ were prepared for the standard curve of the assay which detects protein 
concentrations between 0.5pg/ml and 200 pg/ml. The blanks (PBS, 150 pi), the 
standards (150 pi) and the oxLDL samples (150 pi) were pipetted into a 96-well 
plate, 150 pi of working buffer (provided in the kit) was added in each well and the 
plate was incubated for 30min at 37° C. The absorbance was measured at a 
wavelength of 490nm.
2.2.3.6.2 In vitro treatment of DCs and T cells with oxLDL
For the confocal microscopy studies, cultures of DCs were treated with 100 
pg protein/ml of oxLDL for 48h (This amount was determined for oxLDL protein 
concentration). For the experiments that were run to assess the effect of the apoB- 
100-derived peptides on T cells, oxLDL was used alone or in combination with the
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peptides in three concentrations: 1 pg/ml, 10 pg/ml and 100 pg/ml and incubated 
with T cells for 72h.
2,23.1 Co-culture of T cells with apoB-lOO-derived peptide-loaded DCs
For activation and proliferation assays, naïve CD4^ T cells were co-cultured 
with peptide-loaded DCs (see section 2.2.3.4 for peptide loading of DCs) for 72h in 
24-well plates at a density of 1x10  ^T cells per 0.5x10^ DCs per well for 72h in RPMI 
1640 with 10% FCS, Penicillin-Streptomycin-Glutamine (lOOU/ml, lOOpg/ml & 
2mM respectively).
2.2.3.8 T cell culture with apoB-lOO-derived peptides
Twenty four well plates coated with a mix of rat anti-mouse CD3 (Serotec, 
UK) at 1 pg/ml and anti-mouse CD28 (eBioscience, USA) at 2 pg/ml both diluted in 
PBS were used. Plates were then incubated for 3hrs at 37°C. The antibody solution 
was then removed and the plate was washed twice with PBS. Purified CD4^ T cells 
(see section 2.2.3.2 for the isolation protocol, 10^  cells/well) mixed with RPMI 
media containing 0.4ng/ml of IL-2 were then added to the plates and cultured either 
alone or with oxLDL or ConA (concanavalin A) each at 1 pg/ml, 10 pg/ml or 100 
pg/ml for 24h. The apoB-lOO-derived peptides were then added at a concentration of 
25 pg/ml. Control cultures set in parallel consisted of T cells alone, T cells incubated 
with oxLDL only and T cells plus ConA only. All cultures were allowed to 
proliferate for 72h.
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2.2.3.9 Mixed lymphocyte reaction (MLR)
In the MLR, naïve CD4^ T cells isolated from CDl^ mice were co­
cultured with peptide-loaded DCs (see section 2.2.3.4 for peptide loading of DCs) for 
72h in 24-well plates at a density of 1x10  ^T cells per 0.5x10^ DCs per well for 72h, 
similarly to the co-cultures of CD4^ T cells isolated from apoE' '^ mice.
2.2.4 Flow cytometry
2.2.4.1 Immunofluorecence staining for BMDCs
Flow cytometry was used to analyse the effect of peptide treatment on the 
phenotype and activation properties of BMDCs. Adherent DCs were collected by 
gently scraping the flasks. Cells were then collected by centrifugation and adjusted to 
10^  cells/ ml using PBS/1% BSA/0.05% NaNg. Cells were then incubated with rat 
anti-mouse CDl lb antibody in combination with a second rat anti-mouse antibody 
for one of the following markers: CD 11c, CD86 , CD40 and MHC-II (Serotec, UK) 
for 30min at 4°C in the dark. The following combination was also used for some 
experiments: CD4, CD8, CDllc and one of the following: CDl lb, CD40, CD86 , 
MHC-II. Antibodies were used at a concentration of 0.1 pg/10^ cells (appendix I). 
Cells were then washed with PBS/0.5% (w/v) BSA 1% (w/v) and fixed (Ix fixative 
solution, R&D Systems, UK) and stored at 4°C for flow cytometry analysis (see 
section 2 .2 .2).
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2.2.4.2 Immunofluorescence staining to assess T cell activation
Cells were collected and washed by centrifugation with PBS/0.5% (w/v) BSA 
1% (w/v). Cells (10^/ml) were then incubated with rat anti-mouse CD4 antibody in 
combination with one of the following markers: rat anti-mouse CD25, CD69 and 
CD40-ligand (Serotec, UK) in PBS/0.5% (w/v) BSA 1% (w/v) for 30min at 4°C in 
the dark. Antibodies were used at a concentration of O.lpg/10^ cells (appendix I). 
Cells were then washed with PBS/0.5% (w/v) BSA 1% (w/v) and fixed (Ix fixative 
solution, R&D Systems, UK) and stored at 4°C until analysis (see section 2.2.2 for 
analysis).
2.2.5 Morphological analysis of BMDCs
Experiments to study the morphology of DCs when loaded with the peptides 
were carried out by Dr Alexandra Bermudez-Fajardo. Cells (10^/well) were seeded 
on 8-well Permanox plastic chamber slides (Nalge NUNC International Corp., 
Rochester NY) for 48 hrs and then treated with peptides and/or EPS as described 
above (section 2.2.3.4). On the day of the analysis the supernatant was removed and 
the cells were washed with PBS twice for 5min and then fixed using 1% (v/v) 
Paraformaldehyde (Sigma-Aldrich, UK) in PBS, pH 7.4 for 30min and then 
transferred to slides for staining.
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2.2.5.1 H&E staining for light microscopy
Slides with adherent cells were sequentially treated with 100%, 70% and 50% 
(v/v) ethanol each for 1 minute. The cells were then re-hydrated in dHiO for 1 
minute, incubated with the Ehrlich’s Haematoxylin (GURR-microscopy materials, 
BDH chemicals, Poole, UK) for 15 minutes followed by a quick wash with tap water 
for 1 minute to remove the excess of dye. Differentiation was carried out using 1% 
acid alcohol (1% HCl in 70% ethanol) for 5 seconds. The slides were then rinsed in 
tap water for lOminutes and then transferred to 1% Eosin (GURR microscopy 
materials, BDH chemicals, Poole, UK) for 2 minutes. The excess of staining solution 
was removed by washing the slides twice with tap water for 5 minutes. The slides 
were then dehydrated in 85% (v/v) ethanol followed by 100% (v/v) ethanol for 30 
seconds, and rapidly mounted with VectaShield permanent mounting medium 
(Vector Laboratories Inc. Burlingame, CA) using 24x24mm coverglasses (Menzel- 
Glaser, bought from Fisher). The slides were allowed to dry for 1-2 days before 
microscopy analysis. Morphology was assessed using a Leica (Germany) light 
microscope. Pictures were taken with x40 and xlOO magnification lenses.
2.2.6 Functional assays
2.2.6.1 ELISA
Supernatants were collected from cell cultures and their cytokine content was 
assessed by ELISA as follows. Commercial ELISA kits were used to detect murine 
IL-2, IL-10 and the IL-12 (R&D Systems, UK). Detection limits of the assay were
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15.6 pg/ml to 1000 pg/ml for IL-10 & IL-2 and 7.8 pg/ml to 500 pg/ml for IL-12. 
Standard curves for the assays can be seen in Figure 2.1 - Figure 2.6. Briefly, plates 
were coated with Assay Diluent (50pl/well) and the standard, the control or the 
samples (50pl/well) were assayed in triplicate and incubated for 2hrs at RT. The 
wells were then washed five times with the wash buffer provided in the kit before 
adding the conjugate (lOOpl/well). Plates were then incubated for another 2hrs at RT 
and then washed for five times. The substrate solution (lOOpLwell) was added and 
incubated for 30min in the dark. The stop solution was added (lOOpl/well) and the 
plate was read using a microplate reader as described previously (see section 2 .2 .2).
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Figure 2.1: Standard curve (a) of absorbance against concentration for IL-2 in the ELISA
assay. The assay was performed in the supernatants of DCs incubated with peptides P2 and
P45 using the R&D kit.
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Figure 2.2 : Standard curve (b) used in the ELISA assay for the detection of IL-2. The ELISA 
R&D kit was used to examine the supernatants of DCs incubated with P210.
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Figure 2.3: Standard curve (a) for the detection of IL-10 in the ELISA assay. The
supernatants of DCs incubated with peptides P2 and P45 were examined with the R&D kit.
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Figure 2.4: Standard curve (b) for the detection of IL-10 using the ELISA kit by R&D in the 
supernatants of DCs incubated with peptide P210
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Figure 2.5: Standard curve (a) used for the ELISA detection of IL-12 in the supernatants of
DCs incubated with P2 and P45, obtained using the R&D kit.
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Figure 2.6: Standard curve (b) for IL-12 using the ELISA kit from R&D, in order to detect 
levels of the cytokine in supernatants of DCs incubated with P210.
2.2.6.2 Assessment of the expression of cytokines IL-10, IL-12 and MMP-2, 
MMP-9 in peptide loaded-DCs
2.2.6.2.1 RNA extraction
RNA was extracted from peptide-loaded DCs using the RNeasy mini kit from 
Qiagen, UK following the manufacturer’s instructions. Cells were gently scraped 
from the eell culture plate and plaeed in an Eppendorf tube. Lysis buffer from the kit 
was added to the eell pellet (600pl). The lysis buffer contains p-ME (lOpl/ml) and a 
guanidine isothiocyanate buffer that inactivates RNases and stabilizes the mRNA. 
The mix was centrifuged at maximum speed for 2 min to achieve homogenation and 
ethanol (70%) was added in an equal volume to provide the appropriate binding 
conditions. The solution was mixed well by pipetting and then was transferred to an 
RNeasy mini eolumn, which was placed in a 2 ml collection tube. The RNeasy
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column consists of a RNeasy silica-gel membrane that binds RNA molecules, larger 
than 200bp long. The tube was centrifuged at 8500 x g for 15 sec and the flow 
through was discarded before buffer RWl was added to the mini column. Another 
centrifugation followed at 8500g for 15 sec to wash the column. The column was 
transferred to a new tube, buffer RPE (500pi) was added onto the column and the 
tube was centrifuged (8500 x g, 15 sec). The process was repeated once more with 
the centrifugation time increased in 2 min to dry the membrane. The column was 
then placed in a new collection tube, centrifuged at full speed in the microcentrifuge 
for Imin to ensure all ethanol was removed and transferred in a new collection tube 
for elution. RNase-free water (30pl) was added onto the membrane, the column was 
left to stand for 15 min and then it was centrifuged at 8500 x g for 1 min. This step 
was repeated once more to elute all the RNA.
Total RNA was quantified using the Nanodrop System (Agilent Technologies Ltd, 
UK) by examining just Ipl of the samples. The RNA concentration was measured in 
ng/pl using dEiiO as a blank by the Nanodrop technologies software, version 3.0.0. It 
was stored at -80°C to be used in the RT-PCR in order to obtain DNA.
2.2.6.2.2. Complementary DNA (cDNA) synthesis
Total cDNA was synthesized by reverse transcription reaction (RT) using Ipg 
of the extracted RNA mixed with Ix 1®‘ strand buffer, deoxyribonucleotide 
triphosphate (dNTPs) (ImM), pd(N)6 nucleotides (2.5ng/pl), dithiothreitol (DTT) 
(0.0 IM) (all reagents from Invitrogen, UK). The reaction was first incubated at 80°C 
for 4min and then RNase inhibitor (RNasin) (1.5U/pl) and moloney murine leukemia
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virus reverse transcriptase (MMLV-RVT) (lOU/pl) (both from Invitrogen) were 
added and the mix was incubated as follows:
10 min at 25°C 
40 min at 42°C 
2 min at 90°C 
overnight at4°C
The samples were stored at -20°C until they were used in the PCR to amplify the 
DNA.
2.2.6.2.3 PCR
Analysis of gene expression for cytokines IL-10 & IL-12b and MMP-2 and 
MMP-9 was carried out using PCR. Total cDNA from the cDNA synthesis (5pi) was 
added to the PCR MasterMix® (Ix) (Invitrogen, UK) and mixed with the 
corresponding primers (Table II.II) (0.5pM each).
Table II.II: Forward and reverse primers used in the PCR to detect mRNA encoding murine
Gene Forward primer Reverse primer
IL-10 CTT OCA CTA CCA AAG CCA CA TTT TCA CAG GGG AGA AAT CG
IL-12 AAG GAA CAG TGG GTG TCC AG CAT CTT CTT CAG GCG TGT CA
MMP-2 ACC AGA ACA CCA TCG AGA CC CCA TCA GCG TTC CCA TAC TT
MMP-9 CGT CGT GAT CCC CAC TTA CT AGA GTA CTG CTT GCC CAG GA
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The PCR cycling conditions were as follows:
IX 94°C, 4 min 
35X 94°C, 10 sec
55°C, 30 sec 
72°C, 2 min 
IX 72°C, 10 min 
4°C, overnight
The samples were stored at -20°C to be later examined with gel electrophoresis. 
2.2.6.2.4 Gel electrophoresis
The PCR produets (10 pi) were mixed with 2 pi of 6x loading dye (Promega, 
UK) and loaded on to 1% agarose gels (see section 2.1.4 for gel composition). A 
lOObp DNA ladder (Invitrogen, UK) was loaded too and the gels were run in TBS
buffer at lOOV for approximately 25min. Bands were visualized using a UV
transilluminator and the Gene Genious bioimaging system (section 2.2.2). 
Densitometric analysis was carried out using the Gene Tools software (see section 
2.2.2). Values were normalized against GAPDH mRNA signal levels as GAPDH 
was used as the house-keeping gene.
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2.2.6.3 T cell proliferation assay
T cell proliferation can be measured in several ways, including radioactive 
assays where [^H]-thymidine or bromodeoxyuridine (BrdU) is incorporated to newly 
synthesized DNA; a colourimetric quantitative assay (MTT) that uses the metabolic 
activity of the proliferating cells to give color formazan products and flow cytometry 
to measure for example, the number of CD38 positive T cells (CD38 is a regulator of 
activation and proliferation) [331]. I choose the CyQuant® Cell proliferation assay 
which is a simple, non-radioactive and as sensitive as the other assays. This assay is 
based on the binding of a fluorescent dye to nucleic acid in the proliferating cells. 
The resulting fluorescence is proportional to the amount of cells present in the 
culture. T cells and peptide-loaded DCs were co-cultured for 72h as described in 
section 2.2.3.7. T cells were then isolated, by gently washing the culture with RPMI- 
1640 media, harvested and frozen at -80°C until further analysis. T cell proliferation 
was examined using the CyQuant Cell Proliferation Assay kit (Molecular Probes, 
Invitrogen) following manufacturer’s recommendations. The CyQuant GR dye (that 
binds to nucleic acids in order to measure nucleic acid expansion) was diluted in 
CyQuant cell lysis buffer. The diluted dye was then added to the cells that were 
placed in flat bottom 96-well plates. The absorbance was read using a Spectra Max 
Gemini XS fluorometer (Molecular Devices, U.S.A) using an excitation wave length 
of 485nm and measured at 538nm with a cut-off at 515nm. The analysis was 
performed using the SoflMaxPro software (Molecular Devices, U.S.A). Dilutions (2- 
fold) of known numbers of T cells ranging from 2 0 x 1 to 0.31x10"  ^cells were used 
as a standard for the assay(Table II.III).
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Table II.Ill: The 2-fold serial dilutions of known numbers of cells were used in triplicate to 
construct the standard curve for the T cell proliferation assay.
[# cells] Vol. (nl)
Cells
Vol. (pi) CyQUANT 
GR sol.
20.00x10'*
200 0
10.00x10'* 100 100
5.00x10'* 100 100
2.50x10'* 100 100
1.25x10'* 100 100
0.62x10'* 100 100
0.31x10'* 100 100
0.00x10'* 0 100
From pure
Discard 100pl
2.2.7 Immunostaining of DCs for confocal microscopy study
Round coverslips (Menzel-Glaser, Fisher, UK) were sterilised in 96% ethanol 
and then dried in a culture hood. The coverslips were coated with poly-L-lysine 
(Sigma, UK) by adding 200pl of poly-L-lysine (0.1% w/v in H2O) in the middle of 
each coverslip and leaving them for 2-3h to dry inside the culture hood, before they 
were transferred into the wells of a 6-well plate. The excess of polylysine was 
removed by deeantation, the coverslips were washed with sterile dH20  (just by 
submerging them into a sterile container with sterile water). The coverslips were then 
placed in standing position (in a sterile plate) and allowed to dry before they 
were placed into 6-well TC plates. Following the generation of DCs from bone
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marrow cells and the histopaque purification described in section 2.2.3.1, DCs were 
placed on the coverslips at a density of 10^  cells in a drop of Advanced RPMI-1640 
media (lOOpl). The cells were left to adhere on the coverslips for 4h in 37°C, 
5%C02. Then more media (2ml, supplemented with FCS, PSG, P-ME, mrGM-CSF 
and mrIL-4 as described in section 2.2.3.1) was added to the wells together with the 
Alexa-488-labelled-P45 (5pg/ml) and incubated for 6, 12, 24 or 48h. DC-coated 
coverslips were then washed twice with PBS before fixation with ice-cold methanol 
(Sigma, UK) at -20°C for 5min. After a 5 min wash with PBS, the coverslips were 
removed from the culture plate and a circle was drawn around the cell population 
using a PAP pen (Daido Sangyo, Tokyo). The coverslips were returned to the plate 
and for those that were going to be used in the study of the intracellular markers 
lysosome Associated Membrane Protein-1 (LAMP-1) and transferrin receptor 1 
(TfR-1), were permeabilised using 0.1% v/v Triton/PBS (Sigma, UK) for 30min at 
RT in a humidified chamber.
Following washing, cells were first incubated with 20% goat plasma diluted 
in 0.025% Triton/TBS for 30min and then with Seroblock (a rat monoclonal antibody 
that binds the FcRyll and the FcRylll receptors on the cell surface, Serotec, UK) for 
another 30min at RT to block non-specific binding of antibodies. The primary 
antibodies raised against the intracellular markers LAMP-1, TfR-1 (both from 
Abeam, UK) and the extracellular DC markers CDllc, MHC-I (Serotec, UK), MHC- 
II (Abeam, UK) as well as their isotypes, diluted in 5% goat plasma dilution with 
0.025% Triton in TBS, were added to the cells and incubated overnight at 4°C. 
Untreated cells were used as negative controls and oxLDL-treated DCs were used as 
a positive control for MHC expression on DCs. On the following day, the cells were 
washed four times with PBS for lOmin in the dark and then secondary antibodies
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(Goat-anti-Hamster Alexa Fluor 488, Goat-anti-Rat Alexa Fluor 568, Molecular 
Probes) were added and incubated for 30min at 37°C.
The cells were washed again with PBS four times for lOmin in the dark and 
then the nuclear staining dye, DRAQ5 (40|xM, Biostatus Ltd, UK) in PBS was added. 
Cells were incubated for 30min in the dark and then washed first with PBS for 5min 
and then with tap water before the coverslips were dried. A drop of FluorSave 
(Calbiochem, EMD Chemicals Inc, Germany) was added to mount each coverslip on 
a microscope slide. The coverslip edges were sealed with nail varnish and the slides 
were kept in the dark at 4°C to later be examined by the Confocal Laser Scanning 
Microscope (CLSM), (See section 2.2.2).
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2.2.8 In vivo experiments
2.2.8.1 Immunisation protocol
Male apoE" " mice (7 weeks old) were immunised subcutaneously with PBS 
or iDCs in PBS or tolDCs in 200 pi of PBS (2x10^ cells/ injeetion as reeommended 
by Ludewig et al, 1998 [332] at weeks 1,9,  11 of age (Figure 2.7). Prior to each 
immunisation, blood was collected from the mouse tail artery in order to study the 
plasma lipid levels. Mice were terminated at week 16.
Effect of tolDCs in atherosclerosis
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Figure 2.7: The immunization protocol that was followed for my in vivo experiments.
2.2.8.2 Tissue processing
Upon termination, the spleens of the immunized animals were colleeted and 
dislodged to obtain the splenocytes. Contaminating erythrocytes were removed with 
the Mouse Erythrocyte Lysing kit (R&D Systems, UK) as previously described and
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the remaining cells were used for in vitro cytokine secretion analysis, FoxP3 mRNA 
expression analysis and for the analysis of Tregs using flow cytometry.
Blood was collected from the abdominal aorta to assess plasma lipid profile 
and cytokine levels. Upon collection in heparinised capillary tubes, blood was 
centrifuged for 30mins at full speed in a microcentrifuge to separate the plasma 
which was then collected and stored at -20° C The heart and the aorta of the 
vaccinated animals were perfused for 5min with PBS to remove the blood and then 
extracted for histological analysis of the atherosclerotic plaques. The tissue was fixed 
in 10% neutral phosphate buffered formalin for a minimum of 1 week. The amount 
of fixative used was equal to five times the volume of the specimen.
2.2.S.3 ELISA to measure cytokine levels in the plasma of the immunised 
animals
Plasma from the immunised animals was used for the analysis of the 
secretion of IL-10 and IFN-y using a commercial ELISA from Peprotech (catalogue 
numbers: IL-10 900-K53, IFN-y 900-K98). Detection limits of the assay were 15.6 to 
2000 pg/ml for IFN-y and 23 to 3000 pg/ml for IL-10. The standard curve for IFN-y 
can be seen in Figure 2.8 and the standard curve for IL-10 in Figure 2.9.
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Figure 2.8: Standard curve of absorbance against concentration for the IFN-y ELISA by 
Peprotech.
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Figure 2.9: Standard curve of absorbance against concentration for the IL-10 ELISA by 
Peprotech.
Plates (96-well) were coated with the capture antibody (0.2pg/ml for IL-10 
and 0.1 pg/ml for IFN-y) diluted in buffer (see section 2.1.4 for buffer composition) 
and left to incubate overnight at RT. The wells were washed with wash buffer 
(300pl/well, see 2.1.4 for buffer composition) four times and incubated with the
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blocking buffer (see 2.1.4 for buffer composition) (300pl/well) for Ih at RT. The 
wells were washed again and the standards or the controls or the samples 
(lOOpl/well) were assayed in triplicate for 2hrs at RT. In the case of the samples, 2pl 
of plasma were diluted in 9 8 pi dilution buffer. Following another wash, the detection 
antibody was added (0.05pg/mlin dilution buffer) and left to incubate for 2hrs at RT. 
Avidin- horseradish peroxidase (HRP) conjugate (lOOpl/well) was added following 
washing and incubated for 30min at RT. As a substrate for the detection of avidin- 
HRP, the 3,3,5,5’-tetramethylbendizine dihydrochloride tablets (TMB, Sigma) were 
used. In every well, 0.12mg of TMB diluted in 0.05M phosphate-citrate buffer & 1:6 
30% (w/w) hydrogen peroxide were added. To stop the reaction, H2SO4 (0.05M, 
Sigma) was used and the plates were read immediately in a plate reader, as described 
in section 2 .2 .2 .
2.2.S.4 Purification of Treg subpopulations from the splenocytes of immunized 
animals
Leucocytes were isolated from the spleens of the immunised animals as 
described in section 2.2.3.2. Fifteen million cells were placed per well in culture to 
assess cytokine secretion (see section 2.2.S.5) Cells were also used to purify the 
CD4^ and CDS^ T cells. T cell purification was performed using a cocktail of 
antibodies and goat anti-rat coated magnetic beads as described in the section 2.2.3.2. 
Five millon cells of each purified population were frozen at -20°C for subsequent 
RNA extraction (see section 2.2.8 .7) and the rest were stained for flow cytometry 
analysis using antibodies against CD4 or CD8, CD25 and FoxP3 as described in 
section2 .2 .8 .6 .
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2.2.8.S ELISA to measure cytokine secretion levels from the splenocytes of 
immunized animals
Leukocytes extracted from the immunised animals were eultured in complete 
RPMI-1640 media in a density of 5x10^ cells/ml for 72h. lonomycin (500ng/ml, 
Sigma-Aldrich, UK) and phorbol 12-myristate 13-acetate (lOng/ml PMA, Sigma- 
Aldrieh, UK) were added to the media to stimulate cytokine seeretion. The 
supernatants were then collected and analysed by ELISA to detect the production of 
IL-10 and IL-4 (Th2 response assoeiated) and IFN-y (Thl responses). The ELISA 
assay was performed as described in section 2.2.8.3. Standard curves for each 
cytokine can be found in Figure 2.10, Figure 2.11 and Figure 2.12 Detection of IL-4 
was carried out using a eommercial ELISA (900-K49, Peprotec, UK) with a 
detection limit of 15.6 to 2000 pg/ml. The supernatants (samples) were plaeed in the 
assay wells undiluted.
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Figure 2.10: Standard curve that occurred from the ELISA assay for IL-4 using the 
Peprotech kit.
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Figure 2.11: Graph showing the standard curve for IL-10 using the ELISA kit by Peprotech.
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Figure 2.12: Standard curve of absorbance against concentration for IFN-y using the ELISA 
kit by Peprotech.
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2.2.S.6 Labelling of Treg subpopulations for flow cytometry analysis
Following purification of the CD4^ and the CD8^ T cell population, cells 
were washed with PBS/1% BSA/0.05% NaNg and 10^  cells were incubated with rat 
anti-mouse CD4 and rat anti-mouse CD25 (Serotec, UK) in PBS/1% BSA (w/v) for 
30min, on ice in the dark. Antibodies were used at a concentration of lpg/10^ cells. 
Cells were then washed with 0.5% BSA (w/v) in PBS and fixed with PBS/1% 
formaldehyde (FH, Sigma, UK) for 20min at RT in the dark.
Following fixation, the cells were washed with the PBS/BSA/NaNg buffer 
(see section 2.1.4 for buffer composition) and then washed twice with 
permeabilisation buffer (see section 2.1.4 for buffer composition) and resuspended in 
1ml of the latter for lOmin. Unspecific binding was blocked by incubating the cells 
first with 5% mouse plasma and then with Seroblock (Serotec,UK), both diluted in 
permeabilisation buffer for 20min each. Intracellular staining was carried out with 
anti-mouse FoxPS diluted in permeabilisation buffer (lOOpl) for 30min in the dark. 
FoxP3 was used at a concentration of 0.5 pg/ 10^  cells. Finally, the cells were 
washed first with permeabilisation buffer and then with PBS/BSA/NaNg buffer and 
resuspended in PBS/1 % FH for analysis (see section 2.2.2).
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2.2.S.7 Analysis of the FoxP3 mRNA expression expressed by CD4  ^and the
CD8  ^T cells
2.2.8.7.1 RNA extraction
RNA was extracted from CD4^ and CD8^ T cells by Mr Rueban Anicattu 
Issac in our laboratory from frozen cells using the Ultraspec-II RNA isolation system 
by (Biotecx, Ams Biotechnology Europe Ltd), following the manufacturer’s 
instructions. This system purifies total RNA from cells with a specific RNA binding 
resin in conjuction with some very effective denaturing agents. These are a 14M 
solution of guanidine salts and urea (Chaosolv) in conjuction with phenol. A specific 
RNA binding resin is also used to purify total RNA.
Briefly, the cell pellets where lysed in 1ml Ultraspec”^^ RNA by repetitive 
pipetting. The homogenate was left at 4°C for 5min to allow the dissociation of the 
nucleoprotein complexes before 0.2ml of chloroform were added and the samples 
were shaken for 15 sec and placed on ice for 5min. The mix was centrifuged at 
12000 X g for 15 min. The upper aqueous layer, containing the RNA, was carefully 
collected, placed in a new tube and mixed with half volume of isopropanol, in half of 
the volume of the layer, and then with RNATack"^^ Resin, in 0.05 x the volume of 
the mix. The final mix was vortexed for 30sec and then centrifuged down for Imin. 
The pellet was washed twice with 1ml of 75% ethanol for 30sec. Ethanol was 
removed by evaporation before the pellet was diluted in diethyl pyrocarbonate- 
treated (DEPC) treated water and quantified using the Nanodrop System as described 
in section 2.2.2.
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2.2.S.7.2 cDNA synthesis
cDNA was synthesized by Mr Rafeezul Mohamed in our laboratory using a 
cDNA synthesis kit from Bioline, UK. RNA (l|ig) was mixed with Ijxl of dNTPs 
(lOmM) and Igl of oligo (dT)is primer mix, DEPC water to lOpl and incubated at 
65°C for lOmin. Then, it was placed on ice for 2min before 4pl of 5x RT buffer, Ipl 
of RNase inhibitor (lOU/pl), 0.25pl of Reverse Transcriptase (200U/pl) and 4.75pl 
DEPC water were added. The mix was incubated for 60min at 37°C. The reaction 
was terminated by incubating at 70°C for 15min and then at 4°C overnight.
2.2.S.7.3 Detection of FoxP3 mRNA
The expression of the transcription factor FoxP3 was assessed using PCR. 
Total cDNA (2 pi) that was synthesized in the RT reaction was added to Ix PCR 
mastermix (10 pi) (Invitrogen, UK) and mixed with 1 pi of each of the corresponding 
primers (Table II. IV) and 6 pi of RNase free water.
Table II.IV: Forward and reverse primer used in the PCR to detect mRNA encoding FoxPS. 
Their working concentration was 20pM.
Gene Forward primer Reverse primer
FoxP3 CAA CCT AGC CGC AAG ATG AA CCA GAT GTT GTG GGT GAG TG
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The PCR cycling conditions were as follows: 
FoxPS
IX 95°C, 5 min
35X 95°C, 1 min 
55°C, 1 min 
72°C, 1 min 
IX 72°C, 5 min 
4°C,oo
2.2.S.7.4 Gel electrophoresis
See section 2.2.6.2.4.
2.2.8.8 Assessment of the plasma lipid profile in immunized animals
Blood was taken from the tail artery of the mice prior to each immunization. 
At termination, blood was taken from the abdominal aorta. The blood was in all 
cases centrifuged for 30min at 13000 x g to separate the plasma from erythrocytes. 
The plasma, which formed the top layer after centrifugation, was removed and stored 
at -20°C.
In order to evaluate the effect of the immunisations on the plasma lipid levels, 
I compared plasma samples collected before the first immunization (i.e. before the 
treatment started) with samples collected at termination (i.e. end of experiment). The 
analysis was carried out using 20pl of plasma diluted in 60pl of saline solution (1:4)
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and every sample was examined in duplicate for the triglycerides, total cholesterol, 
LDL and HDL levels using commercial kits from Instrumentation Laboratory, UK. 
The analysis was performed by Dr Max Wong using the ILab 650 instrument 
(Instrumentation Laboratory, UK) and the ILab 650 software, version 1.1. ILab 650 
is an automated clinical chemistry analyzer that uses photometry for in vitro 
quantification of analytes in biological fluids.
2.2.S.9 Histological analysis of paraffin embedded sections
2.2.8.9.1 Tissue fixation and cutting
The heart and the aorta of the animals were extracted following perfusion 
with PBS and fixed in 10% neutral phosphate buffered formalin for a minimum of 1 
week as described in section 2.2.8.2.
To process the fixed heart to wax blocks. Tissue Tec plastic cassettes (Sakura 
Finetec, USA) were used. In order to reach the aortic sinus which was my area of 
study, 2/3 of the distal segment of the heart were cut off. The cut was performed in a 
30° right angle to the horizontal axis of the heart, in an anterior view, to match the 
angle in which the aorta enters the heart (Figure 2.13) and to ensure that a cross- 
section of the three valves will be found in the same geometric plane [333]. The 
proximal segment of the heart was then placed in the cassette pointing up in order to 
carry out the sectioning from distal to proximal. The cassettes were loaded in a 
basket containing 10% neutral phosphate buffered formalin and the basket was 
attached to the automatic tissue processor (Histokinette, British American Optical
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Co. Ltd., Slough). The histokinette was set to process the tissues according to the 
schedule presented in Table II. V
Right
atrium
Left atrium
Left
ventricle
Right
ventricle
Figure 2.13: Figure of a murine heart. The grey line that is drawn across indicates the area 
where the first cut was made to separate the proximal part of heart that was going to be 
processed in the histokinette. The cut was made close to the aortic sinus in order to later 
achieve wax-embedded sections from that area. Furthermore, it was performed in a 30° right 
angle to the horizontal axis of the heart, in an anterior view, to match the angle with which 
the aorta enters the heart.
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Table II.V: Tissue processing in the histokinette
Dehydration 70% ethanol 96 2hrs
85% ethanol 96 2hrs
95% ethanol 96 2hrs
100% absolute alcohol I 2hrs
100% absolute alcohol II 2hrs
100% absolute alcohol III 2hrs
Clearing Toluene I 2hrs
Toluene II 2hrs
Impregnation Parafin wax I 
(Fibrowax, BDH Ltd.,UK)
2hrs
Paraffin wax II 2hrs
When processing was completed, the specimens were transferred from the 
second wax basket of the histokinette to the wax bath of the Blockmaster II 
embedding station (Raymond Lamb). One by one, the cassettes containing the 
specimens were transferred to a grill to drain and the tissue was moved, using heated 
forceps, into melted wax on a Tissue Tec metal base (Sakura Finetec, USA). Care 
was taken to orientate the heart properly so that its distal part was found on the base 
of the mould, i.e. the surface to be cut. The plastic cassette was used as a lid and the 
mould was left on a cold plate to solidify the wax. Once the wax was cold, the blocks 
were taken off the metal base.
The samples were then processed in the microtome (Reichert Jung 2040 
Autocut, Rankin Biomedical, USA) and trimmed while checking the block under the 
microscope regularly to check when the area of interest, the aortic sinus, would be
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reached. When the valve cusps started to appear, there was the sign that the aortic 
sinus had been reached and when all three of them were visible, the block was 
moved to a tray of iced water for 10 min with the trimmed tissue facing down. This 
helps in obtaining good quality sections as the tissue remains firm and that makes it 
more possible to maintain the sections intact. Tissue sections (5pm thick) were then 
cut with a new blade until the valve cusps disappeared and the sections were 
transferred with forceps to float on warm dH20  in a water bath that had been pre­
heated at 50°C. Sections were then mounted on Superfrost Plus(+) slides (Fisher, 
UK) and the slides were left for 1 min on a hot plate to dry and then placed in a dry 
incubator at 3>TC for 24h before proceeding to staining.
2.2.8.9.2 Haematoxylin and eosin staining of fixed tissue sections
H&E was used as a simple staining method to visualize the atherosclerotic 
plaques in the aortic sinus and measure plaque size. Haematoxylin stains the cell 
nuclei blue and eosin stains the cytoplasm pink. The tissue was dewaxed with xylene 
for 3min and gradually rehydrated with 100%, 70% and 50% (v/v) ethanol. Then 
tissue was washed with dHiO and stained with heamatoxylin (GURR microscopy 
materials, BDH chemicals, Poole, UK) for 15min. The specimens were rinsed under 
tap water, incubated with 1% acid alcohol (1% HCl in 70% ethanol) for lOsec to 
remove the haematoxylin background and then they were placed in tap water for 
lOmin to render alkaline. The next step was to counterstain them with 1% Eosin 
(GURR microscopy materials, BDH chemicals, Poole, UK) for 2min, wash them 
with tap water for Imin and perform serial 30sec dehydrations using initially 85%
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and then 100% (v/v) ethanol. They were then cleared with xylene 1 and then xylene 
2 for 30sec with each and mounted with D.P.X (Sigma, UK). Pictures were taken at 
x4 magnification in a light microscope (Leica, UK) using the appropriate software 
(see section 2.2.2).
2.2.S.9.3 Morphometric analysis
Images of the stained tissue sections were taken with a Leica microscope 
connected to a Leica camera using the 4x objective and analysed using the Image J 
software (Wayne Rasband National Institutes of Health, USA, Version 1.44p). To 
quantify the size of the plaques in the aortic sinus, a measuring calibration graticle 
was used to set up the scale by capturing a picture of the graticule using the same 
magnification as for the images taken from the aortic sinus.
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CHAPTER 3 CONFOCAL LOCALISATION OF apoB- 
100-DERIVED PEPTIDES WITHIN BMDCs.
3.1 Introduction
DCs are responsible, amongst others for stimulating naïve T cells and in this 
way help in the initiation of primary immune responses. More specifically, DCs 
present molecules to other cells that have the ability to detect antigens. In sites where 
an infection is taking place, iDCs collect pathogenic antigens and then present 
antigen peptides on their MHC molecules to T cells in the secondary lymphoid 
tissues. When this complex binds to the TCR, T cell activation, clonal expansion and 
cytokine secretion occurs. Inflammation signals in DCs lead to a decrease of antigen 
uptake and surface MHC-II molecule retrieval [334]. Furthermore, the extracellular 
material that has been collected is broken down into peptides that on a later stage are 
loaded onto MHC-II molecules [335]. Other antigens activate DCs by binding to 
their TLRs and this activation leads to their maturation, a process that is driven by 
inflammatory stimuli or microenviromental factors like bacterial products such as 
LPS and locally produced cytokines. When maturation occurs, DCs stop picking up 
antigens and commence to up-regulate adhesion molecules and at the same time 
migrate to lymphnodes. During maturation and migration, they down-regulate their 
endocytotic activity in accordance with the expression of MHC molecules, as well as 
co-stimulatory molecules [336].
In order to address important remaining questions related to the role of the 
apoB-100-derived peptides in immunoregulation of atherosclerosis I decided to first
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investigate their uptake and intracellular processing by DCs. I focused the study on 
investigating the endocytic and phagocytic pathways linked to antigen processing in 
DCs as well as the antigen presentation through the MHC-I and MHC-II complexes 
by using fluorescently labelled antibodies to tag the organelles and the apoB-100- 
derived peptides.
In order to track the uptake and processing of the apoB-100 peptides, I chose to 
study P45, a representative peptide with strong atheroprotective properties based on 
previously published observations by Jan Nilsson’s group [294, 337]; the peptide 
was chemically synthesized by Innovagen AB, Sweden and tagged to Alexa 488 
(section 2.1.1.2). The peptide was conjugated with this fluorescent tag that does not 
interfere with the peptide uptake and processing. A similar approach has been 
already used by Bandholtz et al [338] that used Texas Red to label the human 
cathelicidin LL37 and examine its uptake by DCs in vitro and Dela Cruz et al. [339] 
labelled the extracellular domain of the glucoprotein HER2/neu with the green 
Alexafluore 488. The use of peptides or proteins (i.e. GFP) as a tag would be less 
favourable as they are prompt to degradation in the endosomes as part of the 
proteolytic process or inactivated due to the acid environment inside the endosome 
[340]. The tagging system would also needed to be suitable for cell fixation.
The Alexa-labelled p45 (5 pg/ml) was co-eultured with iDCs for 6h, 24h or 
48h and immunofluorescence was used to assess the location of the tagged 
fluorescent peptide in the cells as described in section 2.3.7; the results were 
visualised using confocal microscopy (section 2.3.2). I first searched if p45 is located 
intracellularly by examining DCs that had been also labelled with anti-CD lie . I then 
looked for p45 in the DC lysosomes that were marked with a fluorescent antibody for 
the intracellular marker for lysosomes LAMP-1 and within the DC endosomes that
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were marked with another fluorescent antibody for the endosomal marker transferin 
receptor 1 (TfR-1). Finally I assessed if the peptide co-localises with the MHC-I or 
the MHC-II complex on the plasma membrane of DCs.
3.2 Localisation of the apoB-100-derived peptide, P45 within DCs
As described, my first step was to localise the peptide P45 within the DCs, ie 
to check that it is internalised by the cells. The Alexa-488-labelled p45 (green) was 
incubated with iDCs for 24h or 48h to compare what happens with the peptide 
localisation over time. In order to clearly visualise the outline of the individual cells, 
I used bright field microscopy in combination with fluorescence microscopy. 
Pictures of P45-loaded DCs using bright field and fluorescence microscopy can be 
seen in Figure 3.1.
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Staining for the membrane marker CD lie  on DCs was another, additional 
way to co-localise the presence of p45 within the cell. CDllc is a phenotypic 
myeloid marker expressed on all subtypes of murine DCs [341, 342] . Labelling for 
CDllc also verified that the cells that have been generated and used in my confocal 
experiments are DCs.
The antibody for CDllc was labelled with an Alexa-568 red dye and the 
incubation time of the cells with the peptide was 6h, 24h and 48h (Figure 3.2). 
CDllc staining was also found localized within the cells, as this surface marker is 
being synthesised in the ER and exported through the Golgi system to the surface of 
the cell. There are areas where it co-localises with the peptide and this supports the 
presence of the peptide within these organelles.
1 observed that the peptide had been up-taken only by a small number of DCs 
in the culture (data not shown). Furthermore, the peptide appeared to be distributed 
in vesicular patterns within the DC and led me to investigate its localization within 
endosomes and lysosomes in order to examine changes in its distribution within 
subcellular compartments (sections 3.4 and 3.5).
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3.3 P45 was found in the endosomes marked with TfR-1.
APCs sample their extracellular environment for antigens mainly through 
endocytosis and secondly through phagocytosis and macropinocytosis [343]. 
Endocytosed antigens are degraded by proteases in endosomes/lysosomes. Initially, 
the endocytosed antigens arrive in early sorting endosomes. During the recycling of 
the endocytosed plasma membrane those early endosomes become late endosomes 
[344, 345]; specific proteins of the membrane stay in the endosome during the 
endosomal maturation process. During this phase, a continuous build-up of luminal 
vesicles (LVs) occurs and that is the reason why late endosomes are also known as 
multivesicular bodies (MVBs). When late endosomes fuse with lysosomes, proteins 
of the membrane remaining in the LVs are targeted for degradation [346].
More specifically, processing of antigens inside the endocytic pathway includes 
unfolding, proteolysis, and reduction of the antigen. Inside the acidic organelles of 
the endocytic pathway, processes like antigen unfolding or dénaturation [347], 
activation of acidic proteases [348], and selection of epitopes that bind to MHC-11 
alleles [347] are promoted.
Since endosomes are the main reservoir of peptide antigens once these have 
been internalised by the cell as they contain proteolytic enzymes required to break 
down the proteins in to peptides, 1 investigated whether P45 co-localises with 
endosomes in P45-loaded DCs. In order to achieve this, endosomes were stained 
with a fluorescently-labelled (red Alexa 568) antibody that recognises the transferin 
receptor 1 (TfRl). TfRl participates in the iron uptake into endosomes. More 
specifically, after binding of transferrin to TfR-1, the complex is endocytosed
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through a clathrin dependent mechanism into endosomes. The low-pH environment 
inside lysosomes leads to iron release (acidification) and the procedure ends with 
TfRl recycling back to the plasma membrane usually through exosomes, with the 
loss of affinity of transferrin for its receptor [349].
Incubation time of the DCs with the P45 was 6h, 24h and 48h. Unfortunately, 
data obtained for 24h were not of good quality. When incubated for 6h and 48h, P45 
(green) co-localised sometimes intracellularly with TfR-1 (red), the marker for 
endosomes (the cell nuclei were stained in blue) (Figure 3.3). Endosomes appeared 
to be located close to the nuclei, which could be revealing their approach to the ER in 
order for the peptide to bind with the MHC-I.
Similar approaches were taken by Dela Cruz et al. [339] who used the rat 
monoclonal anti-CD71 (BD Biosciences) which binds to the early endosome marker 
TfR to study the processing of the glucoprotein HERZ/ngw (with the antigen itself 
being tagged with Alexa-488). Co-localisation appeared after only 90 minutes of 
incubation.
Similar experiments were also performed by Andrieu et al [350] who used 
confocal microscopy to show that an HIV-1 lipopeptide is endocytosed by DCs. The 
marker that they used to demonstrate endocytosis was Dextran and they studied its 
co-localisation with their peptide.
It has been discussed by Kamphorst et al [351] that the mechanism of antigen 
capture can be very important for the efficiency of antigen presentation in DCs 
generated in the presence of GM-CSF. More specifically, these GM-DCs present 
antigens that have been internalised by receptor-mediated endocytosis (receptors like 
DEC-205) or bulk phase pinocytosis very effectively but are almost ineffective when 
the antigen has been internalised via phagocytosis
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Following localisation of my peptide in the early endosomes, my next step 
was to study if it traffics through the other parts of the lysosomal pathway.
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3.4 P45 was also found localised in lysosomes
As described in the previous section, peptide antigens are processed in DC 
endosomes, which then fuse with lysosomes. Inside the lysosomes, cysteine 
proteases like cathepsins S and L are responsible for the formation of the epitope that 
will later bind to the MHC-II alleles [352] and for the degradation of the invariant 
chain li [353-355]. li is part of the MHC-II complex and does not permit peptide 
binding to the complex before maturation. It also takes part in the exportation of 
MHC-II molecules from the ER as well as their transportation to endosomes [356, 
357].
I was therefore interested in investigating if P45 can be found within 
lysosomes by using confocal microscopy images. In order to investigate this, I 
stained DCs incubated with fluorescently tagged green P45 with an Alexa-568- 
marked antibody for the LAMP-1.
LAMP-1 and LAMP-2 contribute to about 50% of lysosome membrane 
proteins [358] and thus their presence is indicative of a lysosomal compartment 
[359]. LAMP-1 and LAMP-2 have been shown to share functions in vivo [360]. It 
has been shown that LAMPs are important for phagosome maturation and more 
speeifically, for the early to late phagosome transition. In addition, it is suggested 
that they are necessary for physiological organelle motility, which is important in the 
phagolysosome fusion [361].
LAMP-1 is a type 1 integral membrane protein that is produced in the Golgi 
network and then transported to endosomes and then lysosomes. This protein shuttles 
between lysosomes, endosomes, and the plasma membrane. It has also been shown to
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co-localize with OSBPLIA at the late endosome [362, 363]. Upon cell activation, 
LAMP-1 transfers to the plasma membrane where it promotes adhesion of human 
peripheral blood mononuclear cells (PBMC) to vascular endothelium [364]. LAMP-1 
also presents carbohydrate ligands to selectins.
P45 was incubated with the cells for 6h, 24h and 48h (Figure 3.4). P45 was 
sometimes seen co-localising with LAMP-1, the marker for lysosomes. In many 
cases, the vesicles were localised under the plasma membrane as seen in z-stacks and 
the peptide was distributed in large or smaller aggregates within the organelles. A 
complementary and confirmatory view of a P45-loaded cell stained for P45 (green) 
and LAMP-1 (red) can be seen in Figure 3.5.
Dani et al. [365] used the rat monoclonal CD 107a (BD Biosciences) which 
binds to the LAMP-1, labelled with the red Alexafluore 568 to study the co­
localisation of a recombinant fusion protein, (GST- Ea 52-68-myc) with the 
lysosomal compartments (with the antibody that was targeting for the antigen being 
tagged with Alexa-488). Co-localisation was observed in yellow.
In experiments where mouse immature BMDCs were exposed to hen egg 
lysozyme (HEL) without LPS, researchers observed the co-localisation of the intact 
lysozyme with the lysosomes (H2-M was used as a lysosomal marker). Peptide 
loading onto MHC-II molecules was not observed [335, 366, 367].
The same experiments showed that with the addition of LPS, DCs mature and 
loading of peptides on MHC-II takes place. Lysozyme continued to localize in 
lysosomal compartments as it did without the administration of LPS, whereas 
peptide-MHC-II complexes were identified in transport vesicles that were not 
characterized by lysosomal markers such as LAMP or H2-M and later on the cell 
surface [366]. My next questions therefore focused on studying apoB-100-derived
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peptide loading on MHC complexes in order to investigate if my peptides can be 
presented by MHC complexes on the surface of DCs.
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Figure 3.5: A closer look in P45- lysosome co-localisation. DCs loaded with P45 (green-Alexa-488) 
for 48h and stained for LAMP-1 (red-Alexa-568). P45 co-localised with LAMP-1 indicating the 
presence of the peptide in the lysosomes. Images were taken at x 63 oil lens and are representative of 
six experiments.
3.5 Potential co-localisation of P45 with MHC-II molecules 
intracellularly.
MHC-II formation occurs in the ER. There, they assoeiate with trimers of the 
invariant chain (li), forming complexes [368, 369]. This is accomplished with the 
help of a motif in the cytoplasmic tail of li that targets the li-MHC-II complexes in 
the endosomal pathway [370] (early sorting endosomes). Once inside the acidic 
endosomal compartments, li is degraded leaving behind a segment called CLIP. At a 
later stage, when peptide loading occurs, CLIP is replaced by peptides of about 15 
amino-aeids long produeed inside the endosomes via proteolysis [371].
Antigen and MHC-11 processing have been shown to eo-localize. More 
specifieally, they occur in the same or nearby compartments of the endosomal/ 
lysosomal system that communicate with each other. Confocal microscopy 
experiments in murine DCs expressing MHC-11- eGFP revealed that iDCs consist 
mostly of vesicular endosomal compartments that contain MHC-11 [372].
Those multivesicular endosomes have been shown to receive internalised 
antigens, process them into peptides, load them into MHC-11 molecules already
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localized in the compartments and finally export the peptide-MHC-Il complexes to 
the cell surface [343]. Peptide loading of MHC-II molecules takes place in 
endosomal compartments and more specifically in MHC-II-positive compartments. 
Those endosomal compartments include multi-vesicular bodies (MVBs) with 
membranes high in cholesterol [373].
I was, therefore, interested in studying if the apoB-100-derived peptide co- 
localises with the MHC-II molecules intracellularly (possibly in the endosomes) and 
on the cell surface. It has been suggested that the peptide-MHC complex presentation 
on the cell surface is not only needed in cases of immune activation but also in 
immunologically quiescent situations. Antigen presentation by iDCs has been 
proposed to play a role in the induction of tolerance to peripheral antigens when 
taking into consideration that constitutive migration of DCs fi*om the periphery to 
secondary lymphoid organs has been observed [374].
Alexa-468-P45-loaded DCs were stained with an Alexa-568 (red)-labelled 
antibody for MHC-II. Incubation of the cell with P45 lasted 6h, 24h and 48h. 
Staining for MHC-II was seen intracellularly and also on the cell surface, particularly 
at 48h. However co-localisation of P45 with MHC-II was sometimes evident in 
endosomal compartments intracellularly, and not on the cell surface (Figure 3.6). 
Figure 3.7 provides a closer look at the intracellular co-localisation of P45 with the 
MHC-II complex. It was important to co-localise P45 with MHC-11 as this could be 
an indication that the peptide is loaded onto the complex in order to be presented to T 
cells and play a role in promoting an atheroprotective immune response. However, 
P45 presentation on the surface of DCs remains to be demonstrated.
In a study where a team of researchers studied the kinetics of formation and 
half-life of a complex between I-B  ^(a MHC-11 allotype) and a pigeon cytochrome C
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(PCC)-derived peptide [374], the researchers detected the complex in the endosomal 
compartments of iDCs 5 min after the endocytosis of the antigen by confocal 
microscopy and on the plasma membrane 1 h after endocytosis by flow cytometry. 
At later incubation times, the complex was endocytosed and then destroyed [374]. 
These experiments demonstrate the importance of studying the antigen-loaded cells 
at various time points in order to determine if the antigen is presented by the MHC-11 
complex on the cell surface. It is possible that at the timepoint of 6h following 
incubation that 1 chose to study the p45-loaded DCs, my peptide-MHC-Il complex 
had already been presented at the surface of the cell and then endocytosed again.
However, it is important to remember that when DCs are immature they are 
highly endocytic and therefore contain more ClIVs intracellularly. It is highly 
possible that in the presence of an inflammatory signal, endocytosis and the number 
of CHVs would decrease and therefore, more MHC-II-peptide complexes would 
form on the cell surface [335]. It has actually been shown by Inaba et al. that when 
DCs were loaded with hen egg lysozyme (HEL), the protein was internalised and it 
co-localised with MHC-11 molecules in endosomes and lysosomes but peptide-MHC- 
Il complexes did not form until DCs were exposed to an inflammatory stimuli. The 
formation process is blocked at the peptide-loading stage (on MHC-II) in late 
endosomes and lysosomes.
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3.6 P45 was found co-localising of MHC-I molecules on DCs.
The MHC-II pathway for antigen presentation has been established as the 
most efficient pathway for presenting extracellular peptide antigens to CD4^ T cells 
[375]. On the contrary, the MHC-I pathway is thought to be superior in the 
presentation of intracellular peptide antigens (viral & bacterial antigens, self­
antigens, tumour cells, allografts) to CD8^ T cells. In MHC-I peptide presentation, 
protein antigens taken up by the endolysosomal compartments are then routed 
directly in the cytosol, are broken down into peptides mostly through the procedure 
of proteolysis that takes place in the proteasome. Peptides produced in this way are 
then transported to the ER by the Transporter associated with Antigen Processing 
(TAP). Inside the ER, newly formed MHC-I dimers interact with the TAP complex, 
peptide loading occurs and the complexes are transported to the cell surface [372]. 
However, a second model has also been proposed to explain the mechanism of 
peptide loading and presentation by MHC-I molecules in DCs [376]. In this model, 
MHC-I molecules encounter peptide antigens in endosomal compartments as MHC- 
11 molecules do. Therefore, I thought that it was worth testing if the apoB-100- 
derived peptide is presented through by the MHC-I complex on the surface of DCs.
In order to test if P45 co-loealises with the MHC-I complex on the cell 
surface, Alexa488-P45-loaded DCs were stained with Alexa-568(red)-labelled 
antibody for MHC-I. Incubation of the cell with P45 lasted 6h, 24h and 48h. I saw 
P45 co-localising with MHC-I intracellularly but not on the cell surface (Figure 3.8).
These data could indicate that MHC-I and MHC-II can both be uploaded with 
the same peptide-antigen from apoB-100. A study has shown both MHC-I and MHC-
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II on DCs uploaded with soluble ovalbumin (OVA) through different uptake 
mechanisms of the antigen. DCs that had been incubated with OVA were shown to 
consist of early endosomes (marked by EEA-1 and Rab-5) containing OVA that had 
been endocytosed via the mannose receptor (MR) and also late lysosomes (identified 
by the expression of LAMP-1, lysotracker, Rab-5) containing OVA that had been 
pinocytosed. The MR-endocytosed OVA was found to be presented by MHC-I and 
the pinocytosed OVA was found to be presented by MHC-II [9]. Therefore, these 
DCs can cross-presented OVA to CD8+ cells as well as activate OVA-specific- 
CD4+ cells. It must be noted that cross-presentation can result in tolerance in the 
absence of inflammatory stimuli [10].
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3.7 Conclusion
The confocal microscopy experiments were a very crucial first step in my 
study on investigation of the meehanism of atheroprotective action that the apoB- 
100-derived peptides provide. 1 confirmed that P45, one of the most effeetive apoB- 
100-derived peptides in reducing plaque size and increasing collagen content [294, 
337], is up-taken by DCs. I demonstrated that the peptide sometimes co-localises 
with endosomal and lysosomal markers and therefore linked it with organelles that 
process extracellular peptide antigens. I then photographed some cases of P45 bound 
to the MHC-II and MHC-I molecules intracellularly. Following these data, my next 
step was to carry on and investigate the effect of the apoB-100-derived peptides on 
the phenotypical and functional properties of DCs, by examining the expression of 
cell surface markers and the expression and secretion of cytokines.
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CHAPTER 4 CHARACTERISATION OF THE EFFECT 
OF apoB-lOO-DERIVED PEPTIDES ON BMDCs
4.1 Introduction
The aim of this study was to test if the apoB-100 derived peptides 
immunomodulate the inflammatory process that leads to the development of 
atherosclerotic plaques via DCs. Following the confocal studies (Chapter 3) which 
indicated that the peptides are taken up by DCs and are present in intracellular 
compartments, the next step in my study was to examine if the apoB-100-derived 
peptides have an effect on the phenotype of DCs. This included the effect of the 
peptides on the morphology of the cells, on the number of DCs expressing specific 
phenotypic (CD 11c, CD 11b) and activation (CD40, CD86, MHC-II) markers, on the 
mRNA expression, the secretion of anti-inflammatory cytokine IL-10 and the pro- 
inflammatory IL-12 and finally on the mRNA expression of MMP-2 and MMP-9 by 
the peptide-loaded cells.
Different doses of the peptides were tested to provide a better evaluation of 
their effects ranging from 2.5 to 25pg/ml. The starting concentration of the peptides,
1.e. the 2.5 pg/ml was the peptide concentration used by Dr Nilsson’s group to 
vaccinate mice for their experiments (Dr J.Nilsson, personal communication). The 
techniques that were used to study the above have been described in full in Chapter
2. I used light microscopy (section 2.3.5) to look at the cell morphology, flow 
cytometry (section 2.3.4) to examine the expression of different markers on DCs,
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RT-PCR and gel elecrophoresis (section 2.3.6.2) to study the synthesis of cytokines 
and MMPs and ELISA (section 2.3.6.1) to measure cytokine secretion from DCs.
4.2 iDCs maintain the same morphology following incubation with 
apoB-lOO-derived peptides in  v itr o .
My first question regarded the morphology of DCs when loaded with the apoB- 
100-derived peptides. We wanted to examine if the peptides were inducing any 
alterations on the morphology of the cells. Morphological changes are characteristic 
of the transition from immature to mDCs and it is widely believed that the 
morphologic change is the basis of BMDC phenotype and funetion [377]. In their 
inaetivated state DCs have been seen to retain a rounded shape and a smooth surface. 
Generally the formation of roughness, protrusion, and ruffles on the cell membrane 
are associated with maturation of BMDCs. More specifically, in comparison studies 
of iDCs and mDCs under atomic force microscopy, a proportion of the BMDCs 
became larger in size with characteristic rough surface, richer ruffles on the cell 
membrane, and bigger, longer protrusions or pseudopodia after treatment with LPS 
[377]. Furthermore, as it was observed with the help of a transmission electronic 
microscope, in mDCs there was a considerable increase of subcellular organelles like 
lysosomes, mitochondria and endoplasmic reticulum as well as enrichment of 
cytoplasm. The above results confirmed morphological differences between mDCs 
and iDCs that had been reported in older studies [378].
The morphological state of mDCs is associated with the LPS-induced 
differentiation and maturation. Those processes require a larger amount of synthetic 
materials, more energy and enhanced cellular metabolism and function. Thus, the
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morphological changes of mDCs constitute adaptations to their new needs. In 
addition, the increase of the surface in mDCs may be of help in the expression of co­
stimulatory molecules and relevant receptors on their surface that take part in their 
interaction with other cells of the immune system [377]. The numerous pseudopodia 
enable them to form multiple interactions with T cells and modulate immune 
functions [378].
Therefore, if DCs maintain their rounded shape in this experiment that could be 
a good first indication, which would later need to be confirmed with functional tests, 
that they are immature and this could possibly be related with a tolerogenic 
disposition [377]. The peptide loaded-DCs were examined using light microscopy by 
Dr Alexandra Bermudez-Fajardo (section 2.3.5). The treatment of the cells involved 
the peptides P2 (5pg/ml), P45 (5pg/ml) and P210 (5pg/ml), LPS (5pg/ml) and 
oxLDL (lOOpg/ml). LPS is known to induce differentiation of DCs so it was used to 
test the maturation of DCs [377]. oxLDL has also been reported to drive DCs to 
maturation [379] and we wanted to test this effect since oxLDL is one of the 
principal antigens involved in atherosclerosis. The effect of the treatments on the 
differentiation of DCs was examined by staining the cells with H&E solution and 
visualising them under the light microseope as described in section 2.3.5.1. No 
significant differences were observed when DCs were incubated with 5pg of P2, P45 
or P210, therefore DCs maintain a rounded phenotype after incubation with the 
peptides which could be an indication for a more immature and potentially 
tolerogenic function by the cells (pictures from a representative plane for each 
incubation are shown in Figure 4.1). In contrast and as expected, LPS and oxLDL did 
promote a morphological change in DCs by driving them to develop dendrite-like 
projections characteristic of DC maturation.
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Figure 4.1: iDCs maintain rounded morphological features following incubation with apoB- 
100-derived peptides. DCs were incubated for 48h with the apoB-100-derived peptides P2, 
P45 or P210 (5pg/ml) in the presence or in the absence of LPS (5pg/ml). They were also 
incubated in parallel with human oxLDL (100 pg/ml) to compare its effects on their 
morphology. Then they were stained using H&E and their morphology was studied using 
light microscopy. No significant effects on the morphology of DCs were observed with P2, 
P45 or P210 as compared to untreated DCs. Both LPS and oxLDL induced the differentiation 
of DCs as compared with non-treated control cells. Images were kindly provided by Dr 
Bermudez-Fajardo. They were taken at a x40 magnification and the insets were taken at a 
xlOO magnification.
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4.3 Peptide-loaded DCs present the same relative expression of 
phenotypic and activation markers as iDCs in  v itr o .
Following the morphological study of peptide-loaded DCs, I further examined 
their molecular phenotype. DCs express a number of co-stimulatory molecules in 
order to carry out their multiple functions. They also express MHC-I molecules in 
order to present intracellular-derived peptide antigens to CD8+T cells, MHC-II 
molecules to present extracellular-derived peptide antigens to CD4+T cells and 
CD Id molecules to present lipid antigens to NKT cells. Furthermore, the APCs can 
regulate subsequent T cell responses by simultaneous expression of different co­
stimulatory molecules like CD40, CD80, CD86 or by actively sustaining any co­
stimulatory molecules during antigen presentation [380, 381]. For instance, DCs that 
take up antigens without TLR stimulation, something that could occur in a non 
infectious state or when a DC encounters an antigen formed under a 
pathophysiological metabolic condition like hypercholesterolaemia, usually present 
antigens without expressing co-stimulatory molecules, which leads to a suppressive 
T cell signal [382].
The activation of T cells by APCs is dependent on the binding of the complex 
peptide-MHC to the TCR. For this interaction to take place the binding of CD4 for 
MHC-11 or CD8 for MHC-I to the MHC molecule is also necessary. APCs also use 
cell surface co-stimulatory molecules to modulate the T cell activation type. Binding 
of co-stimulatory molecules CD80 and CD86 (or B7.1 and B7.2) to CD28 on the T 
cell leads to a strong activating signal [383]. Other strong co-stimulatory signals 
occur when CD40 interacts with the CD40 ligand on the T cell and when the 0x40 
ligand interacts with 0x40 on the T cell. When a peptide- MHC complex binds to a
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TCR without the binding of co-stimulatory molecules, T cell activation fails and 
anergy is induced so that the T cell will not permit subsequent stimulation by the 
same antigen. Additionally, certain ligands for co-stimulatory receptors, like 
cytotoxic T lymphocyte antigen-4 (CTLA-4) which competes with CD80 and CD86 
for binding to CD28 on the T cell, have inhibitory instead of stimulatory signals. 
Therefore, the regulation of co-stimulatory signals represents an important control 
mechanism in immune responses [382, 384].
mDCs have been shown to lose their endocytic activity, increase surface 
expression of MHC molecules, increase stability of MHC- peptide complexes, up- 
regulate the expression of adhesion and co-stimulatory molecules, like CD40, CD80 
and CD86 [341].
Flow cytometry was used to study the effect of the apoB-100-derived 
peptides on the expression of DCs’ surface phenotypic or activation markers such as 
CD lib , CD 11c, CD40, CD86, MHC-II. The cells were labeled for these markers as 
described in section 2.3.4.1 and flow cytometry studies were performed with a 
FACScan flow cytometer (Bector Dickinson, San Jose, CA). The data obtained by 
the detector concerning the cell size and the granularity help distinguish cells in order 
to define a gate R1 of the population to be examined, excluding dead cells and 
debris. To adjust the settings of the cytometer, unstained cells were used. Following 
sample acquisition where fluorescence signals were measured, data analysis was 
performed using the WinMDI software, version 2.8 (WinMDI, USA). The 
percentage of positive cells for surface markers and the mean fluorescence intensity 
per cell of the expressed marker were measured to examine the effect of the stimuli 
on DC differentiation and activation. A representation of the settings used for the 
flow cytometry analysis is shown in Figure 4.2.
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To examine the effect that the peptide treatment (5pg of each peptide: P2, 
P45 and P210) had on DCs I assessed the percentages of double positive cells for the 
following combination of markers: CD 11b & CDllc (Section 4.3.1); CD 11b & 
CD40 (Section 4.3.2); CDllb & CD86 (Section 4.3.3); CDllb & MHC-11 (Section 
4.3.4). CDllb is a lineage marker for DCs. It was included in every combination of 
markers that I examined in order to verify that the cells that are being assessed are 
indeed DCs. This way, the expression of the other markers on this DC population 
could then be studied. CD llc is also a lineage marker expressed on all subsets of 
DCs [341]; CD40 and CD86 are two co-stimulatory molecules expressed on mature, 
activated DCs that bind to the CD 154 and the CD28 receptors on naïve T cells to 
subsequently activate both DCs and T cells and facilitate their maturation [385, 386]; 
MHC-II is a complex of molecules expressed on the surface of activated DCs loaded 
with antigenic peptides to be presented to the naïve T cells [387].
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Figure 4.2: Representative dot plots of settings used for the flow cytometry analysis to 
detect the expression of phenotypic and activation markers on peptide loaded-DCs. 
Unloaded IDCs were used to adjust the settings. In panel A, the cells appear in the Side and 
Forward Scatter. Region 1 (R1) was set to define the population that was believed to include 
DCs for the flow cytometry analysis. It was selected to exclude dead cells. In graphs B, 0  
and D, the cell population in R1 was labelled with the appropriate RPE and FITC isotype 
controls for the markers studied in the experiment. The antibodies lgG2b and IgG are the 
isotypes for the CD11b & CDUc combination of markers (B); lgG2b and lgG2a are the 
isotypes for CD11b & CD40 as well as the CD11b & CD86 combination (0); and lgG2b and 
IgM are the isotypes for CD11b & MHC-II (D). For every combination of isotypes, a quadrant 
was set to define which fluorescence values would be considered to be valid for the 
corresponding fluorochromes in each experiment. The double positive fluorescent population 
was set as the one appearing in the top right square of the quadrant.
4.3.1 Incubation of iDCs with apoB-100-derived peptides does not up-regulate 
CDllc expression.
The first DC marker whose expression I examined on peptide loaded-DCs, 
along with the expression of CDl lb, was CDl Ic, the marker that was examined in 
my confocal experiments too. CDl Ic and CDl lb are both myeloid markers for DCs.
142
At the time these experiments were performed, I believed that the most prominent 
marker for my DCs would be CDl lb. I later discovered though that CDl lb is being 
present on most DC subsets but CDl Ic is present on all of them. [233].
CDllc is considered an important marker for murine DCs but in a study on 
human DCs, plasmacytoid T cells with a CD4^CD 11 c'CD3" phenotype were shown 
to differentiate into DCs [388]. The role of murine CDllc'negative DCs remains 
unknown.
A combination of CDllc and CDllb was used to test the effect of the 
peptides on the differentiation of DCs compared to untreated, iDCs but also 
compared to DCs that have been driven to mature in the presence of LPS. DCs were 
also treated simultaneously with LPS and each of the peptides. It should be noted that 
both CDllc and CDllb are also expressed on eosinophils and neutrophils. But in 
flow cytometry, the eosinophil population is found lower in the forward scatter and 
higher in the side scatter than the monocyte one and the neutrophil population is 
found higher in the side scatter compared to the monocytes [389], so the gating 
strategy used for the DC population R1 (Figure 4.2) made me confident that I was 
only collecting data for CDllc and CDllb positive DCs rather than for any other 
cells.
Figure 4.3 shows representative dot plots from the experiments that were 
used to perform the flow cytometry analysis for CDl lb & CDl Ic co-expression.
iDCs were loaded with one of the peptides, P2 (5pg/ml), P45 (5 pg/ml) and 
P210 (5pg/ml) or LPS (5pg/ml). The percentage of double positive cells in the 
population was assessed using WinMDI as shown in
Figure 4.4. A high percentage of untreated cells were CDl Ic^CDl Ib^ as DCs 
generated from bone marrow differentiate into CDllc^CDllb^ cells in the presence
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of GM-CSF [390]. Peptides P2 and P45 had no significant effects on the percentages 
of cells co-expressing CDllb and CDllc while treatment with P210 resulted in 
significantly fewer cells co-expressing CDllb & CDllc, which was halved after the 
incubation with the peptide (Control mean 69.97 SD ± 5.23, P210 mean 27.40 SD ± 
4.90; p value to control = 0.046) (Figure 4.4B). The percentage of CDllb & CDllc 
positive cells was also half in cultures treated with LPS, either alone (Control mean 
69.97 SD ± 5.23, LPS mean 27.59 SD ± 7.00; p value to control = 0.047) or in 
combination with P210 (Control mean 69.97 SD ± 5.23, LPS+P210 mean 27.70 SD 
± 13.80; p value to control = 0.048) when compared to untreated cells (the same 
occurred with the P2 & LPS treatment; data not shown).
These data show that P2 and P45 had no effect on the number of CDllc^ & 
CDllb^ cells. On the contrary, P210 had an effect on DC differentiation by 
decreasing the number of CDllb & CDllc positive cells by half (Figure 4.4). 
Another case where a protein down-regulates CDllc has been shown by Liu et al. 
[391] where high mobility group box protein 1 induced the differentiation of splenic 
DCs from CDllc“®^ CD45‘'’"' to CD llc‘°"'CD45“®^. Furthermore, the Pertussis toxin 
(PTX) has been shown to inhibit the expression of CDllb when cultured with iDCs, 
but this needs further investigation [392]. The decrease of the expression of the 
phenotypic markers CDllb & CDllc on DCs by P210 might indicate an anti­
inflammatory phenotype for the peptide-loaded cells as it has been previously shown 
that down-regulation of these markers can result in the loss of responsiveness of DCs 
to the action of inflammatory chemokines such as MCP and the macrophage 
inflammatory protein 1 alpha, 1 beta and 3 alpha (MIP-1 a, MIP-1 p and MIP-3 a ) 
[393].
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LPS also influenced DC differentiation as I have shown that it decreased the 
number of CDllb^ & CDl Ic cells. These results agree with the findings from 
Singh-Jasuja et al. [394] that showed CDllc down-regulation in bone marrow and 
spleen- derived DCs upon TLR 3/4/9 activation.
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Figure 4.3: Representative dot plots for the flow cytometry analysis for the number of cells 
expressing CD11b and CD11c. DCs were incubated for 48h with the apoB-100-derived 
peptides P2, P45 or P210 (5pg/ml) in the presence or absence of LPS (5|jg/ml). Flow 
cytometry was used to measure the percentage of double positive cells for CD11b and 
CD11c (top right quadrant). Panel A: apoB-100-derived peptides P2 and P45; Panel B: 
P210. Percentage of the total DC population was calculated using WinMDI.
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Figure 4.4: Effect of peptide treatment on the percentages of peptide-loaded
CD11b‘"CD11c"' DCs. DCs were incubated for 48h with the apoB-100-derived peptides P2, 
P45 or P210 (5pg/ml) in the presence or in the absence of LPS (5pg/ml). Flow cytometry 
was used to assess the expression of CD11b and CD11c. Panel A shows the effect of apoB- 
100-derived peptides P2 and P45 on the number of CD11b^CD11c^ cells. Panel B, as above 
but for peptide P210. P210 or LPS alone, and LPS in combination with P210, all decreased 
the number of double positive cells to almost half. Values represent mean ± SD, N=3, * 
P<0.05 compared to control.
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4.3.2 Incubation of iDCs with apoB-100-derived peptides does not up-regulate 
CD40 expression.
I then went on to assess the effect of the apoB-100-derived peptides on the 
expression of CD40 by DCs. CD40 plays an important role in the final maturation 
stage of DCs and the expression of CD40 on antigen-presenting cells like monocytes 
and DCs is well studied [395, 396]. More specifically, CD40 ligation on monocytes 
and DCs leads to increased cell survival, secretion of cytokines and enzymes, 
increased monocyte tumoricidal activity, NO synthesis and up-regulation of co­
stimulatory molecules like CD54/ICAM-1, CD58/LFA-3, CD80/B7-1, and 
CD86/B7-2. CD40 is also expressed on T and B cells, on macrophages, endothelial 
cells and smooth muscle cells.
Activation of the CD40 receptor through its ligation with CD40L on T cells is 
one of the necessary steps that mediates DC maturation [221]. A figure illustrating 
some of the basic interactions between DCs and T cells can be found in Figure 4.5. 
Although increased levels of IL-12 secretion and CD80/CD86 expression play an 
important role on T cell activation, it seems that additional CD40 response genes 
play a pivotal role in DC function and scientists have identified a number of several 
new genes expressed after CD40 activation through CD40/CD40L ligation [221]. 
According to recent studies, the interaction between CD40-CD40L is also of major 
importance for cross-priming of cytotoxic T lymphocyte (CTL) responses by DCs 
[397]. Furthermore, CD40 appears to be important for the ontogeny of DCs because 
when CD40 on CD34^ hematopoietic progenitors binds with its ligand, it induces cell 
proliferation and differentiation of cells into cells with DC characteristics [398].
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Figure 4.5: DC interacting with T cells. Co-stimulatory molecules CD40, CD80/CD86 binding 
to their respective legands, CD40L and CD28. MHC-I binds to the TCR in cytotoxic T cells 
and MHC-II to the TCR in CD4^ cells. Toll-like receptors are also expressed on the surface 
of DCs. Taken from Thais et al, 2011 [399].
It has been shown in vitro that the interruption of CD40/CD40-L in T cell/ DC 
co-cultures causes a reduced T cell proliferation. Nevertheless, other studies have 
affirmed that CD40/CD40L interactions are bidirectional in nature. Particularly, it 
has been shown in vivo that CD40L cross-linking takes part in producing helper 
function and germinal center formation (the sites of formation of memory B cells) 
[400]. In addition, in vitro studies confirmed that ligation of CD40L on T cells leads 
to up-regulation of cytokine production [401]. Therefore, there is evidence that 
altered CD40 signaling to the APCs and/ or altered CD40-L signaling to the T cells is 
capable of inhibiting T cell responses.
I studied the co-expression of CDllb & CD40 by DCs treated or not with 
peptides as a surrogate indicator of their activation status. Figure 4.6 shows 
representative flow cytometry data of the results. The percentage of double positive 
CDllb & CD40 cells remained the same compared to untreated cells in DCs loaded
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with the apoB-100 peptides (Figure 4.7). The results show that the apoB-100-derived 
peptides have no effect on the number of CD40 positive DCs which remained low.
As previously discussed, CD40 is an important co-stimulatory molecule for 
DCs. CD40 binds to CD40 ligand (CD 154) on T cells [250] and has the role of 
promoting the activation of DCs so that they will express more co-stimulatory 
molecules and secrete cytokines that can in turn induce more T cell differentiation. 
On the other hand, down-regulation of CD40 expression has been reported to reduce 
the activation of DCs and to subsequently induce a tolerogenic effect by inhibiting T 
cell proliferation [392], [402].
The apoB-100-derived peptides did not alter the surface expression of these 
two molecules on DCs after the 48h incubation. These results are important as the 
binding of CD40 with its ligand CD 154 (CD40L) plays an important role in the 
development of advanced lesions. Their binding leads to production of inflammatory 
cytokines, matrix-degrading proteases and adhesion molecules. According to studies, 
blockade of their interaction leads in formation of smaller, less inflammatory and 
more fibrous lesions [403]. It has also been shown that DCs that take up antigens 
without TLR stimulation, something that could occur in a non infectious state or 
when a DC encounters an antigen formed under a pathophysiological metabolic 
condition like hypercholesterolaemia, usually present antigens without expressing 
co-stimulatory molecules, which leads to a suppressive T cell signal [404].
The number of CD40^ cells remained the same when LPS was added in the cell 
culture (Figure 4.7). So LPS did not up-regulate the expression of the activation 
marker CD40 on DCs. Corinti et al, have shown that the low but significant amounts 
of autocrine IL-10 produced by iDCs inhibit the in vitro LPS-induced maturation of 
DCs and the up-regulation of the co-stimulatory molecules on them while IL-10
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secretion increases. When anti-IL-10 neutralizing antibodies were added to the DC 
culture in their experiments, the IL-10 mRNA expression was reduced along with the 
secretion of the cytokine and the expression of the co-stimulatory molecules CD80, 
CD83 and CD86 was significantly increased as well as the capacity of DCs to induce 
naïve CD4^ T cell proliferation [405]. But DCs seem to be influenced by IL-10 only 
when they are in an immature or semi-mature state. Once they have matured, their 
phenotype is stable [406]. Furthermore, it has been shown that LPS-induced 
maturation of DCs can vary according to the mouse strain studied [407].
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Figure 4.6: Representative dot plots of the flow cytometry analysis for the number of cells 
expressing the markers CD11b and CD40. DCs were incubated for 48h with the apoB-100- 
derived peptides P2, P45 or P210 (5pg/ml) in the presence or absence of LPS (5pg/ml). 
Flow cytometry was used to assess the expression of CD11b and CD40 (top right quadrant). 
Panel A: apoB-100-derived peptides P2 and P45; Panel B: P210. Percentage of the total DC 
population was calculated using WinMDI.
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Figure 4.7: Analysis of the activation of peptide loaded-DCs by examining the size of the 
CD11b^CD40^ population shows that the size of the population is the same in peptide- 
loaded and unloaded DCs. DCs were incubated for 48h with the apoB-IOO-derived peptides 
P2, P45 or P210 (5pg/ml) in the presence or in the absence of LPS (5pg/ml). Flow cytometry 
was used to assess the percentage of CD11b^CD40^ cells. Panel A shows the effect of 
apoB-100-derived peptides P2 and P45 on the number of CD11b’"CD40'^ cells. Panel B, as 
above but for peptide P210. Neither the peptides, nor the LPS significantly altered the size of 
the double positive population. Values represent mean ± SD, N=3.
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4.3.3 Incubation of IDCs with apoB-lOO-derived peptides does not up-regulate 
CD86 expression.
I also studied in parallel the effect of treatment on the expression of CD86 by 
CDllb+ DCs as another indicator of their activation status. The reason behind this 
was that although a number of surface molecules have been shown to convey a 
second signal leading to T cell proliferation [408, 409], CD28 seems to play an 
important role in the process. In more detail, CD28 ligation results in T cell 
proliferation, induces IL-2 production and blocks induction of anergy [410, 411]. 
CD28 as well as CTLA-4 bind members of the B7 family of counter- receptors, 
B7.1/ BB-1 (CD80) and B7.2/B70 (CD86) [412,413] (Figure 4.5).
These CD28/CTLA-4 ligands (CD80 and CD86) are normally not expressed in 
resting human leukocytes [414,415] with the only exception of a weak expression of 
CD86 on monocytes [414]. Activation of monocytes and B cells leads to up- 
regulation of CD86 expression firstly and CD80 later [414,416]. Therefore, delivery 
of a co-stimulatory signal by DCs is only possible when DCs are differentiated and 
activated. The maturation and activation of Langerhans cell populations has been 
shown to be linked with an enhanced CD80 expression [417]. McLellan and his team 
demonstrated that CD86 is the earliest expressed and functionally the most important 
co-stimulatory CD28/CTLA-4 ligand on DCs [418]. They were puzzled with the fact 
that activated DCs express both CD80 and CD86, which bind the same ligands on T 
cells. A possible explanation is that the two molecules transmit different signals to T 
cells or maybe modulate Thl or Th2 responses [419] or, according to others, CTLA- 
4 may convey a negative signal [420]. The initial maximal stimulator effect, required 
for DCs to function as proper primary APCs, is closely correlated to the spatial
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(membrane clustering) and kinetics of these different ligand interactions [418]. The 
minimal CD28/ CTLA-4 ligand expression as evidenced on directly isolated blood 
DCs [418], suggests that these cells become fully functional APCs in vivo after 
exposure to the proper cytokine and cellular environment. This results in control of 
the co-stimulator activity, and may make ftill DC co-stimulatory activity an antigen- 
specific event since co-stimulator activity requires the participation of specific T 
cells. It might also block the inappropriate induction of an autoimmune response, and 
thus act as a mechanism of peripheral tolerance [418].
Figure 4.8 shows representative dot plots of the analysis performed. DCs were 
incubated for 48h with the apoB-100-derived peptides P2, P45 or P210 (5pg/ml) in 
the presence or in the absence of LPS (5pg/ml). Flow cytometry was used to assess 
the percentage of CDllb^CD86^ cells. None of the peptides had a significant effect 
on the percentage of cells expressing CD86 (Figure 4.9). As mentioned above, CD86 
is an important co-stimulatory molecules for DCs. CD86 binds the CD28 receptor on 
T cells [421] and is responsible for enhancing the stimulation and activation of T 
cells which has already been initiated by the interaction of the antigen with the TCR. 
Inhibition of CD86 expression reduces the activation of DCs and induces a 
tolerogenic effect by inhibiting T cell proliferation [392], [402].
The fact that the number of CD86-expressing cells remain low following 48h 
incubation with the peptides is an important finding as co-stimulation through CD86 
is believed to play an important role in atherosclerosis development. Studies on this 
subject area have shown that transfer of CD4^ cells to apoE'^7 SCID mice accelerates 
the development of atherosclerosis [422] while on the other hand, 
hypercholesterolaemic mice deficient in IL-12, INF- y, CD80/CD86, CD40L, 0x40, 
CD4 and T-bet are less affected by atherosclerosis [308, 423-425]. This study
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supports my hypothesis that the low numbers of DCs expressing CDllb and CD86 
following incubation with the peptides could be an indication that the peptides can 
immunodulate the inflammatory response that leads to atherosclerosis.
However, another study evidenced that deletion of CD8CK 86, CD28 or ICOS 
led to depletion of Tregs and that this effect when combined with blocking of CD25 
with anti-CD25 antibodies, led to considerably increased plaque formation [426, 
427]. Therefore, a very delicate balance seems to exist on achieving the desired 
immune response through modulation of the expression of CD86 on DCs and this 
should be taken into account when the apoB-100-derived peptides are being 
examined for their effect on CD86 on DCs.
The CD86^ cell population remained the same when DCs were treated with 
LPS, contrary to what was expected. A possible explanation for this could be 
autocrine IL-10 secretion. As discussed above in section 4.3.2, autocrine IL-10 
produced by iDCs can inhibit the LPS-mediated up-regulation of the co-stimulatory 
molecules on them [405]. When anti-IL-10 neutralizing antibodies were added into a 
culture of DCs, the IL-10 mRNA expression was reduced along with the secretion of 
the cytokine while the expression of the co-stimulatory molecules CD80, CD83 and 
CD86 was significantly increased as well as the capacity of DCs to induce naïve 
CD4^ T cell proliferation [428].
When Zhang et al. induced endotoxin tolerance in mice by four daily 
intraperitoneal injections with LPS, the expression of CD40 and CD86 remained 
unaltered in DCs from endotoxin tolerant mice compared to those from control mice 
and only the MHC-II and CD80 surface expression increased [429]. These data 
combined with the fact that DCs from endotoxin tolerant mice produced less IL-12 
after treatment with LPS, made the authors suggest that this difference in MHC-
155
II/CD80 and CD86/CD40 expression might strengthen DCs’ antigen presenting 
ability without the superfluous secretion of pro-inflammatory cytokines and 
mediators. These data could indicate that CD86 expression is not always proportional 
to the antigen presenting ability of DCs and therefore conclusions on the ApoB-100 
peptide presentation by DCs can be drawn only when examining all the activation 
and presenting molecules involved.
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Figure 4.8: Representative dot plots for the apoB-100-derived peptides expressing the 
markers CD11b and CD86 that were used for the flow cytometry analysis. DCs were 
incubated for 48h with the apoB-100-derived peptides P2, P45 or P210 (5pg/ml) in the 
presence or in the absence of LPS (5pg/ml). Flow cytometry was used to measure the 
percentage of double positive cells for CD11b and CD86 (top right quadrant). Panel A: apoB- 
100-derived peptides P2 and P45; Panel B; P210. Percentage of the total DC population 
was calculated using WinMDI.
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Figure 4.9: Analysis of the activation status of peptide-loaded DCs by examining the 
CD11b^CD86^ population shows that the size of the population is the same in peptide- 
loaded and unloaded DCs. DCs were incubated for 48h with the apoB-100-derived peptides 
P2, P45 or P210 (5pg/ml) in the presence or in the absence of LPS (5pg/ml). Flow cytometry 
was used to assess the percentage of CD11b’"CD86"  ^cells. Graph A refers to the apoB-100- 
derived peptides P2 and P45 while graph B refers to P210. The number of P2, P45 and 
P210-loaded DCs expressing CD11b & CD86 was the same as the number of unloaded DCs 
expressing both markers. The CD11b‘"CD86'' population also remained unaffected by the 
LPS treatment of DCs. Values represent mean ± SD, N=3.
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4.3.4 Incubation of iDCs with apoB-lOO-derived peptides does not up-regulate 
MHC-n expression.
Finally, I wanted to examine the expression of MHC-II. MHC-II is an 
activation molecule expressed on the surface of BMDCs and is characteristic of their 
mature stage as already described in Chapter 1, section 1.17. The DC maturation 
state is of major importance in the initiation of an appropriate immune response 
[430]. This study was also considered crucial as MHC-II complexes are responsible 
for presenting extracellular peptide antigens that are found already engulfed in the 
cytoplasm of DCs by delivering them to the surface of DCs [387]. More specifically, 
DCs express MHC-I molecules in order to present intracellular-derived peptide 
antigens to CD8^ T cells, MHC-II molecules to present extracellular-derived peptide 
antigens to CD4^ T cells and CD Id molecules to present lipid antigens to NKT cells 
[347].
Therefore, the interaction between MHC-II-peptide complexes on APCs with 
the TCR on T cells is an important stimuli to initiate an immune response [387] 
(Figure 4.5). When the MHC-II complex binds to the TCR, T cell activation, clonal 
expansion and cytokine secretion occurs. mDCs have been shown to lose their 
endocytic activity, increase surface expression of MHC molecules, increase stability 
of MHC-peptide complexes, up-regulate the expression of adhesion and co­
stimulatory molecules, like CD40, CD54, CD80 and CD86, and secrete pro- 
inflammatory cytokines such as IL-1, IL-6, IL-12, IL-18 and IL-23 [341].
DCs were incubated for 48h with the apoB-100-derived peptides P2, P45 or 
P210 (5pg/ml) in the presence or in the absence of LPS (5pg/ml). Flow cytometry 
was used to assess the percentage of CDllb^MHC-If^ cells. Representative dot plots
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used for the flow cytometry analysis of the cells expressing MHC-II on CDl Ib^ DCs 
is shown in Figure 4.10. The results show that the percentage of CDllb+ DCs 
expressing MHC-II is not significantly different on peptide-treated and untreated 
cells (Figure 4.11) so no effect was noted on the antigen presenting molecule MHC- 
II by the peptides. However, it was also shown that the number of cells expressing 
MHC-II^ was quite low in all treatment groups when measured by flow cytometry. 
This is an intriguing contrast compared to the results seen with confocal microscopy 
where most of my DCs were expressing MHC-II. An explanation for this is that the 
cells examined in the flow cytometry CDllb+ while the cells examined in confocal 
microscopy are C D llc \ Therefore a higher number of CDllc^ cells was 
demonstrated to express MHC-II compared to CDllb+ cells. This observation shows 
how important it is to determine the most reliable marker in order to mark all the 
DCs contained in my cell population. Another possible explanation for the apparent 
difference in MHC-II expression could be due to the fact that different antibodies 
were used. So, the experiments could be repeated using another antibody for MHC- 
II.
These results could be a potential indication that maybe the peptides are not 
presented to T cells through the MHC-II complex, so there is a need for further 
investigation to physically demonstrate that the peptides are properly presented by 
the MHC-II molecules on the surface of DCs. This will be further discussed in 
Chapter 7.
The experiments carried out using LPS show a similar result of very few 
MHC-II^ cells; their number is equal to untreated iDCs cultures. LPS has been found 
to interact with Toll-like receptor 4 on DCs and to increase peptide-loading on MHC- 
II through this interaction [431]. It could be that in the absence of antigen, up-
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regulation of MHC-II does not take place. Furthermore, IL-10 autocrine secretion in 
DCs reduces the expression and presentation of MHC-II complexes on the surface of 
DCs and interferes with antigen presentation to T cells [432].
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Figure 4.10: Representative dot plots for the peptide-loaded DCs expressing the markers 
C D llb  and MHC-II that were used for the flow cytometry analysis. DCs were incubated for 
48h with the apoB-100-derived peptides P2, P45 or P210 (5pg/ml) in the presence or in the 
absence of LPS (5pg/ml). Flow cytometry was used to assess the percentage of 
CD11b^MHC-ir cells (top right quadrant). Panel A shows the analysis for apoB-100-derived 
peptides P2 and P45 while B shows the study of P210. Percentage of the total DC 
population was calculated using WinMDI.
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Figure 4.11: Analysis of the activation of peptide-loaded DCs by examining the 
CDIIb^M HC-ir population shows that the size of the population is the same in peptide- 
loaded and unloaded DCs. DCs were incubated for 48h with the apoB-100-derived peptides 
P2, P45 or P210 (5pg/ml) in the presence or in the absence of LPS (5pg/ml). Flow cytometry 
was used to assess the expression of MHC-II on CD llb+ cells. Graph A refers to the apoB- 
100-derived peptides P2 and P45 while graph B refers to P210. There was no significant 
effect on CDl 1 b^MHC-lP cells with any of the peptides or the LPS. Values represent mean ± 
SD, N=3.
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4.3.5 Higher concentrations of the apoB-lOO-derived peptides do not up-regulate
the expression of markers on DCs.
Following my study for the effect that 5 pg/ml of apoBl 00-derived peptides 
have on the phenotype of iDCs, I then decided to examine the effect that different 
concentrations of the peptide have on the expression of the above mentioned markers 
on DCs. As explained in this chapter’s introduction, the concentrations that I have 
been using are the same ones that the Nilsson group were using to inject whole 
organisms so I expected to see effects. However, it is worth checking what would be 
the effect of lower and higher peptide concentrations on DCs. With this experiment I 
aimed to investigate potential dose-dependent effects; a very common practice to 
investigate the effect that a peptide has on DCs [338].
Therefore, I used a concentration which was two-times smaller than in my 
previous experiments, ie 2.5 pg, I still included my original dose of 5pg and finally 
added a concentration ose which was five-times higher, ie 25pg of each peptide. This 
time I decided to perform the analysis of my flow cytometry data by assessing the 
mean fluorescence intensity (MFI) of markers CDllc, CD40, CD86 and MHC-II 
expressed on CDl Ib^ cells. The MFI values refer to the mean levels of expression of 
a surface marker on the surface of each cell. I chose to assess the MFI for this assay 
since it could be a more precise way to refine the effect that the different 
concentrations of apoB-100-derived peptides have on expression of the 
differentiation and activation markers on DCs, compared to measuring the number of 
double positive cells for these markers. This method allows identification of the level 
of expression of the marker in each individual cell instead of the whole population 
and also refines differences that are only evident in one dimension.
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It must be noted that this experiment was only ran once to get an idea of the 
trends in the mean expression of the markers in question on the surface of the cells. 
Therefore these are preliminary results that need further confirmatory analysis. I saw 
a trend by P2 and P210-loaded DCs to down-regulate the expression of co­
stimulatory markers CD40 and CD 8 6 as well as the MHC-II when higher 
concentrations of the peptides had been used to treat the cells (Figure 4.12). On the 
contrary, P45-loaded DCs presented the same trend of lowering the expression of 
these same markers when the peptide had been used in low concentrations. P2 and 
P45 down-regulated CDllc when used in high concentrations. On the contrary, low 
concentrations of P210 downregulated CDllc and these data agree with the data 
presented in section 4.3.1 while a high concentration of P210 (25pg/ml) upregulated 
the expression of the marker.
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Figure 4.12: Analysis of the maturation and activation of peptide-loaded DCs by flow 
cytometry following incubation with increasing doses of the peptides shows there are some 
trends of up-regulation or down-regulation of the mean expression of the surface markers on 
the cells for each peptide. Incubation time was 48h. All the peptides down-regulated C D llc  
expression on DCs proportionally to the concentration of the peptide used (graph A). The 
only exception was P210, when used at a concentration of 25pg/ml, which increased the 
expression of the marker. The peptides P2 and P210 down-regulated the expression of the 
co-stimulatory molecule CD86 and also that of the MHC-II complex (graph B) on DCs, when 
used in high concentrations and the expression of CD40 when used at 5pg/ml (graph A). 
Low concentrations of P45 down-regulated the expression of CD40, CD86, MHC-II on the 
cells. Values represent the mean fluorescence intensity for the combination of markers 
shown (MFI), N=1.
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4.3.6 The phenotype of the generated DCs is linked to tolerance and is preserved 
when they are loaded with apoB-lOO-derived peptides
In addition to studying the phenotypic and activation markers on peptide- 
loaded DCs, it was also important to characterise more fully the phenotypic status of 
bone-marrow derived DCs in “resting” state and the effect of treatment with P2, P45 
and P210 on the development of different subsets of DCs. As I have mentioned 
before in section 4.3.1, murine DCs in lymphoid organs (spleen and lymph nodes) 
are separated to CDlIc CD4^CD8'CD1 lb \  CD 11 c^CD4'CD8^CDlib" (also present 
in thymus), CDl lc^CD4‘CD8' CDl Ib^ and CDl lc^CD4'CD8' CDl lb' populations.
The groups of Dr Shortman and Dr Kang have looked at the CD8^CDllb' and 
CD8'CDllb^ subpopulations in murine splenic DCs [433, 434]. CD8a'CDllb^ DCs 
do not produce large amounts of IL-12, most of the time induce Th2 responses and 
do not cross-prime CD8^ T cells [435, 436]. The CD8a'CDllb^ DC subset is further 
separated into a CD4^ subset and a CD4" subset [433] but the differences in function 
between those subsets are yet to be determined [437]. On the other hand, CD8  ^
CDllb" DCs produce considerable amounts of IL-12, induce Thl responses and 
cross-prime CD8^ T cells [435,436].
In the thymus, the CD8a"CDllb^ DCs also express the Sirpa protein and have 
been shown to be generated extrathymieally [225]. They are believed to play a role in 
thymic tolerance to peripheral self and non-self antigens as they have been found to 
present self antigens [438] and induce CD4^CD25^FoxP3^ Tregs [439]. On the 
contrary, CD8^CDllb" DCs are Sirpa negative and arise intrathymically. Unlike 
their counterparts in the spleen though, both CD8a"CDl Ib^ Sirpa^ and CD8^CD1 lb"
167
Sirpa' DCs can present antigens to CD4'*’ cells and CD8  ^cells for negative selection, 
ie the deletion of CD4^ self-reactive thymocytes.
I thought that to identify the subset that is more prominently generated in my 
peptide experiments, would allow me to leam more about the type of immune 
response that the peptides induce. An experiment with these aims was performed by 
Dr Alexandra Bermudez-Fajardo and it has been included in this chapter to link the 
subsets with their potential function. Dr Bermudez-Fajardo performed this 
experiment only once but later on other group members repeated it and the results 
obtained were the same. The fact that the same DC subsets were identified at 
different times from different people confirms the validity of the data shown.
Dr Bermudez-Fajardo labelled untreated and peptide-loaded DCs with 
fluorescently tagged antibodies targeting DCs phenotypic (CD4, CD8, CDllc and 
CDllb) and activation markers (CD40, CD86 and MHC-II) and carried out analysis 
of their expression using flow cytometry as described in section 2.3.4.1. She found 
that around 70-80% of DCs (with and without peptides) displayed a 
CDl Ic^^^^CDl lb^^^CD8a'CD4" (double negative, DN) phenotype while the 
remaining 15-20% of cells had a CDlIc'^^CDllb^^CD8a"^CD4' (CD8a"l 
phenotype (Figure 4.13-A). This pattern was not affected by the treatment of DCs 
with different doses of peptides. A very small percentage of 
CDl Ic '^^^CDl lb^'^CD8a+CD4^ DCs (CD8a+CD4^ were detected in my cell 
preparations (less than 3%, data not shown). Therefore, the majority of the cells 
generated following incubation with the peptides are DN which have been shown to 
exert tolerogenic properties in vitro and in vivo. Therefore, my results suggest that 
treatment with apoB-100-derived peptides does not affect the tolerogenic phenotype 
displayed by DCs in vitro.
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An interesting observation in a review by Moser et al. [440] is that many 
experiments have shown that the type of DC subset on which an antigen is loaded 
will determine the type of immune responses generated. So, it seems that when mice 
were injected with CD8a’ DCs that had been pulsed ex v/vo with keyhole limpet 
hemocyanin, a Th2 response was induced while when CD8a^ DCs were pulsed with 
the same protein and injected to mice, Thl responses were generated [441, 442]. The 
CD8a' phenotype that my generated cells displayed, therefore, could be a good start 
in determining the immune responses produced by these cells when loaded with 
antigens.
As for the maturation markers, the percentage of cells in each subset 
expressing the co-stimulatory markers CD40 and CD86 as well as MHC-II showed 
no differences compared to the groups previously studied that had received lower 
doses of the peptides (Figure 4.13-B, Figure 4.14-A & B).
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Figure 4.13: The DC subsets generated for these experiments, remain unaltered following 
treatment with apoB-100-derived peptides and have been associated with tolerogenic 
responses. The majority of the DCs that were generated from murine bone marrow (70-80%) 
displayed a CDl 1 c' '^ '^^CD11 b" '^ '^^CD8a'CD4' (double negative) phenotype and 15-20% cells 
displayed a CDl 1 c^'^^CD11 b^'^^CD8a^CD4' (CD8o^) phenotype. When the cells were 
incubated with 2.5 pg/ml or 25 pg/ml of peptide for 48h, my cells continued to display the 
same phenotype. Furthermore, the DN and the CD8o^ populations remained constant 
following incubation of the cells with the peptides as did the DN-CD40^ population and the 
CD8o^CD40^ population. Values represent the mean fluorescence intensity for the 
combination of markers shown (MFI), N=1.
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Figure 4.14: The DC subsets generated in this project remain the same following treatment 
with apoB-100-derived peptides and have been linked with tolerance. As mentioned in the 
figure above, the 70-80% of DCs generated for my experiments displayed a 
CD11 c' '^ '^^CD11 b'^'^'^CD8a'CD4' (double negative) phenotype and the other 15-20% displayed 
a CD 11 c'^ ' '^^ CD 11 b '^^"^CD8a^CD4" (CDOo" )^ phenotype. The cells maintained this phenotype 
even following incubation with 2.5 pg/ml or 25 pg/ml of apoB-100-derived peptide for 48h. 
The DN-CDOe”" population, the CD8a''CD86‘" population, the DN-MHC-lT population and the 
CD8a^ MHC-ir population remained constant when 2.5 pg/ml and 25 pg/ml of peptides were 
used to load IDCs. Values represent the mean fluorescence intensity for the combination of 
markers shown (MFI), N=1.
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4.4 Treatment of iDCs with the apoB-lOO-derived peptides does not 
alter the IL-10 and IL-12 mRNA expression levels.
Since my aim in this project was to create a DC phenotype that could 
immunomodulate atherosclerosis, in this section I examined the pattern of cytokines 
IL-10 and IL-12 secreted by peptide-loaded DCs and how these can be linked with 
the immune response that could be triggered by the peptide-loaded DCs.
IL-10 renders DCs tolerogenic while originally it had been described as a 
cytokine-synthesis-inhibiting factor (CSIF). It has been also shown to exert 
suppressive effects on a variety of lymphocyte populations. Exposure of human or 
murine DCs to IL-10 reduced surface expression of MHC-I and MHC-II molecules 
and also T cell co-stimulatory molecules of the B7 family [443-445]. Moreover, the 
release of pro-inflammatory cytokines (i.e. IL-1, IL-6, TNF-a, and IL-12) was 
abolished following IL-10 treatment [446, 447]. In contrast, mDCs seem to be 
insensitive to IL-10 and display a stable phenotype [448, 449]. In accordance with 
their reduced MHC and B7 expression, IL-lO-treated DCs lag behind in T cell 
stimulation in contrast to fully activated DCs. However, there is evidence that IL-10 
modulates DC maturation enabling the induction of T cells with regulatory 
properties. For instance, when isolated Langerhans cells were exposed to IL-10, they 
inhibited proliferation of Thl cells but had no effect on Th2 cells [450]. In addition, 
peripheral blood IL-lO-induced DCs can induce a melanoma-antigen specific anergy 
or anergy in CD4^ and CD8^ T cells [451, 452]. Further analysis of these anergic T 
cells showed reduced production of IL-2 and IFN-y and unlike genuine Tregs, 
reduced expression of the IL-2 binding subunit of the IL2 receptor, CD25. The 
appearance of genuine Tregs has also been observed in vivo after IL-10
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administration [453], so IL-10 induced DC modulation may play a role in generation 
of Tregs in vivo. Addition of IL-10 to in vitro cultures differentiated DCs to a 
CD45^‘^  tolerogenic phenotype, and along with regulatory Trl cells, this phenotype 
is significantly enriched in spleens of IL-10 transgenic mice [453]. There is also 
evidence that Tregs control DC functions showing that there are feedback loops 
between them [454]. Co-culture of DCs with Tregs retained their immature state and 
showed low rate of T cell proliferation and increased production of IL-10 [448]. 
Moreover, in an experiment where 15-deoxyspergualin, an anti-rejection drug was 
used to induce high levels of splenic CD4^CD25^ Tregs and iDCs [455], when these 
Tregs isolated fi*om the tolerant recipients were incubated with DC progenitors, DCs 
with inferior T cell stimulatory capacity and IL-10 production were generated. 
Prolonged immunosuppression can be obtained with this positive feedback loop of 
IL-10 production. The ability of the IL-10 modulated DCs to prevent autoimmunity 
and increase significantly graft survival in mice could have therapeutic use [456, 
457].
At the same time, the early production of IL-12 determines the development of 
both innate resistance and adaptive immunity to many intracellular pathogens. 
Although the main source for this production upon microbial stimulation was 
considered to be the macrophages, experiments of immunolocalization and flow 
cytometric analysis demonstrated that DCs are the initial IL-12 producing cells in 
spleens of mice exposed to microbial stimulants. This production was rapid, INF-y 
and CD40 ligand independent, and was followed by an increase in DC number, by 
migration of DCs to the T cell areas and also by appearance of interdigitating DC 
markers. Interdigitating DCs are a subset of DCs exhibiting low antigenic processing 
ability but a high expression of MHC-II and co-stimulatory molecules, so they have a
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strong lymphocyte stimulatory potential. [458]. Therefore, DCs function at the same 
time as antigen-presenting cells and as IL-12 producing accessory cells during the 
initiation of cell-mediated immunity to intracellular pathogens suggesting a model of 
DC action which doesn’t require a three-cell interaction for Thl differentiation [459].
Because of its role in Thl cell responses and innate immunity, IL-12 has been 
the focus of extensive research [460]. Macrophages produce IL-12 through two 
pathways. In the first one, macrophages and T cells interact and the first ones 
produce IL-12 after stimulation by T cell-derived, membrane-bound or soluble 
CD40L. In the second one, products of pathogens directly stimulate macrophages 
[461]. Little is known about the effects of microbial stimuli in IL-12 production by 
DCs. It is believed that the main mechanism is through DC-T cell interaction and that 
activators of macrophages like LPS or bacteria have less effect on the process [447, 
462-464]. IL-12 produced in this way is induced through the CD40- CD40L ligation 
as well as through direct signaling by MHC-II molecules cross-linked by the TCR 
[447,462,465].
The data described above have led to a unified model of IL-12 production 
which results in Thl development. According to this model, macrophages bridge 
innate and adaptive immune responses. More specifically, in the first phase, 
microbial stimulation of macrophages leads to IL-12 production and sets the basis for 
Thl development [466-468]. In a later phase, DCs interacting with antigen-specific T 
cells commence to produce IL-12, which, accompanied by IL-12 produced by 
macrophages, promotes Thl differentiation [469,470].
In my experiments, I decided to look first at the IL-10 and IL-12 pattern of 
expression, by measuring their relative mRNA expression (section 4.4.1) and then at
174
their pattern of secretion by measuring their level of secretion in the supernatant of 
peptide-loaded DC cultures (section 4.4.2).
4.4.1 apoB-lOO-derived peptides do not affect the mRNA expression 
levels of IL-10 and IL-12 in DCs.
DCs were treated with 5pg/ml of P2, P45 or P210 for 48h and the mRNA 
expression levels of IL-10 and IL-12 were measured in the treated DCs and their 
controls using RT-PCR as described in section 23.6.2.
The apoB-100-derived peptides did not affect the relative expression of mRNA 
encoding IL-10 compared to immature/non-stimulated DCs, resembling a 
tolerogenie-like phenotype. IL-10 expression was increased by LPS treatment of DCs 
(Control mean 1.80 SD ± 0.45, LPS mean 3.10 SD ± 0.29; p value to control = 
0.003), (Figure 4.15). These results are going to be discussed in the next section 
(4.4.2) in correlation with the secretion data for IL-10.
Peptide treatment of iDCs did not also alter the expression levels of IL-12 
mRNA compared to untreated cells (Figure 4.16). IL-12 secretion however was 
induced in the LPS-treated DCs (Control mean 26.67 SD ± 8.92, LPS mean 133.38 
SD ± 7.06; p value to control = 0.001) (Figure 4.16). These results are going to be 
discussed in the next section, 4.4.2 along with the IL-12 secretion results.
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Figure 4.15: Analysis of IL-10 mRNA expression in DCs incubated with apoB-100-derived 
peptides, with or without LPS, showed that the levels of expression are the same in peptide- 
loaded or unloaded DCs. Cells were treated with the peptides (5pg/ml) and/or LPS (5pg/ml) 
and the mRNA expression was analysed by RT-PCR, normalising IL-10 mRNA levels with 
GAPDH mRNA. IL-10 mRNA levels were the same in unloaded DCs and peptide-loaded 
DCs (A, B). IL-10 expression was higher when LPS was used to treat the cells (B). Values 
represent mean ± SD, N=6, * P<0.05, ** P<0.01 compared to control.
176
400A
300
200
100
P45Control P2
B 400
'0
« 300
I
IJ  200 01
100
*>!<
■
Control P210 LPS P210+LPS
Figure 4.16: Analysis of IL-12 mRNA expression by peptide-loaded DCs incubated with or 
without LPS, showed that the levels of expression were the same as in iDCs. Cells were 
treated with the peptides (5pg/ml) and/or LPS (5pg/ml) and the mRNA expression for IL-12 
was normalised using GAPDH and examined by RT-PCR. IL-12 mRNA levels following 
peptide incubation of the iDCs remained equal to the levels expressed in unloaded DCs (A, 
B), but when the cells were incubated with LPS they increased significantly (B). Values 
represent mean ± SD, N=6, * P<0.05, ** P<0.01 compared to control.
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4.4.2 The apoB-lOO-derived peptides do not alter IL-10 and the IL-12 pattern of 
secretion in DCs.
I then went on to study the secretion of IL-10 and IL-12 from peptide-loaded 
DCs by ELISA using the supernatant from peptide-treated cultured DCs after 48h as 
described in section 2.3.6.1. The analysis showed that secretion of IL-10 by DCs 
treated with P2, P45 and P210 (5pg/ml) was not significantly different to untreated 
cells (Figure 4.17). These data correlate very well with the IL-10 mRNA expression 
presented in section 4.4.1. It is known that IL-10 is constitutively secreted by DCs 
even at a basal level to ensure maintenance of tolerance during homeostasis [471]. Its 
continuous secretion even in the presence of IL-12 [472] contributes to the 
development of anti-inflammatory responses [471, 473]. It appears that the peptides 
are not affecting the synthesis and secretion of IL-10, allowing the cells to retain a 
tolerogenic phenotype. As already described, IL-10 down-regulates DC antigen- 
presenting function, induces T cell tolerance [474] and also inhibits the release of IL- 
12 and its effects on T cells, thus down-regulating Thl responses [475].
Treatment of DCs with LPS alone (5pg/ml) or in combination with the 
peptides induced the secretion of IL-10 (Control mean 0.00 SD ± 0.74, LPS mean 
11.41 SD ± 6.52; p value to control = 0.00, LPS + P210 mean 13.09 SD ± 7.34; p 
value to control =0.00) (Figure 4.17). It has been observed that time-dependent 
events can drive in vitro cultured DCs towards tolerance or immunity. More 
specifically, the exposure schedule of GM-CSF-generated BMDC to bacterial 
lipolysaccharide (LPS) determines the pattern of cytokine secretion. Thus, when 
Jiang et al [472] exposed freshly purified BMDC (day 6, early DCs) early to LPS IL- 
10 production was induced, while a delayed administration of LPS for up to 22h (late
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DCs) induced IL-12 production. Both DC populations expressed similar levels of 
MHC-II and co-stimulatory CD86 and CD4; the cytokine profile was the one 
affected by the incubation time with LPS. Although, the exact mechanisms and the 
involved signaling pathways of this early DC-IL-10/late DC-IL-12 response are not 
fully understood, the DC maturation state determines their immunostimulatory 
properties [476, 477]. IL-12-producing late DCs induce an increased level of 
allergenic, naive T cell proliferation in comparison with IL-lO-producing early DCs, 
upon LPS stimulation. Thus, the DC maturation state and the cytokine-secretion 
pattern may control the induction of tolerance or immunity [478, 479]. Canine DCs 
secrete high levels of both IL-10 and IL-12 upon LPS stimulation [480]. Moreover, 
IFN-y secretion has been shown to increase IL-10 production by murine DCs [472].
I used the same supernatant to assess the secretion of IL-12 also using 
ELISA. IL-12 is a pro-inflammatory cytokine secreted by activated, mDCs in large 
amounts and its main role is to induce IFN-y secretion from DCs and can drive the 
differentiation of naive T cells into Thl cells [459] in vitro and in vivo [481]. 
Peptides P45 and P210 did not affect the secretion of IL-12; the cytokine was present 
in the media at low levels as it was the case with iDCs (Figure 4.18). This is an 
indication that the peptides P45 and P210 do not induce DC activation. However, P2 
increased the secretion of IL-12 (Control mean 0.00 SD ± 3.36, P2 mean 10.96 SD ± 
4.83; p value to control =0.023). This result comes as a contradiction to the data 
presented previously on the lack of effect fi*om P2 on activation markers on DCs that 
have been linked with their maturation. An interesting study by Gricoleit et al. that 
used the human cytomegalovirus (HCMV) to study its effect on DCs activation, 
showed that the immunostimulatory ability of DCs was reduced by down-regulation 
of CD40, CD86, MHC-II under the effect of the virus and allogenic T cell
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proliferation was inhibited by DCs even though pro-inflammatory TNF-a production 
was increased [482] The same could be happening for IL-12 in my experiments 
examining P2-loaded DCs. The induction of secretion of the pro-inflammatory IL-12 
in P2-loaded DCs could explain why this peptide has not been this effective in 
reducing atherosclerosis when vaccinated in mice compared to peptides P45 and 
P210 (Dr J. Nilsson, personal communication).
IL-12 was also significantly up-regulated by cells treated with LPS, alone or 
in combination with the peptides (Control mean 0.00 SD ± 0.99, LPS mean 127.02 
SD ± 75.75; p value to control =0.00, LPS + P210 mean 116.07 SD ± 71.40; p value 
to control =0.00), an indication of their maturation on that stimuli (Figure 4.18). It is 
well known that LPS induces IL-12 secretion from DCs through TLR binding [483]. 
It must also be noted that DCs that have been generated in the presence of GM-CSF 
and IL-4 have been shown to secrete higher levels of IL-12 compared to DCs that 
had been generated in the presence of GM-CSF alone [472].
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Figure 4.17: The secretion levels of IL-10 by peptide-loaded DCs are the same as in iDCs. 
The supernatant of cells cultured for 48h with the peptides (5pg/ml) was used to assess the 
secretion of the IL-10 anti-inflammatory cytokine using an ELISA assay. The peptide-loaded 
DCs maintained the same levels of secretion of the cytokine (A,B). LPS (5pg/ml) was 
responsible for the enhanced secretion of IL-10, when used alone or in combination with the 
peptides (B). Values represent mean ± SD, N=9, * P<0.05, ** P<0.01 compared to control.
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Figure 4.18: Secretion of IL-12 by DCs induced by apoB-100-derived peptides rests in the 
same levels as in untreated DCs. The supernatant of cells cultured for 48h with the apoB- 
100-derived peptides (5pg/ml) was used to assess the secretion of the IL-12 pro- 
inflammatory cytokine using an ELISA assay. P2 induced IL-12 secretion in iDCs (A, B). LPS 
however, alone (5pg/ml) or in combination with the peptides, did up-regulate IL-12 secretion 
(B). Values represent mean ± SD, N=9, * P<0.05, ** P<0.01 compared to control.
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4.5 apoB-lOO-derived peptides do not influence the matrix 
metalloproteinase mRNA synthesis pattern in DCs
Lastly, I examined the secretion of MMP-2 and MMP-9 by peptide-treated 
DCs as these two MMPs have been described to play a crucial role in atherosclerosis. 
MMPs are involved in collagen breakdown in atherosclerotic plaques [484] and they 
have been found to be produced by DCs [485] which will probably allow their 
movement within the plaques to form the necessary associations with other cells to 
facilitate inflammatory responses. MMP2 is believed to be a pro-atherogenic 
metalloproteinase [486] while, in contrast, MMP9 is thought to have an anti­
inflammatory role in atherosclerosis [487].
Researchers have shown that MMP-2 deficiency leads to decreased 
development of plaque lesion in apoE mice. Moreover, in the aortic sinus region, 
they observed a decreased plaque volume, less areas containing macrophages and 
SMCs, and less collagen in the plaque lesions of MMP-2' 'apoE' ' mice than those of 
MMP-2^^ '^apoE' ' mice. The fact that MMP-2 and macrophages are found to be 
colocalized in atherosclerotic plaque lesion of aortic sinus in mice, something that 
also seems to apply for human atherosclerotic lesions [486, 488, 489], may propose 
that MMP-2 plays a role in migration of monocytes into the intima or that MMP-2 
plays a role in their proliferation in the same region. In the aortic arch region of 
MMP-2' '^apoE' '^ mice, a reduction in the atherosclerotic lesion and less SMC areas 
were also observed but there were no observed differences in macrophage and 
collagen-positive areas between the two genotypes [490, 491]. Furthermore, in 
MMP-2^^ '^apoE' '^ mice, a region with thicker fibrous cap, rich in SMCs and collagen
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was observed, which indicates that MMP-2 regulates plaque stability through SMC 
accumulation in the fibrous cap.
It is hypothesized that MMP-2 modulates the accumulation of macrophages 
in the atherosclerotic lesions in a different manner for every area [486]. This might 
resemble the effect of MMP-9 on macrophage accumulation in the atherosclerotic 
lesions, since deficiency in MMP-9 enhances macrophage accumulation in 
brachiocephalic artery lesions but decreases their collection in carotid artery and 
descending aorta in apoE ''' mice [487, 492, 493]. Therefore, MMP-9 seems to 
function in a different way at distinct artery regions during the atherosclerosis 
development, a hypothesis based on the observed deficient MMP-9 function during 
formation of atherosclerotic lesions as well as the observed changes in cell type and 
number at the lesion site. For example, MMP-9 deficiency decreased the plaque size, 
macrophage content, and collagen deposition in aortic lesion of apoE ' '^mice [493]. 
But another more recent study suggested that MMP-9 deficiency increases plaque 
size, macrophage accumulation and reduces the SMCs population in the 
brachiocephalic artery in apoE mice [487].
When atherosclerotic lesions from apoE/MMP-9 double knockout mice were 
examined in comparison with apoE single knockout controls, they presented an 
unstable plaque phenotype. Remarkably, results from MMP-9 knockout mice 
studying the effects of arterial injury [494], flow cessation [495], and atherosclerosis 
formation [493] on smooth muscle cell behavior demonstrated that MMP-9 possibly 
modulates directly smooth muscle migration. In contrast, other evidence shows that 
MMP-9 is not the major regulator of macrophage migration [496]. There is also the 
interesting possibility of direct effect of MMP-9 on thrombus maturation and 
dissolution since MMP-9 can inhibit platelet aggregation as a response to thrombin
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or collagen [497] and can also degrade fibrin [498]. Moreover, thrombus formation is 
able to modulate MMP-9 secretion fi*om surrounding leukocytes [499]. For this 
reason, MMP-9 could decrease thrombus size and its elevated secretion could drive 
smooth muscle cell-directed healing after atherosclerotic plaque rupture, affecting in 
retardation of plaque expansion and increased stability of the newly forming cap. In 
fact, patients with acute coronary syndromes have higher plasma levels of MMP-9 
when compared with patients suffering from stable effort angina [500, 501]. Thus, 
these data suggest that MMP-9 is involved in the process of acute plaque rupture
[502] while other results suggest the alternative possibility of increased plasma 
concentration of MMP-9 as a result of the healing response after an acute coronary 
event [487].
Studies have shown that MMP-9 (gelatinase B) is produced by DCs; this was 
not unexpected considering that DCs are among the most capable APCs in migration
[503]. Moreover, it was shown that MMP-9 is involved in the migration of 
Langerhans cells and their subsequent maturation [504, 505]. TNF-a and IL-ip can 
up-regulate the zymolytic and net gelatinolytic function of DCs, while IFN-P has 
been found to down-regulate significantly the net enzymatic function [506].
MMPs are characterized by overlapping activities and as a result, a potential 
loss of MMP-2 can be partially counterbalanced by MMP-9. But the MMP-9 mRNA 
level in MMP-2'^ apoE' " mice was shown to be only slightly higher than that in 
MMP-2^^^apoE' '^ mice and tissue inhibitor of MMPs (TIMP) expression was 
decreased in MMP-2' deficient mice [486]. This data could result in the hypothesis 
that MMP-2 might be of significance in modulating TIMP expression.
mRNA was extracted from DCs that were incubated with the peptides 
(5pg/ml) in the presence or absence of LPS (5pg/ml) for 48h and RT-PCR was
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performed to study the expression of MMP-2 and MMP-9. The levels of expression 
of the genes was normalised against the levels of expression of the home keeping 
gene GAPDH.
The levels of mRNA expression of MMP-2 in P2, P45 and P210-loaded DCs 
were equal to the levels of expression in unloaded DCs (Figure 4.19). No significant 
effect on the expression was observed after treatment of the cells with LPS either. 
The levels of MMP-9 mRNA expression also remained unchanged following 
incubation with the peptides and/or LPS (Figure 4.20).
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Figure 4.19: The effect of apoB-lOO-derived peptides on MMP-2 mRNA synthesis is not 
significant when compared to untreated DCs. DCs were incubated with peptides (5pg/ml) 
and levels of mRNA encoding MMP-2 normalised to GAPDH mRNA and were analysed by 
RT-PCR. The peptides P2, P45 and P210 did not alter significantly the synthesis of 
transcripts for MMP-2 (A, B). Neither did LPS, alone (5pg/ml) or in combination with the 
peptides (B). Values represent mean ± SD, N=6.
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Figure 4.20: The effect of peptides on MMP-9 mRNA synthesis does not differ significantly 
to IDCs. DCs were incubated with peptides (5pg/ml) and levels of MMP-9 mRNA were 
analysed by semi-quantitative RT-PCR, where GAPDH was used as a house-keeping gene. 
There was no effect on MMP-9 mRNA expression by the other peptides or LPS (5pg/ml) 
compared to unloaded IDCs (A, B). Values represent mean ± SD, N=6.
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4.6 Conclusion
Cultures of apoB-100-peptide-loaded CDllb^ DCs displayed the same 
percentage of CD 11c, CD40, CD86 and MHC-II positive cells as cultures of 
untreated CDllb^ DCs. Incubation of DCs with P210 (5pg) decreased the percentage 
of CDllc and CD lib  positive cells by half, indicating that P210 has an effect on 
DC differentiation. It must be noted that the flow cytometry experiments studying the 
expression of activation markers on DCs are comparable with my light microscopy 
results used to visualize the morphology of peptide-loaded DCs. All four peptides 
seem not to have an effect on the immature phenotype on DCs as no change in cell 
morphology was observed compared to the effect induced by LPS in which dendrite­
like differentiated morphology was observed.
Higher doses of the peptide (25 pg) did not change the effect of the peptides 
on the expression of activation markers on DCs. A study of the DC subsets that are 
generated from my bone marrow isolations showed that most of them (around 80%) 
belong to the putative tolerogenic CDl lc^ *®^ CDl lb^^^^CD8a'CD4‘ subset and the rest 
(about 20%) to the CDl Ic^^^^CDl lb^^^CD8a^CD4" subset that has been implicated 
both in tolerogenic and inflammatory responses.
apoB-100 derived peptides do not influence the IL-10 and IL-12 mRNA 
expression and secretion in comparison to their levels in untreated DCs nor MMP-2 
and MMP-9 mRNA expression.
Following the phenotypic and activation profile of peptide-loaded DCs, in the 
next chapter I go on to examine the effect that the apoB-100-derived peptides have 
on the functionality of DCs by studying them in co-cultures with CD4^ cells.
189
CHAPTER 5 EFFECT OF apoB-lOO-DERIVED 
PEPTIDES ON FUNCTIONAL PROPERTIES OF BMDCs
5.1 Introduction
In the previous chapter, iDCs were treated with apoB-100-derived peptides 
and a series of experiments were run to characterise their morphology, using light 
microscopy, and their phenotype, as described by surface markers and cytokine 
expression & secretion, using flow cytometry, PCR and ELISA. My results showed 
that peptide-loaded DCs retain a tolerogenic morphology and phenotype, similar to 
unloaded iDCs. The next step in my study regarded the function of peptide-loaded 
DCs. My aim in this project was to assess if the peptides have an immunomodulatory 
effect on DCs that could influence T cell responses involved in atherosclerosis.
Physiologically, when antigens that enter the organism are captured by DCs, 
the latter carry them from peripheral tissues towards lymph nodes where T cells 
circulate. The presence of those antigens in T cell regions leads to primary and 
memory T cell responses. More specifically, chemokines like the secondary 
lymphoid-tissue chemokine (SLC) and the macrophage inflammatory protein 3b 
(MIP-3b) play an important role, when binding to the corresponding chemokine 
receptors on DCs, in the process of DC maturation and their transportation through 
the lymphatic system towards the lymph nodes where they interact with naïve T cells 
resulting in their activation [507-509]. After their activation, T cells (called now 
effector T cells) differentiate, proliferate, transport through blood and lymph vessels.
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move through activated blood vessels, and finally reside to the region under 
infiammation [507, 508].
The encounter between antigen and DCs results in the secretion of large 
quantities of inflammatory cytokines, like IL-12 [459] and IFN-a [510] by DCs. 
mDCs promote the initiation of T cell responses: the process of correct MHC- 
peptide complex recognition by naive CD4+ T cells through their antigen-specific 
TCR results in the generation of a signal that prepares T cells for full activation [511, 
512]. Moreover, DCs have the ability to polarize the immune response towards Thl 
or Th2 responses [513-515] as well as to enhance memory of T cells [478, 516]. 
Nevertheless, TCR-MHC-peptide complex interaction alone is not sufficient for T 
cell activation and may lead in the induction of a T cell non-responsiveness state or 
anergy [517-520].
DCs have the ability to induce antigen specific unresponsiveness (or tolerance 
or anergy) in central lymphoid organs as well as in the periphery [254]. More 
specifically, DCs can induce tolerance by deleting self-reactive T cells in the thymus. 
In addition, DCs can induce tolerance in peripheral lymphoid organs: The presence 
of low doses of antigens, which interact with the DC receptors responsible for 
antigen uptake, results in corresponding T cell deletion and unresponsiveness to 
antigen encounter of stronger dose [254]. On the other hand, when a DC maturation 
stimulus is administered simultaneously with the antigen, immunity occurs in mice, 
accompanied with IFN-y-secreting effector T cells and memory T cells [254]. 
Furthermore, DCs have been attributed the ability to promote the proliferation and 
differentiation of T cells which repress other immune T cells [254].
This chapter examines what happens to the phenotype and function of naïve 
CD4^ T cells, the subgroup of T cells that is involved in the recognition of
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extracellular antigens, such as peptides, when they are co-cultured, and therefore 
interact, with peptide-loaded DCs. This involved examining whether peptide loaded- 
DCs have an effect on the phenotype of CD4^ cells. I studied this by looking at the 
surface markers CD25 and CD69, known to be involved in T cell activation. The 
second important question was if they influence CD4^ proliferation. This was tested 
by analysing the effects on both syngeneic and allogeneic T cell proliferation. My 
final question regarded the mechanism via which the peptides could act on T cells 
and if this is indeed mediated by DCs or if the peptides can act on T cells directly. 
That was examined by a series of proliferation experiments where T cell proliferation 
was triggered by different stimuli and then peptides were added to the culture to 
investigate if they can influence proliferation.
5.2 Incubation of T cells with apoB-100 peptide-loaded DCs does not 
up-regulate CD25 or CD69 expression on T cells.
The first step was to examine the effect of peptide-loaded DCs on the 
phenotype of CD4^ T cells. I analysed the expression of surface markers such as 
CD25 and CD69 on T cells to judge this. CD25 is a growth factor receptor and a 
transmembrane protein characteristic of activated T cells and activated B cells. 
Along with CD 122 it comprises the IL-2 receptor [521]. When T cells are activated, 
IL-2 is produced and CD25 is expressed [522]. IL-2 binds to the IL2R and since it is 
the most critical cytokine for inducing the clonal expansion of recently-activated T 
cells [523], T cell proliferation is initiated. CD25 is a characteristic marker of 
CD4+FoxP3+ Tregs in mice and humans as well as of resting memory T cells in 
humans [524]. It has been shown that co-culture of T cells with lipopolysaccharide
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treated or CD40L pre-treated human DCs resulted in enhanced CD25 expression on 
T cells. Additionally, anti-CD25 antibodies prevent DCs from priming T helper cells 
[525]. Furthermore other studies show that during maturation murine myeloid DCs 
up-regulate the expression of CD25 among others [526]. A team of researchers 
focused on examining the responsiveness of macaque monocyte-derived DCs to 
different maturation stimuli like CD40L, LPS, Poly I:C, PGE(2)/TNFalpha, and a 
cocktail mixture of PGE(2)/TNFalpha/IL-1 beta/IL-6 and they reported enhanced 
CD25 expression following all stimuli. Furthermore, soluble CD40L stimuli lead to 
variable expression of CD25 [527].
CD69 is a dimeric glucoprotein whose expression is induced immediately 
after lymphoid activation [528]. It functions as a signal receptor in lymphocytes, 
natural killer (NK) cells, and platelets and is implicated in lymphocyte proliferation 
[529, 530]. It is the earliest inducible cell surface antigen expressed during 
lymphocyte activation and its activation has been shown to activate the secretion of 
TNF-a, a pro-inflammatory cytokine [528]. CD69 has been found expressed in vitro 
by lymphocytes activated by different stimuli and in vivo infiltrating in sites of 
chronic inflammation. CD69 has been found to be transiently expressed during Ag- 
specific T cell division in experiments studying T cell activation in lungs following 
the transfer of Ag-pulsed BMDCs into the airways of naive mice [531]. It has also 
been shown to induce bystander T cell proliferation through pDC IL-2 production 
and T cell sensitization to IL-2 without affecting antigen-driven T cell proliferation 
[532].
According to some studies, CD8  ^ splenic DCs that come from steady-state 
mice cannot generate CD4 T cell proliferation as effectively as CD8" DCs. However,
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both subtypes have been found to equally activate CD4 T cells as it occurs by the 
observed CD69 and CD25 up-regulated expression [533].
As described in section 2.3.3.2,1 extracted splenocytes from apoE' '^ mice and 
isolated the population of naïve CD4^ T cells by negative selection. I added them in 
cultures of peptide-loaded DCs for 72h and at the end of the incubation time, I 
carefully collected T cells (that float), taking care not to touch the bottom of the well 
where DCs tend to adhere to the culture plate surface.
Two experiments were run to test the percentage of CD4^CD25^ or 
CD4^CD69^ T cells that were generated following co-culture with peptide loaded- 
DCs: the first one (A) involved co-cultures with P2, P45-loaded DCs as well as 
unloaded DCs. LPS-treated DCs were tested to examine if they acted as a positive 
control for increasing the numbers of CD25 and CD69-expressing T cells. Another 
culture involved LPS-treated DCs that had been incubated with P2 and P45, 24h 
following the treatment with LPS. The hypothesis behind this was to check if the 
peptides are able to influence the effect that LPS has on the function of DCs, more 
specifically to inhibit the activation that the LPS induces, and therefore also affect 
the response that the DCs induce on T cells. The second experiment (B) comprised of 
co-culture of unloaded DCs, P210-loaded DCs, LPS-treated DCs and the DCs that 
had been treated with both LPS and peptide.
T cells were washed and labelled with antibodies against CD4 and CD25 or 
CD4 and CD69 markers. The percentage of CD4^ T cells expressing the CD25 or the 
CD69 activation marker was analysed by flow cytometry. A representation of the 
settings used for the flow cytometry data analysis is shown in Figure 5.1. The cell 
population that I set as the T cell population within my collection from the co-culture 
is seen in Region 1 and was selected to exclude debris, dead cells or DCs (larger
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cells) (Figure 5.1-1). An isotype negative control for every marker was used to label a 
group of cells in order to set a baseline for the positive readings of the corresponding 
marker (Figure 5.1-II, Figure 5.1-III).
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Figure 5.1: Representative dot plots of the settings used for the flow cytometry analysis of T 
cell phenotypic (CD4) and activation (CD25, CD69) markers. In graph I, the cells appear in 
the SSC and FSC and the T cell population that was selected for the flow cytometry study 
can be seen in the Region 1 (R1). In graphs II and III, the cell population appears labelled 
with an RPE and an FITC isotype that are used as controls. Graph II depicts the pair of 
isotypes for CD4 & CD25 and graph III the pair of isotypes for CD4 & CD69. The top right 
square of the quadrant defines the positive values for the fluorescence of the fluorochromes.
The percentage of double positive cells for CD4 and CD25 (Figure 5.2) or 
CD4 and CD69 (Figure 5.3) was measured by the flow cytometry software following 
examination of the top right quadrant in the dot plots. This quadrant was set as the 
area of the graph where both markers emit fluoreseence based on the readings that 
the isotype controls had provided (Figure 5.1).
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Figure 5.2: Representative dot plots from the flow cytometry analysis corresponding to each 
co-culture of DCs and T cells. A: peptides P2 and P45, B: P210. Both panels include the 
corresponding controls. The cells that were expressing both CD4 and CD25 are found in the 
top right quadrant and the percentage they represented to the whole cell population was 
calculated using the WinMDI software.
196
$
Q
U
2 2
Control
2
P2
è
P45
7.18%
2
8.39%
2
7.60%
m . 2 2
f
2 f t ; ' 2 & 2 . # 3  ; - :10° 10 10= 10° 10 10° 10 10= 10° 10 10° 10 10= 10°
LPS
2
LPS&P2
2
LPS & P45
5.61%
2
5.05%
2
4.35%
2 2 :;ÿ # :
& i 2 #
10° 10 10= 10° 10 10° 10 10= 10° 10 10° 10 10= 10° 10’
Control
10.71%
10°
â  ■
■'io' 'io= 10=
P210
08.43%
~ W  i P -
B
LPS
09.58%
1 0 ' 10= 10= 10 '  10° 10 '
LPS & 
P210
10.80%
10= 10 '
CD4
Figure 5.3: Representative dot plots from the flow cytometry analysis in T cells co-cultured 
with peptide- loaded DCs for the CD4 and CD69 markers A: peptides P2 and P45, B: P210. 
Both panels include the corresponding controls. The double positive cells are found in the 
top right quadrant and their percentage in the whole cell population has been calculated 
using the WinMDI software.
A comparison of the percentage of double positive cells for each co-culture is
shown in the bar charts (Figure 5.4). The P2, P45 and P210-loaded DCs did not
significantly alter the number of CD4 and CD25 positive cells compared to control T
cells alone (For experiment A, control mean 8.86, SD ± 2.09, P2 mean 7.94, SD ±
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2.76; p value to control = 0.74, P45 mean 7.77, SD ± 2.38; p value to control= 0.67. 
For experiment B, control mean 16.6, SD ± 1.85, P210 mean 15.11, SD ± 4.55; p 
value to control = 0.58). This indicates that the peptides do not influence the ability 
of DCs to induce the expression of the CD25 activation marker by T cells. 
Noticeably, this was also the ease for the LPS (control mean 16.6, SD ± 1.85, LPS 
mean 21.08, SD ± 12.08; p value to control = 0.65) or the combination of LPS and 
peptide (control mean 16.6, SD ± 1.85, LPS & P210 mean 17.29, SD ± 0.38; p value 
to control = 0.74).
Control
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Figure 5.4: Peptide-loaded DCs and LPS-treated DCs do not affect the expression of CD25 
on naïve CD4 T cells. Flow cytometry was performed following 72h co-culture of naïve T 
cells with peptide-loaded or LPS-treated DCs. The number of the CD4^CD25^T cells was the 
same in the cultures of peptide-loaded DCs and in the cultures of unloaded DCs (A, B). LPS- 
treated DCs or LPS & peptide treated DCs did not induce the expression of CD25 on more T 
cells either (B). Values represent mean ± SD. N=3.
When the percentage of the double positive CD4 and CD69 cells was 
compared amongst all the eo-cultures, no significant effect was observed (For 
experiment A, control mean 6.29, SD ± 1.26, P2 mean 6.51, SD ± 2.66; p value to 
control = 0.93, P45 mean 6.32, SD ± 1.81; p value to eontrol= 0.99. For experiment 
B, control mean 10.17, SD ± 0.76, P210 mean 10.76, SD ± 3.29; p value to control =
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0.87) (Figure 5.5). This suggests that peptide-loaded DCs do not to activate naïve 
CD4^ T cells as judged by the expression of CD69. This finding agrees with the 
finding from the CD25 experiment: Peptide-loaded DCs do not affect neither the 
expression of CD25 nor the expression of CD69.
Surprisingly, LPS did not influence the ability of DCs to activate CD69 on T 
cells (Control mean 10.17, SD ± 0.76, LPS mean 13.23, SD ± 5.16; p value to control 
= 0.60) and neither did the combination of LPS and peptide (Control mean 10.17, 
SD ± 0.76, LPS & P210 mean 13.83, SD ± 4.29; p value to control = 0.49). My 
results showed the same for the expression of CD25, although I would expect the 
both CD25 and CD69 expression to be up-regulated by LPS-treated DCs. However, 
the standard deviation for the expression of CD25 and CD69 on T cells induced by 
LPS-treated DCs was very high, indicating a large variation of values between the 
replicates. If more time was available, I would have repeated this experiment in order 
to confirm the validity of the data and to exclude the possibility of experimental 
errors.
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Figure 5.5; Peptide-loaded DCs and LPS-treated DCs do not affect the expression of CD69 
on naïve CD4 T cells. Flow cytometry studies were performed following a 72h co-culture of 
naïve T cells with peptide-loaded DCs. No significant alteration was seen on the size of the 
CD4'"CD69'^ population when peptide-loaded DCs were present in the culture compared to 
unloaded DCs (A, B). All LPS treated-DCs showed a trend to favour the presence of 
CD4'’CD69‘" T cells in the co-culture but it was not statistically significant (B). Values 
represent mean ± SD. N=3.
5.3 Peptide-loaded DCs fail to induce syngeneic CD4^ T cell 
proliferation
Peptide-loaded DCs did not induce the activation of T cells as measured by 
the expression of CD25 and CD69. To further assess the effect of peptide-loaded 
DCs on T cell proliferation I  examined what happened to the number of CD4^ T cells 
when they are cultured with syngeneic peptide-loaded DCs in comparison to cultures 
with syngeneic unloaded DCs. This experiment served as a control to check whether 
the peptide-loaded DCs had a proliferating effect on T cell proliferation.
Peptide-loaded DCs were co-cultured with naïve CD4^ cells for 72h and the 
proliferation of naïve syngeneic T cells was evaluated with the CyQuant T cell 
proliferation kit (Figure 5.6). P2, P45 and P210-loaded DCs did not have an effect on 
T cell proliferation (Exp A: Control mean 23227.52, SD ± 3056.67, P2 mean
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21306.89, SD ± 1356.83; p value 1.00, P45 mean 18089.95, SD ± 2217.76; p value 
0.91, Exp B: Control mean 70736.25, SD ± 4564.91, P210 mean 77144.17, SD ± 
3477.27; p value 0.49). LPS treated-DCs induced T cell proliferation compared to the 
control as was expected (Exp A: Control mean 23227.52, SD ± 3056.67, LPS mean 
49739.82, SD ± 4585.00; p value 0.00). In experiment B, the results for LPS induced 
T cell proliferation via DCs was not significantly different from the control and this 
was probably due to the high standard deviation in the control sample. The 
combination of LPS and peptide treatment of DCs also increased significantly T cell 
proliferation- to same levels as LPS alone (Exp A: Control mean 23227.52, SD ± 
3056.67, LPS & P2 mean 46858.87, SD ± 2035.24; p value 0.01, LPS & P45 mean 
42033.46, SD ± 3326.64, p value 0.14, Exp B: Control mean 70736.25, SD ± 
4564.91, LPS & P210 mean 136481.33, SD ± 37027.99; p value 0.12).
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Figure 5.6: Peptide loaded-DCs do not induce T cell proliferation. DCs were co-cultured with 
syngeneic naïve CD4* T cells for 72 hours. T cell proliferation was assessed using the 
CyQuant T cell proliferation kit (Invitrogen, USA) assay kit. P2-, P45- and P210-loaded DCs 
did not affect the number of T cells present in co-cultures (A, B). LPS-treated DCs induced 
proliferation and this effect was not significantly altered by the simultaneous treatment of 
DCs with the peptides (A, B). Values represent mean ± SD. N=3, * P<0.05 to control.
I also measured the secretion of IL-2 into the supernatants from the same co­
cultures as another surrogate marker of T cell activation/proliferation. The binding of 
an antigen to a TCR promotes IL-2 and IL-2 receptor (IL-2R) production [534, 535]. 
IL-2/IL-2R binding leads in the induction of proliferation, differentiation and 
survival of antigen-specific CD4^ and CD8^ T cells [536-538].
It has been shown that murine DCs are also capable of producing IL-2 
following activation by different inflammatory stimuli in murine models [539]. In
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this case, IL-2 production is strictly regulated and occurs immediately after microbial 
and T cell-mediated activation [539]. IL-2 production has been demonstrated in vitro 
and in vivo as well as in different DC subtypes, such as CD8^ and CD8" splenic DCs 
and epidermal Langerhans cells [539].
IL-2 production by DCs gives them the ability to prime T cell responses. It 
has been shown that early, bacterially activated, IL-2-deficient DCs were 
characterized by impaired induction of allogeneic CD 8  ^ and CD4^ T cell 
proliferation in contrast to wild-type DCs [540]. Furthermore, cytomegalovirus, an 
immunosuppressive virus, prevents IL-2 production by DCs, and impairs their ability 
to activate T cells [541]. Additionally, it has been demonstrated that IL-2 produced 
by DCs is necessary for DC-mediated NK cell activation [542].
IL-2 secretion in a co-culture with T cells and peptide-loaded DCs was 
measured using ELISA (Figure 5.7). IL-2 secretion was reduced in the co- culture 
that contained P45 compared to the control (P45 mean 0, SD ± 1.52; Control mean 
3.80, SD ± 4.42; p value 0.27). P2 and P210 did not influence the IL-2 secretion (Exp 
A: Control mean 3.80, SD ± 4.42, P2 mean 12.52, SD ± 5.37; p value 0.05, Exp B: 
Control mean 128.67 ± 18.29, 114.98 ± 10.5; p value 0.29. On the other hand, LPS 
increased the synthesis of EL-2 secretion as seen in figure A. Both the peptide and the 
LPS results combined well with the effect of the peptide-loaded DCs on the T cell 
proliferation and indicate that P45 might have a tolerogenic effect on DCs that could 
inhibit T cell proliferation. One way that this could be achieved would be by 
reducing IL-2 secretion either on DCs or on T cells or on both cell cultures in order 
to prevent T cell activation and subsequent proliferation. The experiment in figure B 
should be repeated to check with LPS did not trigger IL-2 secretion and to verify the 
effect of P210 against a positive control.
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Figure 5.7: Peptide-loaded DCs do not induce IL-2 secretion. DCs were co-cultured with 
syngeneic naïve CDA T cells for 72 hours. IL-2 secretion by T cells was assessed using an 
ELISA assay kit by R&D. P2, P45 and P210-treated DCs did not induce IL-2 secretion by T 
cells (A, B). LPS-treated cells up-regulated IL-2 secretion (A). The cytokine levels triggered 
by LPS-treated DCs remained similarly high in cultures where peptides had been used to 
treat DCs simultaneously with LPS (A, B). Values represent mean ± SD. N=3, * P<0.05 to 
control.
5.4 Effects of peptide-loaded DCs on allogeneic T cell proliferation.
Peptide loaded-DCs did not induce T cell proliferation when syngeneic T 
cells were used, either because no stimuli was provided to T cells by the DCs or 
because they did favor a tolerogenic type of response. An experimental model I
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thought of to test this hypothesis was the study of allogeneic T cell proliferation. It is 
known that when iDCs are placed into culture with allogeneic T cells, T cell 
proliferation is induced as iDCs from another species are recognized as “foreign” 
compared to T cells and there is no need for an additional antigen to exist to trigger a 
response.
Higher doses of the peptide and different incubation times were used in this 
experiment to test if they would allow better evaluation of the response of T cells 
following incubation with peptide-loaded DCs. It should be noted that this 
experiment should have had more replicates in order to be conclusive therefore any 
conclusions drawn from it are purely speculative. BMDCs derived from apoE'^' were 
cultured with apoB-100 peptides (2.5pg, 5pg or 25pg) for 12h (Figure 5.8), for 24h 
(Figure 5.9), 48h (Figure 5.10) and T cells isolated from CDl® mice were added for 
72h as described in section 2.2.3.9. Following the incubation, the cells were 
collected, washed and T cell proliferation was assessed using the CyQuant T cell 
proliferation kit.
I observed that DCs loaded with 2.5pg of P2 seemed to inhibit T cell 
proliferation as evaluated at 12h (Figure 5.8) and 48h (Figure 5.10) of culture. On the 
other hand, DCs loaded with 5pg of P210 seemed to down-regulate T cell 
proliferation for up to 12h (Figure 5.8), and for up to 48h when they were loaded 
with 25pg of the peptide (Figure 5.9 and Figure 5.10). However, these first results 
are purely observations and need to be further confirmed by repeated experiments in 
order to statistically analyse the results. Unfortunately, the time and the resources 
needed were not available during this project.
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Figure 5.8: Allogeneic T cell proliferation seemed to be inhibited by peptide-loaded DCs 
following a co-culture for 12h. iDCs were incubated with apoB-100 peptides for 12h and co- 
cultured with naïve CD4+T cells isolated from CD1® mice for 72 hours. The DCs that had 
been loaded with 2.5 pg of P2 or 5 pg of P210 seem to halt the proliferation of T cells 
compared to the proliferation induced by unloaded DCs. T cell proliferation was assessed 
using CyQuant T cell proliferation kit (Invitrogen, USA). Values represent mean ± SD; N=3.
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Figure 5.9: Allogeneic T cell proliferation appeared to be inhibited by peptide-loaded DCs 
following a 24h co-culture. iDCs were incubated with the apoB-100 derived peptides for 24h 
and co-cultured with naïve CD4+T cells isolated from CD1® mice for 72 hours. T cell 
proliferation was measured with the CyQuant (Invitrogen, USA) assay kit. The DCs that had 
been loaded with 25 pg of P210 showed a tendency to inhibit the proliferation of T cells 
compared to the proliferation induced by unloaded DCs. Values represent mean ± SD; N=3.
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Figure 5.10: Allogeneic T cell proliferation seemed to be inhibited by peptide-loaded DCs 
following a co-culture for 72h. iDCs were incubated with the apoB-100 peptides P2, P45, 
P210 for 48h and co-cultured with CDl® naïve CD4+T cells for 72 hours. The CyQuant 
(Invitrogen, USA) assay kit was used to evaluate T cell proliferation. The DCs that had been 
loaded with 2.5 pg of P2 or 5 pg of P210 or 25 pg of P210 showed a tendency to inhibit the 
proliferation of T cells compared to the proliferation induced by unloaded DCs. Values 
represent mean ± SD; N=3.
5.5 apoB-100 peptides inhibit the proliferation of syngeneic CD4^ T 
cells induced by oxLDL and/or IFN-y- activated DCs
The previous experiments showed that peptide-loaded DCs did not induce 
syngeneic T cell proliferation. Therefore, my next step was to carry out further 
experiments to examine if the peptide-loaded DCs had a potential tolerogenic or anti­
inflammatory effect. I set up an in vitro model where DCs were first activated by 
oxLDL or IFN-y or oxLDL and IFN-y together and T cell proliferation was induced. 
The peptides where then added to the cultures to test their effect on the proliferation. 
I used this model first with syngeneic T cells which resemble more closely what 
happens in inflammation-induced atherosclerosis.
OxLDL was used to activate DCs as it is indicated that it may have the ability 
to cause immature DC activation and therefore subsequent T cell activation.
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According to a recent study, a considerable increase in MHC-II expression was 
observed following the administration of a physiological concentration of oxLDL on 
iDCs. Therefore, oxLDL may function as a proinflammatory stimulus on iDCs [543]. 
The exact mechanism remains unknown but potentially the increased lipid levels 
overload the local scavenging system, causing free hydrophobic molecules to 
activate cell-surface receptors such as the Toll-like receptors (TLR). As already 
mentioned, TLR signaling activates antigen-presenting cells like DCs which in turn 
lead to T cell activation [544]. Another study has also shown that DCs undergo 
activation and maturation following administration of mildly or highly oxidized LDL 
[545]. In addition, it has been shown that oxLDL in certain quantities results in 
monocyte differentiation to DCs [546].
IFN-y was used to activate DCs as it has been shown that its administration 
on monocyte-derived DCs leads in increased expression of MHC-II and co­
stimulatory molecules and promotes the differentiation of Thl and Thl7 cells [547]. 
It has been shown that the differentiation of Thl cells depends on IFN-gamma as 
well as IL-12 and to a lesser extent IL-2 [548]. Another study showed that IFN- 
gamma along with uncarinic acid C induce Thl polarization which is accompanied 
with an increased migration capability of T cells [549].
I first incubated DCs with oxLDL (100 pg/ml) or IFN-y (5 ng/ml) or the 
combination of both for 48 hours. mDCs were then co-cultured with naïve CD4^ 
cells for 24h after which apoB-100 peptides (25pg/ml or 50 pg/ml of each peptide, 
P2, P45 and P210) were added to the co-culture and cells were incubated for another 
48h. Cells were then collected and proliferation was measured.
OxLDL and/or IFN-y-treated DCs induced T cell proliferation and this was 
inhibited when the peptides (25 pg/ml) were added to the cultures (Figure 5.11). All
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three peptides, P2, P45 and P210 had a similar inhibitory effect on the proliferation 
of T cells, independently of whether they acted on DCs that had been activated with 
oxLDL or with IFN- y or with the combination of both. [Control oxLDL mean 
119160.00 SD± 57260.00, P2 25pg mean 42427.22 SD±4437.22; p 0.05], [Control 
oxLDL mean 119160.00 SD± 57260.00, P45 25pg mean 17515.00 SD±15050.55; p 
0.05], [Control oxLDL mean 119160.00 SD± 57260.00, P210 25pg mean 35556.67 
SD± 11843.33; p 0.05], [Control IFN-y mean 110283.30 SD ±44882.22, P2 25pg 
mean 30271.67 SD±6628.33; p 0.05], [Control IFN-y mean 110283.30 SD 
±44882.22, P45 25pg mean 32802.22 SD±19980.00; p 0.05], [Control IFN-y mean 
110283.30 SD ±44882.22, P210 25pgmean 52296.11SD±5061.66; p 0.05].
An increased peptide dose (50 pg/ml) had a similar effect to the lower dose. 
It was only treatment of IFN- y activated DCs with 50pg of P2 and treatment of ox­
LDL and IFN-y activated DCs with 50pg of P45 which were not found to 
significantly inihibit the proliferation of T cells due to the large standard deviation 
among replicates. [Control oxLDL mean 119160.00 SD± 57260.00, P2 50pg mean 
42020.56 SD± 2025.00; p 0.05], [Control oxLDL mean 119160.00 SD± 57260.00, 
P45 50pg mean 34983.33 SD±4038.88; p 0.05], [Control oxLDL mean 119160.00 
SD± 57260.00, P210 50pg mean 35556.67 SD±11843.33; p 0.05], [Control IFN-y 
mean 110283.30 SD ±44882.22, P45 50pg mean 46425.56 SD±16585.56; p 0.05], 
[Control IFN-y mean 110283.30 SD ±44882.22, P210 50pg mean 22434.44 
SD±23766.66; p 0.05]. No significant difference was observed to the level of 
inhibition of the proliferation between the two doses.
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Figure 5.11: apoB-100 peptides inhibit the proliferation of T cells induced by oxLDL and/or 
IFN-y activated DCs. iDCs were incubated with oxLDL or IFN-y or the combination of both 
for 48h and co-cultured with syngeneic naïve CD4^T cells for 24 hours. Then, apoB-100- 
derived peptides were added after washing and the co-culture was incubated for another 
48h. The peptides abbrogated the proliferation of T cells that had been induced by the 
inflammatory stimuli of oxLDL and IFN-y. T cell proliferation was assessed by the CyQuant 
(Invitrogen, USA) assay kit. Values represent mean ± SD, N=3. Statitistical analysis was 
performed using the non-parametric Kruskal Wallis test. * P<0.05 to control (Control is 
peptide = 0 pg/ml).
5.6 Apo-B 100 peptides might be capable of affecting T cell 
proliferation by direct interaction with T cells.
I then went on to assess the inhibition of T cell proliferation by peptides 
incubated with T cells on their own without the mediation of DCs.
To answer to the question above, I decided to test the effect of the peptides on 
T cell proliferation of T cells alone in a culture. Proliferation of T cells was induced 
first by incubation of naïve T cells in tissue culture plates coated with anti-CD3 and 
anti-CD28 antibodies and then further stimulated with Con A or oxLDL as described 
in section 2.2.3.8.
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ConA is a lectin extracted from the jackbean. It has been reported that Con A 
induces T cell proliferation with simultaneous activation of both T helper and T 
suppressor eell responses [550]. More specifically, ConA induces activities like 
mitogen stimulated cell proliferation, cytotoxic T cell proliferation, precursor 
suppressor cell activation and helper T cells induction on murine and human systems 
[550].
Three doses of ConA and oxLDL were used: 1 pg/ml, 10 pg/ml, 100 pg/ml. 
Then the peptides (25 pg /ml) were added and the cells were cultured for another 48h 
and T cell proliferation was then measured. To my surprise ConA and oxLDL did not 
induce T cell proliferation (Figure 5.12) and this effect was independent of the doses 
of ConA and oxLDL used (data shown corresponds to 100 pg/ml of ConA and 100 
pg/ml of oxLDL).
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Figure 5.12: T cell proliferation is not induced by ConA or oxLDL. T cells were incubated for 
24h with ConA or oxLDL (100 pg/ml) and then the apoB-100 derived peptides were added in 
the culture for another 48h. No proliferation was detected in the cultures where cells were 
incubated with ConA or oxLDL alone. The addition of the peptides did not significantly alter 
the number of cells. Values represent mean ± SD. N=3.
This initial experiment, therefore, did not work since the positive controls did 
not work as expected. Due to this, no conclusion can be drawn for the effect of the
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peptides on T eells. The setup of the experiment could be revised though: it would be 
very interesting to repeat it by altering the conditions (such as the dose and the 
ineubation time of ConA or oxLDL or both with T cells) and also it would be worth 
trying a new vial of each in order to study if they can induce T cell proliferation and 
then be able to examine the effect of the peptides on this induced proliferation.
The last experiment that I performed aimed to investigate if the peptides were 
acting directly on T cell proliferation. I used T cells cultured as above and treated 
them with P2 or P45 or P210 for a longer time, 72h in order allow more time for the 
cells to proliferate. The peptides did not induee proliferation of eells (Control mean 
28546, SD ± 3854.57, P2 mean 35069, SD ± 2944.94, p value 0.116; P45 mean 
26876.75, SD ± 3479.18, p value 0.664; P210 35951.23, SD ± 6806.93, p value 
0.080) (Figure 5.13).
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Figure 5.13: apoB-100 derived peptides do not induce T cell proliferation. T cells were put 
into culture along with the antibodies anti-CD3 and anti-CD28 that activate receptors CD3 
and CD28 to keep T cells alive and sustain the culture. P2, P45 and P210 were added and 
the number of T cells was measured. apoB-100 derived peptides did not induce T cell 
proliferation. Values represent mean ± SD. N=3.
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5.7 Conclusion
In this chapter, I showed that when peptide-loaded DCs are co-cultured with 
T cells for 72h, the percentage of CD4^CD25^ or CD4^ CD69^ activated T cells is 
the same as when unloaded iDCs are stimulating them. Furthermore, syngeneic T 
cell proliferation induced by unloaded DCs remained stable when peptide-loaded 
DCs were used instead to co-culture. P45 inhibited the proliferation as well as 
reducing IL-2 secretion. These data could indicate that the ApoB-100-peptide-loaded 
DCs might be triggering a tolerogenic T cell response and P45 might be the most 
efficient peptide in promoting it.
Interestingly, T cell proliferation had a tendency to halt when allogeneic 
peptide-loaded DCs were used. Most interestingly, syngeneic T cell proliferation that 
had been induced by oxLDL-treated DCs and/or IFN-y-treated DCs, was halted when 
apoB-100-derived peptides were added in the co-culture. In an experiment performed 
to examine the potential effect of the peptides alone on T cell proliferation was not 
conclusive.
This chapter and the two previous ones examined the potential effect of a 
specific antigen, the apoB-100 peptides, on the morphology, phenotype and function 
of dendritic cells that could be used in modulating the immune response in 
atherosclerosis. I showed that ApoB-100-derived peptides are internalised by DCs. 
They are sometimes found inside endosomes and lysosomes and they are also 
sometimes found co-localising with MHC-I and MHC-II inside DCs indicating that 
they might be presented by them. The peptide-loaded DCs maintain the immature 
phenotype that unloaded DCs display as well as the same levels of expression of 
activation markers CD40 & CD86 and of the antigen-presenting MHC-II. The cells
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are CD4'CD8', indicating a tolerogenic potential and there are less of them 
expressing the differentiation markers C D llc & CDl lb. Cytokine mRNA 
expression and secretion (XL-10 and XL 12) is not affected nor is the metalloproteinase 
mRNA expression (MMP-2, MMP-9). When the peptide-loaded DCs are co-cultured 
with T cells they do not have an affect on T cell activation markers, CD25 and CD69 
and they do not induce T cell proliferation or IL-2 secretion. They even inhibit T cell 
allogeneic proliferation and they can also inhibit a syngeneic T cell proliferation that 
had been induced by ox-LDL or IFN-y-activated DCs.
My next step was to study the effect of tolerogenic DCs, generated in vitro in 
the immune responses and the atherosclerotic plaque progression in apoE'^' mice in 
vivo.
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CHAPTER 6 ASSESSMENT OF THE 
ATHEROPROTECTIVE PROPERTIES OF tolDCs IN  
VIVO IN ATHEROSCLEROSIS
6.1 Introduction
This project focused on investigating the potential use of DCs to 
immunomodulate atherosclerotic plaque formation and development as DCs have a 
very important role in influencing the immune responses not only towards immunity 
but also towards tolerance [551, 552] . In the previous chapters I examined the effect 
of three specific antigens, the apoB-100 derived peptides on DC activation and 
function. It has been shown, however, that DCs can work in an antigen independent 
way in order to maintain tolerance [254]. This function of DCs is apparent in 
infectious-fi*ee organisms and it has been already discussed in section 1.18 of the 
Introduction. In this chapter, therefore, I have examined whether tolDCs can have an 
effect on the development of atherosclerosis.
More specifically I have studied the effect that tolDCs, generated in vitro, 
have on atherosclerosis in apoE'^" mice. I wanted to check if tolDCs would be more 
effective in reducing the atherosclerotic process than apoB-100-peptide-loaded DCs 
as the former are not linked with a specific epitope.
Lu et al. were the first to produce in vitro regulatory DCs [553] from murine 
bone marrow after GM-CSF administration. Those DCs were found to be immature 
in phenotype and able to promote in vitro Ag-specific hyporesponsiveness in 
allogeneic T cells. Administration of those donor-derived iDCs, a week before
215
transplantation in a murine cardiac transplantation model characterized by a full 
MHC-mismatch and without pharmacologic or biologic immunosuppressive cover, 
led to enhanced graft survival when compared to untreated mice [554].
Since then, the research has been focused towards optimizing DC handling 
and delivery in order to achieve an improved tolerogenic capability. Researchers 
have also been trying to determine the specific DC subset that will lead to enhanced 
alloAg-specific graft survival [555]. Regulatory DCs are being used in therapeutic 
models in rats and mice through the usage of donor or recipient DCs, in combination 
with or without short-term immunosuppression or other biological substances [555].
More specifically, the strategies using donor DCs usually target the 
expression of co-stimulatory molecules or their interactions with their ligands on T 
cells. This is accomplished with the production of iDCs [479, 556-558] that are 
subsequently administrated in combination or without monoclonal antibodies binding 
to the T cell ligands mentioned above or CTLA4-Ig targeting of important co­
stimulatory molecules expressed by mDCs [557, 559-561]. In cardiac allograft 
models, when co-stimulation abrogation occurs, graft survival is significantly 
prolonged [555]. In order to overcome the chronic vascular rejection problem, 
researchers also studied the effects of the administration of donor iDCs in 
combination with anti-CD40L (CD 154) monoclonal antibodies in a murine aortic 
allograft model [558]. Their results demonstrated almost complete inhibition of 
vascular sclerosis which was accompanied with significant reductions in T cell and 
humoral immunity to donor [558].
The strategies using recipient DCs are also based on the generation of iDCs 
[562, 563] and on increased targeting of the indirect pathway. The latter is 
accomplished through pulsing of recipient DCs with donor peptide or donor cell
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lysate [563-566], with or without the addition of pharmacologic or biologic 
treatment. Theoretically, recipient DCs, which are more available than donor DCs, 
could help towards minimizing the chronic rejection which leads in late graft failure 
during organ transplantation in humans. More specifically, researchers have 
accomplished donor-specific, indefinite heart graft survival in rats after 
administrating ex vivo -generated, recipient-derived, regulatory (or 
immunosuppressive, ISDCs) iDCs [567], [568]. Nevertheless, the mechanism 
involved have not yet been clarified, although implication of the indirect pathway is 
indicated [568].
Several compounds have been found to induce tolDCs. VAF347, a ligand 
which activates aryl hydrocarbon receptor (AhR) signaling, is one of them [569]. 
Estriol (E3) has also been shown to induce the production of tolDCs that confer 
protective ability against experimental autoimmune encephalomyelitis (EAE) [570]. 
Furthermore, tolDCs can be generated in vitro in several ways [555]: by incubation 
with anti-inflammatory cytokines such as IL-10 and TGF-p [571], chimeric fusion 
protein CTLA4-Ig [557] as already mentioned above and Vitamin D3 or by using 
ultraviolet-p radiation [572]. Recently researchers showed that iDCs also have the 
ability to engulf apoptotic and necrotic DCs in vitro and that this uptake results in 
suppression of LPS-induced maturation as well as elevated TGF-pi and TGF-P2 
production which in turn leads to differentiation of naive T cells towards FoxP3^ 
Tregs [573].
Researchers have demonstrated the existence of a regulatory feedback loop in 
vivo between tolDCs generated in vitro and Tregs. tolDCs generated in vitro are 
capable of producing Tregs also in vitro. When these Tregs are transferred in in vivo 
models, they lead in increased levels of tolDCs, indicating the existence of a
217
regulatory feedback loop. This co-administration reduces the occurrence of allograft 
rejection and enhanced allograft survival after heart transplantation [574].
I generated tolDCs by incubating iDCs with TGF-P and IL-10 as described in 
section 2.3.3.5.1 then adoptively transferred tolDCs in PBS by injection in to apoE* '^ 
mice following the immunisation protocol described in section 2.2.7.1. I used three 
groups of eight animals each to vaccinate them with PBS, iDCs and tolDCs 
respectively. Animals were terminated at week 16.
The first part of my study was to examine the effect of the immunisations in 
the inflammatory process that leads to the formation of atherosclerotic plaques. I 
extracted the spleen of the immunised animals and I examined the percentage of the 
Treg population in the extracted splenocytes by flow cytometry and then the relative 
expression of FoxP3 in the two subpopulations of these splenocytes, CD4^ and 
CD 8\ by PCR. I also measured the synthesis of IL-4, IL-10 and INF-y by the 
splenocytes, when these were stimulated in vitro by PMA and ionomycin, using 
ELISA. IL-10 and IL-12 levels were also measured in serum fi-om immunised 
animals before and after each immunisation and at termination. Serum was also used 
to measure the total cholesterol, HDL, LDL and triglyceride levels in the animals.
I then went on to examine the effect of adoptively transferred tolDCs on 
atherosclerotic plaque development. I performed these experiments using the heart of 
immunised animals and controls, which was collected at termination and then fixed 
in 10% neutral phosphate buffered formalin. Atherosclerosis development in terms of 
plaque size was assessed in the aortic sinus.
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6.2 Generation of tolDCs in vitro
As already described, prior to carrying out the in vivo experiment, I needed to 
generate tolDCs in vitro, which would then be used to immunise apoE'^' mice in vivo.
I decided to generate tolDCs in vitro by culturing iDCs from apoE knockout mice 
with TGF-P and IL-10 for 6 days as is proposed by Sato et al. [571]. I followed the 
protocol as described in section 2.2.3.1 to generate the iDCs and then tried different 
combinations of various TGF-P and IL-10 doses, as described in section 2.2.3.5, to 
incubate them with (Figure 6.1). After the 6-day incubation period of iDCs with the 
cytokines, naïve CD4^ T cells from CDl® mice were added in the culture and left to 
incubate for 72h. T cell proliferation was measured at the end of the experiment. The 
combinations of doses that significantly inhibited the T cell proliferation induced in 
this MLR according to the non-parametric statistical test were: the 100//100 [Control 
mean 150531.77, SD 675.78 vs 100//100 mean 102812.90, SD 582.06; p value 0.03], 
and the 20//50 [Control mean 150531.77, SD 675.78 vs 20//50 mean 91438.64, SD 
973.72; p value 0.049]. In order to achieve an efficient but also cost-effective in 
terms of use of reagents generation of tolDCs, I decided to use the combination of 
20ng/ml of IL-10 and 50ng/ml of TGF-P per 10  ^ DCs/ml to generate tolDCs that 
would be used to immunise apoE' " mice (3x10^ cells/ injection).
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Figure 6.1: Generation of tolDCs in vitro using different concentrations of IL-10 and TGF-p. 
Cultures of DCs (10® cells/ml) were incubated for 6 days with a range of doses of IL-10 and 
TGF-p to test which combination of doses are the most potent to generate tolDCs. Following 
incubation, DC cultures were co-cultured with allogeneic T cells for 72h and then the 
proliferation of T cells was measured. A DC culture that had not been incubated with IL-10 or 
TGF-p was included in the experiment as a control. The 20//50 and the 100//100 doses were 
found to inhibit significantly the proliferation of T cells. Values represent mean ± SD, N=2. * 
P<0.05 to control
6.3 Immunisation with tolDCs affects the size of the Treg
subpopulations in the spleen of apoE mice
The effect of the treatment with tolDCs on atherogenesis was evaluated in 
tissue sections of both treated and control animals. The number of Tregs in the spleen 
was used as a surrogate to evaluate the effect of treatment with tolDCs in immunised 
animals compared to those that received PBS or iDCs in PBS only.
Tregs are FoxP3-expressing immunosuppressive T cells that play an 
important role in regulating autoimmunity [575, 576]. Their reduction, for example 
with anti-CD25 treatment, worsens the atherosclerosis state [426], whereas their 
induction leads in an improvement of atherosclerosis in apoE~^~ mice [577]. It has 
also been observed that the suppressive properties of Tregs are reduced in apoE~^~
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mice when compared to wild-type mice [578] and that the number of Tregs is 
reduced in human atherosclerotic plaques in comparison to normal tissues or 
different inflammatory lesions [579].
Activation of a Treg response has been observed when inhibition of 
atherosclerosis is achieved by oral immunization with HSP60 [580, 581] or with 
oxidized LDL [582]. Another study has shown that treatment of atherosclerotic 
plaques with IL-2 induces Treg expansion and results in rapid plaque shrinkage in 
apoE~^~ mice fed with Western diet [583]. In the same study, an association was 
established between reduced plaque size and increased number of intra-plaque Tregs 
[583].
Finally, researchers have shown that MDA-LDL administration with 
complete Freund’s adjuvant (CFA) leads to Treg induction and associated 
atheroprotection [584-586].
Flow cytometry allowed me to measure the percentage of four different Treg 
subpopulations, CD4+CD25^oxP3% CD4^CD25ToxP3\ CD8^CD25"ToxP3^ and 
CD8^CD25'FoxP3*, in the spleens of the immunised groups of mice. When the 
spleens were extracted from the immunised animals, the leukocytes were purified 
using the method described in section 2.3.3.2. I measured the percentage of 
CD4^CD25^FoxP3^ and CD4^CD25'FoxP3^ cells in the CD4^ T cell population and 
the percentage of CD8^CD25^FoxP3^ and of CD8^CD25'FoxP3^ cells in the CD8  ^T 
cell population of the extracted splenocytes.
The percentage of the CD4^CD25^FoxP3^ decreased significantly in mice 
injected with control DCs (cDCs) [PBS mean 2.19, SD 1.26 vs cDCs mean 0.00, SD 
0.00 p value 0.00]. The increase of the CD4^ CD25^FoxP3^ population was not 
found to be statistically significant in mice injected with tolDCs as there was a large
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standard deviation among the animals of that group [PBS mean 2.19, SD 1.30 vs 
tolDCs mean 7.05, SD 8.36; p value 0.37] (Figure 6.2).
The CD4^CD25'FoxP3^ population (Figure 6.3) was not significantly 
different between the three immunised groups (tolDCs and controls), although again 
there was a large standard deviation for the percentage of these Tregs in the tolDCs- 
immunised group [PBS mean 0.53, SD 0.80 vs tolDCs mean 2.41, SD 5.30; p value 
0.37].
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Figure 6.2: The CD4'^CD25^FoxP3^ Treg population in the spleens of immunised apoE'^' 
mice is not significantly altered following immunisation with tolDCs. The percentage of the 
population in the cDCs group was lower than in the control PBS group. As for the animals 
that had been immunised with tolDCs, the percentage of the CD4^CD25"^FoxP3^ population 
was not significantly different from either of the control groups although a large standard 
deviation was observed in this group. Values represent mean ± SD, N=8, **P<0.01.
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Figure 6.3: The CD4'’CD25'FoxP3'^ Treg population in the spleens of immunised apoE'^' 
mice does not vary between treatment groups. The percentage of the population was not 
significantly different between the three groups although a large deviation was observed 
among the animals immunised with tolDCs. Values represent mean ± SD, N=8.
The percentage of the CDS CD25 FoxP3 population in the CDS population 
(Figure 6.4) was not significantly different between the three immunised groups. 
However, it has to be noted that a large standard deviation for the group immunised 
with PBS was observed. [PBS mean 0.83, SD 1.47 vs tolDCs mean 0.18, SD 0.35; p 
value 0.53].
As regards to the CDS CD25 FoxP3^ population (Figure 6.5), an increase in 
the percentage for this subpopulation of Tregs was observed in the tolDCs- 
immunised group, compared to the control groups (PBS, untreated iDCs), [PBS 
mean 0.03, SD 0.10 vs tolDCs mean 2.45, SD 1.60; p value 0.01], [cDCs mean 0.00, 
SD 0.00 vs tolDCs mean 2.45, SD 1.60; p value 0.01].
It appears, therefore, that immunising mice with tolDCs had the effect of 
increasing the CD8^CD25'FoxP3^ Treg population. This finding correlates well with 
my hypothesis that tolDCs can contribute to the prevention of atherosclerosis, since
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Tregs have been shown to have immune-modulatory and immuno-suppressive 
properties.
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Figure 6.4: The CD8^CD25^FoxP3'^ Treg population in the spleens of apoE'^' mice remains 
unaffected following immunisation with tolDCs. No significant differences to the control 
groups were observed in the group that had been immunised with tolDCs. The percentage of 
Tregs in the PBS group showed a large fluctuation. Values represent mean ± SD, N=8.
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Figure 6.5: The CD8’"CD25‘FoxP3^ Treg population in the spleens of apoE '"' mice increases 
significantly in mice immunised with tolDCs. The percentage of this Treg subpopulation was 
the same in the two control groups. The percentage in the group that had been immunised 
with tolDCs increased significantly compared to the cDCs and to the control PBS group. 
Values represent mean ± SD, N=8, **P<0.01.
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6.4 The expression of FoxP3 in CD4^ and CD8^ splenocytes of apoE  ^
mice is not affected by immunisation of the animals with tolDCs
I then went on to the analysis of the expression of FoxP3 in T cells recovered 
from immunised and control animals using PCR. I looked for the FoxP3 gene within 
the CD4^ population and within the CD 8  ^population in the spleens of immunised 
mice. The FoxP3 transcription factor plays a key role in Treg cell development and 
function [587]. CD4^ and CD8^ splenocytes were purified and processed for 
quantitative PCR as described in section 2.3.8.4.
No significant difference was observed in the relative FoxP3 expression 
(normalised to GAPDH expression) between the three immunised groups (PBS, iDCs 
and tolDCs). However, there was a large standard deviation observed in all groups 
and this will be further discussed in Chapter 7. The FoxP3 expression in CD4^ 
splenocytes (Figure 6.6) was PBS mean 80560.14, SD 24920.09 vs cDCs mean 
61608.85, SD 35593.07; p value 0.573, and PBS mean 80560.14, SD 24920.09 vs 
tolDCs mean 71315.00, SD 12381.64; p value 1.00. And in CD8^ splenocytes: PBS 
mean 59285.66, SD 20000.42; vs cDCs mean 62656.00, SD 24359.82; p value 1.00, 
and PBS mean 59285.66, SD 20000.42 vs tolDCs mean 65646.80, SD 7854.82; p 
value 1.00.
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Figure 6.6: Immunisation with tolDCs does not affect the FoxP3 relative mRNA expression 
in the splenocytes of apoE^ mice. Semi-quantitative PCR was used to examine the 
expression of FoxP3 in the T cell population in the spleen of the three groups of animals. 
FoxP3 relative expression to GAPDH in CD4^ cells in shown in figure A and its expression in 
CD8^ cells in figure B. The statistical analysis showed no significant difference of expression 
of the gene between the three immunised groups neither in the CD4‘" population nor in the 
CD8^ population. Values represent mean ± SD, N=8.
6.5 Treatment with tolDCs induces the synthesis of IL-4, IL-10 and 
IFN-y in apoE KO mice.
Following the analysis of the Treg population in the splenocytes recovered 
from immunised apoE' " mice and controls in vitro, 1 also measured the synthesis of
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IL-4, IL-10 and IFN-y produced by the same splenocytes after activation with PMA 
and ionomycin. The cytokines IL-4 and IL-10 have been linked with the 
atheroprotective Th2 response while production of IFN-y has been linked with the 
atherogenic Thl response.
More specifically, IL-4 is produced by Th2 cells and its secretion induces the 
differentiation of these same cells in a feedback loop. This differentiation results in 
production of increased levels of IL-4 and IL-5 but decreased levels of IFN-y [426]. 
Consequently, the Th2 response has been considered to bear athero-protective 
effects. Nevertheless, the exact role of Th2 response in atherosclerosis development 
has not been clarified and it seems to be different depending on the experimental 
model studied as well as lesion stage and site [426] .
Th2 response has been shown to prevent early fatty streak formation in 
murine models that are relatively resistant to atherosclerosis [304]. In more 
permissive models using LDLr " mice however, impairment of IL-4 had no effect on 
lesion formation [588] but an association between IL-4 impairment and reduced 
development of atherosclerotic lesions had been observed in another study [589], 
something that indicated its potential proatherogenic role. In addition, 
hypercholesterolemia in atherosclerotic animal models is accompanied with 
increased IL-4 production. IL-4 deficiency has been shown to block plaque 
progression and thus IL-4 increased production in the aforementioned model may 
play a role in plaque progression [423].
IL-10 plays a key role in the regulation of both innate and adaptive immunity 
and its production takes place in macrophages and lymphocytes. IL-10 deficiency is 
known to induce atherosclerotic lesion development which is accompanied by 
increased infiltration of inflammatory cells, the majority of them being T cells, and
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by enhanced pro-inflammatory cytokines secretion [307, 590, 591]. Therefore, IL-10 
produced by leukocytes seems to be of major importance in blocking atherosclerotic 
lesion formation and in the regulation of collagen plaque formation [592].
IL-10 gene transfer leading to systemic or local IL-10 over-expression in 
collar-induced carotid atherosclerosis of LDLr ''' mice was shown to be significantly 
athero-proteetive [593]. Furthermore, IL-10 over-expression due to activated T cells 
led to a decreased atherosclerosis state in LDLr ''' mice [594], indicating the athero­
protective role of Trl-like cells. It has also been shown that when Trl cell clones are 
transferred in this murine model, they lead to decreased lesion formation [577]. In 
addition, promotion of endogenous adaptive Trl cell response results in reduced 
atherosclerosis development [577].
In contrast, Thl responses are implicated in atherogenesis resulting in high 
levels of IFN-y. IFN-y activates monocytes/ macrophages and DCs, which also 
produce IFN-y, thus forming a positive feedback loop [595].
Deficient IFN-y receptor or IFN-y have been shown to decrease lesion 
formation and up-regulate plaque collagen content in apoE knock out mice [305, 
424], whereas exogenous administration of IFN-y leads to increased lesion 
development [305]. Furthermore, when IFN-y function was blocked with the help of 
a gene transfer of a soluble mutant IFN-y receptor in adult apoE'^' mice, it led to a 
better atherosclerotic plaque phenotype. More specifically, it blocked established 
plaque progression and remodeled them into more stable ones [596].
Research on the effects of IFN-y on proliferation of smooth muscle cells has 
produced contradictory results. In vitro and in vivo studies on models of mechanical 
injury in T cell-competent or T cell-deficient animals showed that IFN-y prevents 
smooth muscle cell proliferation [597]. On the other hand, other groups have
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observed that an IFN-y treatment leads in induction of smooth muscle cell 
proliferation in vitro [598]. In addition, IFN-y has been reported to confer smooth 
muscle cell proliferation and hyperplasia of the intima during the transplantation of 
pig or human arteries into the aorta of immunodeficient mice [599]. In studies 
involving a model of immunodeficient mouse with human coronary artery grafts 
which were intravenously given an adenovirus with a human IFN-y transgene, it was 
observed that IFN-y, along with the effects of TORCl or ribosomal protein S6 kinase 
1, modulated smooth muscle cell proliferation as well as expansion of the intima 
[600].
In order to measure the secretion of the cytokines discussed above in 
immunized animals and their controls, I extracted their spleens as explained in 
section 2.3.8.2 and cultured the splenocytes by incubating them with ionomycin and 
PMA for 3 days (section 2.3.8.5). Ionomycin is a calcium (Ca^^ ionophore that has 
been shown to bear T cell proliferative abilities. More specifically, it causes T cell 
proliferation when monocytes are present and simultaneous IL-2 and IL-2R 
production takes place [601]. PMA is a potent tumor promoter and it has been shown 
to stimulate some cell lines to generate T cell growth factor, IL-2 [602]. PMA and 
ionomycin promoted and boosted intracellular cytokine production. The cytokine 
levels that had been secreted by the cells were measured as described in section 
2.3.S.5.
The levels of IL-4 that were secreted by the splenocytes of the animals that 
had been immunised with PBS were very low [mean 1.48, SD 3.43] (Figure 6.7). The 
levels of secreted IL-4 by the splenocytes of animals immunised with cDCs were 
found to be significantly higher; however this was not the case for the animals 
immunised with tolDCs due to the large standard deviation observed in this group
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[cDCs mean 207.44, SD 171.34; p value to PBS 0.05, tolDCs mean 365.36, SD 
389.37; p value 0.09]
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Figure 6.7: The levels of IL-4 secreted by the splenocytes of the apoE" mice are higher in 
mice vaccinated with cDCs than in mice that have been vaccinated with PBS. In the case of 
the animals vaccinated with tolDCs, there is a lot of fluctuation among the data in the group 
for the increase of the levels of IL-4 to be considered significant. Values represent mean ± 
SD, N=8, * P<0.05.
The levels of IL-10 that were secreted by the splenocytes of the animals that 
had been immunised with PBS or iDCs were very low [PBS mean 45.80, SD 74.62, 
mean cDCs 63.00, SD 154.31; p value 1.00] (Figure 6.8). However, in the group that 
had been immunised with tolDCs, the levels of the cytokine were significantly higher 
[PBS mean 45.80, SD 74.62, mean tolDCs 688.41, SD 303.48; p value 0.001], [mean 
cDCs 63.00, SD 154.31, mean tolDCs 688.41, SD 303.48; p value 0.001]. Therefore, 
injection of apoE'^' mice with tolDCs induced IL-10 secretion by the splenocytes of 
the immunised animals.
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Figure 6.8: The levels of IL-10 secreted by the splenocytes of apoE" mice are higher in 
mice vaccinated with tolDCs than in mice that have been vaccinated with PBS or cDCs. 
Values represent mean ± SD, N=8, **P<0.01.
When I looked at the levels of IFN-y secreted by the splenocytes of apoE" " 
mice that had been vaccinated with PBS, they were quite high (Figure 6.9). The same 
high levels of the cytokine were secreted by the splenocytes of the animals that had 
been vaccinated with tolDCs [PBS mean 2727.55, SD 323.95, mean tolDCs 3016.66, 
SD 147.60; p value 0.17]. However, IFN-y secretion is inhibited when untreated DCs 
are used to vaccinate the animals [PBS mean 2727.55, SD 323.95, cDCs mean 
1629.59, SD 683.97; p value 0.01], [cDCs mean 1629.59, SD 683.97, mean tolDCs 
3016.66, SD 147.60; p value 0.004].
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Figure 6.9: The levels of INF-y secreted by the splenocytes of apoE^ mice are higher in 
mice vaccinated with tolDCs than in mice vaccinated with cDCs. The splenocytes of the 
animals in the group that had been immunised with tolDCs had secreted statistically 
significant higher levels of INF-y than the splenocytes of the animals in the groups that had 
been immunised with cDCs. However, the splenocytes of the animals in the group that had 
been immunised with PBS had secreted equally high levels of INF-y. Values represent mean 
± SD, N=8, **P<0.01.
To conclude, it was observed that immunisation of apoE' " mice with tolDCs 
resulted in the increased secretion of IE-10 from the splenocytes of the immunised 
animals. Since IL-10 has been associated with inhibition of atherosclerotic plaque 
formation and increase of the collagen content of the plaques, as mentioned above, 
this result supports the hypothesis that immunisation with tolDCs can help in 
atheroprotection in apoE' '^ mice.
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6.6 Serum levels of IL-10 and INF-y are higher in apoE  ^ mice 
immunised with toIDCs than in mice immunised with PBS or 
untreated DCs.
Following the measurement of the levels of cytokines that are produced by 
the splenocytes of the vaccinated mice, I then went on to measure the levels of some 
of the cytokines in their serum. When the animals were terminated, blood was 
perfused from their aorta and the serum was separated. Then the levels of anti­
inflammatory IL-10 and the pro-inflammatory IL-12 in the serum were measured 
with an ELISA.
IL-10 has been linked with the atheroprotective Th2 response. IL-10 levels in 
the serum of animals that had been injected with PBS or cDCs were low [PBS mean 
0.02500 SD 0.00, cDCs mean 0.02503 SD 0.0002; p value 0.692]. Low levels of the 
cytokine were also secreted when tolDCs were used to immunise the animals 
however the statistical analysis showed that they were significantly higher than the 
PBS group [PBS mean 0.02500 SD 0.00, tolDCs mean 0.02527 SD 0.0006; p value 
0.03], (Figure 6.10).
These results correlate very well with my finding on the increase of IL-10 
secretion fi'om the splenocytes of immunised animals with tolDCs and they 
complement the suggestion that immunisation with tolDCs could be used in the 
treatment of atherosclerosis.
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Figure 6.10: Immunisation with tolDCs increases the IL-10 levels in the serum of apoE ' 
mice. The levels of IL-10 were higher in the group of animals that had been immunised with 
tolDCs compared to the groups that had been immunised with untreated DCs and PBS. 
Values represent mean ± SD, N=8, **P<0.01.
IFN-y has been linked to the atherogenic Thl response. No significant 
difference was observed between the three immunised groups in the levels of 
secreted IFN-y [PBS mean 8119.62 SD 1234.82, cDCs mean 7829.37 SD 1198.64 p 
value 0.67]. For the animals immunised with tolDCs there was a lot of fluctuation in 
the data possibly affecting the statistical significance of these findings [PBS mean 
8119.62 SD 1234.82, tolDCs mean 10495.89 SD 8049.64 p value 0.23]. (Figure 
6.11).
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Figure 6.11: The IFN-y levels in the serum of some of the apoE'^' mice were not statistically 
significant among the three immunised groups. The levels of IFN-y were higher in some of 
the mice that had been immunised with tolDCs compared to the mice in the group that had 
been immunised with untreated DCs or PBS alone but there was a lot of variation in the IFN- 
y secretion within the immunised group, therefore these results were not conclusive. Values 
represent mean ± SD, N=8.
6.7 The levels of serum lipids in the apoE mice are effected 
following immunisation with tolDCs
An important parameter in this in vivo experiment was to examine the levels 
of serum lipids following the vaccination of the apoE'' '^ mice with tolDCs. Blood 
lipids, such as LDL, contribute to the formation of atherosclerotic plaques [603]. 
Triglycerides are also considered a risk factor [604]. HDL on the other hand, is 
thought to be protective of the disease [603, 605].
Lack of the apoE gene in apoE-deficient C57BL/6J mice leads to increased 
total plasma cholesterol, HDL cholesterol and triglyceride levels as well as HDL/TC, 
and HDL/LDL ratios. apoE-KO mice are characterized by normal growth and 
development but they also develop atherosclerosis and xanthomatosis which decrease 
their life span. In this paper it was shown that apoE bears a key role in modulating
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lipid levels and atherogenesis without altering lipase activities, endogenous anti­
oxidant potential or neurodegenerative markers in 37-week-old male mice [606].
Researchers used C57BL/6J mice under different diets to study whether 
hyperhomocysteinaemia (HHcy) independently accelerated atherosclerosis or 
whether its observed function was dependent on dietary factors leading to increased 
plasma lipids and/or inflammation, such as methionine. Plasma total cholesterol was 
found to be increased in mice fed with a Western or atherosclerotic diet. Western diet 
increased LDL/IDL and HDL levels while atherosclerotic diet did not led in 
increased HDL but resulted in increased plasma VLDL and LDL/IDL levels. Groups 
fed with methionine did not show alterations in plasma total cholesterol levels 
compared to control groups. This study showed that HHcy does not independently 
result in atherosclerotic C57BL/6J mice even when increased total plasma lipids are 
present (W diet) but can enhance atherosclerotic lesion formation when increased 
plasma VLDL levels and/or inflammation are present (methionine supplementation) 
[607].
Blood was collected from the tail of the animals before the immunisation 
schedule took place and then again at termination through perfusion of the aorta. The 
serum was separated and the lipid levels were measured using the ILab 650 
instrument.
Triglyceride serum levels were measured and were found not to alter 
significantly in apoE' '^ mice following immunisation with untreated DCs or tolDCs 
(Figure 6.12). In animals vaccinated with PBS however, they decreased [PBS start 
mean 1.71 SD 0.35, PBS term mean 0.56 SD 0.35; p value 0.002].
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Figure 6.12: Immunisation with tolDCs does not affect the triglyceride levels in the serum of 
apoE’ '^ mice. The levels of triglycerides were the same before and after immunisation in the 
groups that had been treated with cDCs or tolDCs. Therefore, immunisation with tolDCs did 
not affect the levels of triglycerides in the serum of the animals. The levels of triglycerides 
decreased in animals vaccinated with PBS. Values represent mean ± SD, N=8, **P<0.01 to 
all the groups in the experiment.
Total cholesterol levels did not differ significantly between pre-immunisation 
and termination in any of the immunised groups (Figure 6.13). However, the 
statistieal analysis indieated that they were signifieantly lower in the group of 
animals that had been immunised with tolDCs than in the control group that had been 
immunised with PBS alone [PBS term mean 4.42 SD 1.14, tolDCs mean 2.29 SD 
0.80; p value 0.00].
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Figure 6.13: The cholesterol levels in the serum of apoE" mice dropped following 
immunisation with tolDCs. The levels of cholesterol in the group that had been immunised 
with tolDCs were lower than the levels of cholesterol in the group that had been vaccinated 
with just PBS. Values represent mean ± SD, N=8, **P<0.01.
HDL cholesterol serum levels were not significantly affected by 
immunisation with tolDCs (Figure 6.14). The animals in all three groups, whether 
they were immunised with PBS, untreated DCs or tolDCs maintained at termination 
the levels of HDL that they had in their serum pre-immunisation. Furthermore, there 
was no significant difference observed among the three groups at termination.
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Figure 6.14: The HDL cholesterol levels in the serum of apoE" mice do not significantly 
differ following immunisation with tolDCs. The levels of HDL were not affected by the 
vaccination of the mice with tolDCs. Values represent mean ± SD, N=8.
The levels of serum LDL did not alter significantly following immunisation 
with PBS alone or untreated DCs, nor were there any significant differences among 
these two control groups at termination (Figure 6.15). A tendency for the LDL serum 
levels to increase was observed in the animals that had been immunised with tolDCs 
compared to pre-immunisation but also compared to the LDL levels in the other 
groups at termination. However, the standard deviation was so big that the validity of 
this result was questioned [tolDCs start mean 0.073 SD 0.046, tolDCs term mean 
0.602 SD 0.464; p value 0.197], [cDCs term mean 0.197 SD 0.128, tolDCs term 
mean 0.602 SD 0.464; p value 0.519] [PBS term mean 0.074 SD 0.017, tolDCs term 
mean 0.602 SD 0.464; p value 0.198].
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Figure 6.15: The LDL levels In the serum of apoE'^' mice showed a tendency to increase 
following immunisation with tolDCs but there is a lot of variation within the group for these 
results to be conclusive. Values represent mean ± SD, N=8.
The examination of the serum lipids in apoE' '^ mice immunised with tolDCs 
showed a decrease in the cholesterol levels following immunisation which could 
indicate that tolDCs could be used as a treatment for atherosclerosis.
6.8 The size of the atherosclerotic plaques in the apoE mice remain 
the same following immunisation with tolDCs
When all the biochemical and cellular analysis was performed and the study 
of the immune response towards the immunisation with tolDCs had been completed, 
my next step was to examine the effect of this vaccination on the size and content of 
the atherosclerotic plaques of the immunised animals.
Many experiments have been performed in order to investigate the effects of 
immunizations on atheroprotection by measuring the size of the atherosclerotic 
plaques. A team of researchers used apoE " mice which had been immunized with
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homologous MDA- LDL. Those mice were characterised by high concentrations of 
antibodies against MDA-LDL and remarkably smaller in size lesions at the aortic 
sinus when compared to control mice immunized with PBS. However, the cellular 
content of the atherosclerotic plaques remained unchanged between MDA modified 
LDL-immunized and control mice [608]. Studies that followed reported that when 
LDL"" mice were immunized with MDA-LDL, they developed different antibody 
classes against specific oxLDL epitopes and lesions were significantly reduced in 
size. Furthermore, immunization of apoE"^" mice with homologous plaque 
homogenates or homologous MDA-LDL, resulted in both cases in decreased lesion 
development [21, 586].
This was achieved using different histological methods. More specifically, 
the perfused heart of the immunised animals was extracted at termination and fixed. 
The tissue was then cut with a microtome in order to reach the area of the aortic sinus 
and then six consecutive sections of 5pm each were taken and stained with H&E. 
Cross sections are shown in Figure 6.16. The ImageJ Java image processing software 
was used to measure the total plaque area in each section.
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Figure 6.16: Cross sections of the aortic sinus (5pm) of ApoE’'"' mice that have been 
immunized with A) PBS B) cDCs and 0) tolDCs. Images were taken at x 4 magnification.
The average total plaque area in the aortic sinus for each immunised group is 
seen in Figure 6.17. No significant difference in the total plaque area was observed 
among the three groups [PBS mean 40131.36 SD 19409.95, cDCs mean 52674.72 
SD 31849.97; p value 0.302], [PBS mean 40131.36 SD 19409.95, tolDCs mean 
49994.93 SD 27211.91 p value 0.512].
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Figure 6.17: The total plaque area (pm^) in the aortic sinus of the immunised animals is the 
same between the three vaccinated groups (PBS, cDCs, tolDCs). No statistical difference 
was observed. Values represent mean ± SD, N=8.
6.9 Conclusion
In this chapter, I carried out a series of experiments to determine if 
vaccinating apoE' ' mice with tolDCs would have an effect on atherosclerosis in these 
mice.
I showed that immunisation with tolDCs affected the percentage of the Treg 
subpopulations in the spleen of immunised mice. The percentage of the CDS CD25' 
FoxP3^ subpopulation increased in these mice compared to mice that have been 
immunised with PBS or untreated DCs. In an additional experiment to determine the 
Treg population in the spleen of the immunised animals, I analysed FoxP3 
expression by PCR; however no significant differences in expression of the FoxP3 
gene were observed among the immunised groups.
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I went on to study the effect of the immunisation with tolDCs on the secretion 
of cytokines IL-4, IL-10 and IFN-y from the splenocytes of the immunised animals 
and I noticed an increase on the levels of IL-10. The levels of IL-4 and IFN-y were 
not affected significantly by the vaccination. Cytokine IL-10 was also increased in 
the serum of vaccinated animals; in contrast serum IFN-y was not affected by the 
immunisation. When the levels of serum lipids were examined, cholesterol was also 
shown to be effected by the immunisation with tolDCs, with its levels dropping 
following immunisation.
My histological study showed that the average total plaque area in the aortic 
sinus of the immunised animals did not differ significantly between the three 
immunised groups (PBS, untreated DCs, tolDCs).
In the next chapter I will discuss these findings further along with the 
findings from the previous chapters in order to put them into context with what is 
currently known on vaccinations that could potentially be used to treat 
atherosclerosis.
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CHAPTER 7: GENERAL DISCUSSION AND FUTURE 
WORK
7.1 General Discussion
The hypothesis of this PhD project was that DCs can immunomodulate the 
inflammatory responses that induce atherosclerosis and therefore may be used as 
therapeutic tools in vaccines designed to offer atheroprotection.
DCs are able to pick up antigens and in the absence of inflammatory agents 
present them to MHC molecules without expressing co-stimulatory molecules and 
therefore signal suppression to Tregs [609] or else tolerance. Tolerance can be 
described as an active state of unresponsiveness of T lymphocytes to a particular 
antigen as a result of their exposure to this antigen. Autoantigens are currently being 
used in research to develop vaccines for many autoimmune diseases such as 
Alzheimer’s, multiple sclerosis, rheumatoid arthritis and type 1 diabetes [610-612].
In the first part of the project, my study focused on the use of apoB-100 
derived peptides as potential antigens for DCs in order to modulate the immune 
response towards an atheroprotective response. As previously discussed, these 
peptides present a very specific target for immunotherapy in contrast to using whole 
oxLDL that contains numerous epitopes. Immunisation with one of these, the peptide 
P210, reduces plaque size by 60% and increases collagen content [327]. P45 also 
promotes atheroprotection since a recombinant IgGl against p45 also reduces plaque 
size and macrophage content [613]. The peptides dissolve well in water, except P2 
that needs DMSO to dissolve. Maybe P45 and P210 are located in the exterior of the
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oxLDL molecule and therefore are hydrophilic. If P2 is hydrophobic, it could be 
located in the interior of the molecule, and therefore be more difficult for APCs or 
Abs to recognise it. However it has been shown that immunisation with P2 reduces 
the size of atherosclerotic plaques in the aorta by 40% and increases the collagen 
content of the plaques [614].
The generation of antibodies is important for atheroprotection since B cells 
have been found to accumulate in the atherosclerotic plaque and they can recognise 
native antigens like oxLDL. However T cells are more specific: they can encounter 
every possible antigen within a protein as the latter is chopped up by APCs and all its 
peptide-components are presented. Furthermore, when considering the design for a 
vaccine against a disease, we are talking about creating memory in the immune 
response. Memory exists only in T cell responses. This is why T cell-mediated 
responses can play an important role in treating atherosclerosis.
It must be noted that another type of T cell mediated response has been 
highlighted since the research in this project was performed and these are the Thl7 
responses that are believed to be working along Thl responses in atherosclerosis 
development (Figure 7.1). [615].
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Figure 7.1: T cell responses involved in the inflammation underlying atherosclerosis. 
Reproduced from Klingenberg R, Hansson GK. [616]
My results showed that the apoB-100 peptide P45 is taken up by CDllc^ 
cells. P45 was chosen as at the time that these experiments were conducted, it had 
been shown to have a very strong effect on atherosclerosis by reducing 
atherosclerotic plaque area by 48% in ApoE ' mice [613]. Furthermore, an IgG 
antibody against p45 has been shown to be associated with a decrease in the severity 
of carotid stenosis in humans [617] There were not enough resources (animals or 
reagents) to examine all three peptides. However, there is a possibility that different 
peptides may localise in different organelles in DCs and P2 and/or P210 might not 
follow the same processing or presentation route as p45.
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I have shown that the peptide is taken up only by a small number of cells and 
possibly localised in the ER and Golgi compartments. It is also taken up by 
endosomes and lysosomes. It loads onto MHC-II and MHC-I complexes inside 
endosomes.
This could indicate that MHC-I and MHC-II can both upload the same 
antigen but through different uptake mechanisms and for a different function. A 
study showed that DCs incubated with soluble ovalbumin contain MR-endocytosed 
OVA in the early endosomes (marked by EEA-1 and Rab-5) and also pinocytosed 
OVA in late lysosomes (identified by the expression of LAMP-1, lysotracker, Rab- 
5). MR endocytosed OVA was presented by MHC-I and pinocytosed OVA was 
presented by MHC-II [618]. These DCs therefore cross-presented OVA to CD8+ 
cells as well as activating 0VA-specific-CD4+ cells. It must be noted that cross­
presentation can result in tolerance in the absence of inflammatory stimuli [619].
With regard to my observation that the MHC-peptide complex is not 
presented on the cell surface, as visualised by confocal microscopy, it must be noted 
that even if the peptide is internalised in DCs, there is no guarantee that it will be 
presented in its native state; it could be edited in the proteasome. Furthermore, as 
mentioned in Chapter 3, a study has shown that it is crucial to observe the antigen- 
loaded cells at various time points following incubation in order to determine 
whether the antigen is presented by MHC-II and/or MHC-I since presentation on the 
cell surface might not last for long in the absence of T cells and stimuli provided by 
them [374]. Shorter incubation times like 30min could potentially better show both 
the endocytocis and presentation (if any) process. Time lapse fluorescence 
microscopes could be used to monitor peptide internalisation from time 0 [338].
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Long incubations might also cause peptide degradation. A way to deal with 
degradation would be to structurally modify the peptide such that it contains some D- 
amino acids which would render it more stable and less easily degraded by proteases. 
A D-amino acid is an optical isomer of an L-amino acid and is its mirror image. 
Studies have shown that L-peptides can be modified into D-peptides that resist 
degradation while still retaining their antibody-binding properties [620]. The new 
synthetic peptides are even more stable when amino acids in both their C and N 
terminus are substituted with D-amino acids.
Moreover, a way to examine if degradation is indeed taking place is to use 
molecular probes with Forster resonance energy transfer (FRET). FRET is a 
technology process through which an excited fiuorophore (donor) transfers its energy 
to a nearby light-absorbing molecule (acceptor) allowing measurement of their 
distance apart [621]. So if it is used to measure the distance of the two ends of my 
peptide, if the peptide stays intact in the cell, then it should give out one signal. If it 
is broken up, it will give two or more signals. However, it could be that the peptides 
are activating another type of receptor on DCs instead of MHC, for example a Toll­
like receptor, that would induce receptor-specific effects on the cells.
The round shape of peptide-loaded DCs, the low expression of activation 
markers CD40, CD86 and of the presenting complex MHC-II could support the 
hypothesis that peptides induce a tolerogenic phenotype in DCs. As already 
mentioned, researchers have shown that even if Ag presentation takes place, when 
the expression of co-stimulatory molecules is low, T cell anergy/apoptosis and the 
generation of Tregs mediated by IL-10 and TGF-(3 are induced [622]. These 
observations are further enhanced by the 50% reduced expression of CD llc and 
GDI lb on P210-treated DCs compared to untreated DCs, as well as the
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demonstration that peptide-loaded DCs are CD8'CD4'. It is likely though that the 
results obtained for the co-stimulatory molecules CD40 and CD86 as well as for the 
antigen-presenting MHC-II are specific to the GDI Ib^ cells that have been generated 
in my culture and that they did not represent the whole DC population that I have 
been studying. This is why it is important to repeat the flow cytometry experiments 
on peptide-loaded DC activation using CDllc as a DC label marker as it is believed 
to be a more prominent marker for these cells [623]. Furthermore, the way that the 
flow cytometry results were analysed could be crucial to my findings. This is why I 
thought of analysing my results by measuring the average MFI on each cell in 
addition to the percentage of marker expressing cells. Unfortunately, there was not 
enough time to do this analysis for the experiments presented in sections 4.3.1 -  
4.3.4 but MFI analysis was performed for the data presented in section 4.3.5. The 
expression of the same markers (CDllc, CD 11b, CD40, CD86 and MHC-II) on 
peptide-loaded DCs as in sections 4.3.1 to 4.3.4 was measured in section 4.3.5 using 
a range of doses of the peptides including the one used in sections 4.3.1 -  4.3.4. The 
conclusions from these experiements were consistent with each other, in spite of the 
use of two different analysis methods. The levels of expression of the markers on 
peptide-loaded DCs were quite low and this correlates well with the low number of 
cells expressing them.
The cytokine and metalloproteinase experiments support the hypothesis that 
peptide-loaded DCs induce tolerogenic DCs: the peptides alter neither the IL-10 nor 
IL-12 secretion from DCs nor the MMP2 and MMP-9 mRNA expression in them. 
The effect of the peptides on MMPs however should be further tested with a 
zymography assay that measures the activity of the enzyme. Unfortunately, my first 
attempt to perform zymography assays was not succesful. ELISA assays for MMPs
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secreted from DCs incubated with the peptides may also be required to further 
investigate if the apoB-100 peptides affect the levels of MMP-2 and MMP-9 
produced. Reports in the literature support that immunodetection studies are suitable 
to identify detectable amounts of MMPs produced both in vivo and in vitro [485]. 
However, the net activity levels of the enzymes might be different than those 
indicated in the assay as some amount of the enzyme produced by the cells might be 
compromised and inactivated [506].
It is also important to study shorter incubation times of the peptides with DCs 
than 48h as DC activation decreases if T cells are not present in the culture -  this is a 
two-way activation process [250],[624]. Instead of LPS, another potent antigen to be 
used as a positive DC maturation control would be oxLDL.
Variation in all experiments can be explained by a number of factors: the age 
of the mice when isolation of cells was performed was not always the same and the 
day that the treatment started following isolation was not always the same. At the 
time these experiments were performed, I was facing problems with the breeding of 
the mice and therefore it was not possible to have the right number of animals 
required for every experiment at exactly the same age. Furthermore, I did not think 
that the day that the treatment of the cells should start following their isolation could 
be significant. Thinking about it retrospectively and taking into consideration the 
large variation between data, it would have been preferable to control for these two 
variables.
The peptide-loaded DCs did not activate CD25 and CD69 on T cells or 
induce T cell proliferation or IL-2 secretion. This was expected since DCs were 
shown in previous experiments not to be activated. Interestingly P45 inhibited 11-2
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secretion and P2 the proliferation of the cells, which might indicate that the peptides 
are suppressing T cell function.
It must be noted that the changes in the T cell proliferation assay are bound to 
be very low, as very few T cells (clones) are going to recognise the peptide (1-2 cells 
in millions). Every TCR is genetically encoded to recognise certain antigens (even if 
it has not encountered any antigens before as is the case for naive T cells). T cells, 
therefore, have a higher specificity for antigens than DCs and every T cell is very 
specific for the antigens that it will recognise. So the assay is not sensitive enough to 
detect such small differences in proliferation. We could try using a larger initial 
number of T cells in order to improve the robustness of the assay.
In future experiments, I could also test the effect of a peptide with scrambled 
sequence as a positive control for the induction of pro-inflammatory responses as 
Bandholtz et al. did when they tested the effect of the human peptide LL-37 on the 
activation of DCs [338]. If the scrambled peptide has no homology to mouse, then it 
should induce T cell proliferation.
It would also be worth repeating some of the key experiments regarding the 
effect that the peptides have on the phenotype and function of dendritic cells using 
MDA-modified peptides in order to check if these would have a different effect. 
Using the MDA-modified peptides would represent better what actually happens in 
the context of atherosclerosis with the oxLDL. The Nilson group have examined this 
potential in their experiments by measuring the antibody response towards the 
peptides and the results showed that the binding of the IgM antibodies was more 
significant for the MDA-modified peptides but the pattern that was followed was the 
same [297].
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The fact that apoB-100 peptides had no promoting effect on T cell activation 
markers and syngeneic T cell proliferation could be explained by the immature state 
of DCs and the low expression of the important co-stimulatory molecules on the DCs 
required for complete T cell stimulation and activation [213]. Therefore, the peptides 
might have an anti-inflammatory DC-mediated effect by inhibiting T cell activation 
and clonal expansion and subsequently inhibiting a pro-inflammatory cell-mediated 
immune response. The results from the IL-2 secretion experiment, where the peptides 
had no increasing effect on the measured cytokine secretion and P45 even decreases 
it, contribute to this hypothesis. It has been reported that IL-2 secreted from T cells 
stimulates DCs and enhances their efficiency to prime a Thl response [249].
To further investigate this, the study of the effect of the peptide-loaded DCs 
in an allogeneic proliferation assay (MLR where MHC is incompatible with TCR) 
needs to be repeated since the first attempt using only one replicate showed some 
intriguing results.
The most important result is that the peptides can inhibit syngeneic T cell 
proliferation when they were added to a DC and T cell co-culture, whereas oxLDL or 
fFN-y-treated DCs had previously activated T cells. Does this indicate that they are 
acting on T cell through DCs or directly? My attempt to elucidate this with a culture 
of T cells previously activated with ConA and oxLDL was not successful as ConA 
and oxLDL did not induce proliferation. Therefore this experiment needs to be 
repeated with different doses and incubation times. It could be though that the 
peptides act on T cell responses via DCs, but that even tolerogenic DCs need to be 
mature. Raich-Regue et al have shown this when they generated tolDCs using what 
he has named “a pro-inflammatory cocktail of cytokines” (cytokines TNF-a, IL-lp 
along with prostaglandin PGE2) at the same time as a tolerogenic agent, la,25-
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dihydroxyvitamin D(3) [625]. The tolDCs generated by the Raich-Rague group had a 
tolerogenic function but they had required a combination of inflammatory signals in 
order to mature and be functional. The same could be the case for my peptide-loaded 
DCs; they might need stimulation in the presence of inflammatory agents in order to 
mature and exert their tolerogenic function.
These last experiments leave many interesting questions to be answered in the 
future, regarding the effect of the apoB-lOO-derived peptides on T cells. It remains to 
be proven if they are interacting directly with T cells and if so through which 
receptor, or if their effect on T cells is mediated through DCs and antigen 
presentation. The peptides could also be affecting T cells both ways, directly or 
indirectly through DCs.
Some researchers use the Syjÿeithei database (www.syfpeithi.de) in order to 
predict the potential that a peptide epitope has to bind to MHC complexes and if so, 
which amino acids in its sequence serve as the anchor [626]. Another database used 
from biostatisticians is the MHC-Peptide Interaction Database version T (MPID-T) 
which allows the study of peptide and MHC interactions as well as the interactions 
between as peptide-MHC complex and a TCR receptor, when structural information 
for the latter is known [627]. These two tools could also be used to examine further if 
the apoB-100 peptides are being presented by MHC molecules on APCs.
The magnitude of the response provoked by apoB-100 peptides is not as 
important as its quality: further investigation is required on the subset of T cells that 
are present in the co-cultures with the peptide-loaded DCs. Naïve T cells could 
differentiate to T regs in response to the antigenic peptides. Studies suggest that 
imDCs have the capacity to induce peripheral self-tolerance by promoting naïve
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CD4^ and CD8^ T cells to differentiate into IL-lO-producing T regulatory/suppressor 
cells [628],[629].
Alternatively, they could be Th2 cells; there are two groups of signals that 
stimulate imDCs to induce Thl versus Th2 differentiation [630]. Molecules derived 
from pathogens, such as lipopolysaccharide, bacterial CpG DNA and double­
stranded viral RNA, as well as T cell signals such as CD40 ligand and IFN-y, all 
promote imDCs to produce IL-12 and prime for Thl responses. By contrast, anti­
inflammatory molecules such as IL-10, TGF-p, PGE-2, and corticosteroids, all 
inhibit imDC maturation and IL-12 production, and induce Th2 or regulatory T cell 
responses. The peptides could have a similar effect on these molecules. Th2 
responses control Thl responses; the former have been shown to be linked with 
atheroprotection in humans by Nilsson’s group who measured high numbers of Th2 
cells (ie CD3^CD4^interleukin-4^ cells) independently associated with decreased 
carotid intima-media thickness and a reduced risk of acute myocardial infarction in 
women. [631]. Also, IL-4 secretion from activated mononuclear leukocytes was 
independently associated with a reduced risk of CVD. Therefore, it would have been 
interesting to collect the supernatants from the co-cultures of T cells with DCs and 
measure IFN-y (an indicator of Thl pro-inflammatory responses) and IL-4 (an 
indicator of Thl pro-inflammatory responses) to distinguish which type of T cell 
response was taking place.
It is important to note that, along with IL-4, Th2 cells also secrete IL-5, both 
of which are cytokines involved in antibody production (IgE) and class-switching, 
followed by APC activation through the binding of Abs with Fc receptors. So a Treg 
response would be preferred over a Th2 response as it only involves anti­
inflammatory actions. CD25 remained low in my T cell activation experiments
255
(section 5.2) so T cells in the co-culture could be Tregs (one of the Treg subsets that 
is CD25- ie, Trl subset which is CD4^CD25'FoxP3^). This subset is linked with IL- 
10 secretion [632]. A useful assay to determine the presence of Tregs would be the’ 
Suppression Response Assay’ (SRA). This involves co-culture of peptide-loaded DCs 
with T cells and allowing them to proliferate by potentially triggering Tregs. I would 
also prepare a second co-culture in parallel involving DCs with T cells from a 
different species (an MLR reaction) in order to induce strong proliferation. Then I 
would add the T cells generated from the first co-culture with the peptide-loaded 
DCs into the MLR and test whether they inhibit the proliferation, in which case they 
are Tregs.
It must be noted that the induction of Tregs to fight against an autoimmune 
disease needs stringent control as it could compromise the body’s defence against 
infections and cancer cells. Therefore, any treatment aiming to activate Tregs should 
be antigen specific, involving an antigen known to be implicated in atherosclerosis, 
and also proven to have an effect only on the atherosclerotic plaque.
A more concrete answer as to whether the peptides protect against 
atherosclerosis could be given in vivo, in a whole organism. A preliminary 
experiment by Dr Bermudez-Fajardo in our group to examine the homing properties 
of peptide-loaded DCs when they were introduced into apoE' '^ mice showed that they 
localise mostly in the spleen, heart and lymph nodes [633]. Hansson’s group has 
performed experiments on a similar basis by pulsing DCs ex vivo with the whole 
sequence of apoB-100 along with IL-10 and used this to immunise 
hypercholesterolemic mice, transgenic for LDLR and apoB-100, intravenously [634]. 
CD4^ infiltration into atherosclerotic plaques was reduced and CD4^ splenocytes 
were able to suppress the activation of apoB-100-reactive T cells in vitro. The
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vaccinated animals presented a decrease of 70% in the atherosclerotic lesions in the 
aorta. Two factors that might have made Hansson’s efforts in using apoB-100 
antigens to confer atheroprotection more successful than our own, would be the route 
of administration (intravenous) and the simultaneous treatment of apoB-lOO-pulsed- 
DCs with an anti-iflammatory agent (IL-10). Furthermore, since DCs were cultured 
with the whole apoB-100 protein, it remains to be investigated which epitopes in the 
protein were presented on DCs and which of those are responsible for this response. 
Another study from the same group showed that when apoE' '^ mice were vaccinated 
with DCs pulsed with MDA-LDL, atherosclerosis is further induced and antigen- 
specific responses are promoted [635]. These findings suggest that the complexity of 
the whole LDL molecule is such that when loaded to DCs, many epitopes are 
presented through the APCs and some may be atherogenic, highlighting the 
importance of targeting specific antigens to treat atherosclerosis.
Another issue is the use of apoE' '^ and LDLR' " mice to investigate the role of 
the different types of immune response in atheroprotection. The LDL receptor, in 
addition to apolipoprotein E, may also play an important role in lipid antigen 
presentation. More specifically, circulating apolipoprotein E as part of lipoprotein 
particles, mediates the binding of lipid molecules to receptors such as the LDL 
receptor and their subsequent delivery to endosomal compartments in APCs that 
contain CDl. Sometimes, apoE is also secreted by APCs in order to survey the local 
environment and detect lipid antigens to be presented to them. Therefore, these 
experimental models that are apoE and LDLR knock-outs present some limitations as 
lipid presentation may not be performed efficiently and atherosclerosis development 
may not be accurately modelled [636].
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In the work performed during this project, it has not been determined 
unequivocally whether the apoB-100 peptides immunomodulate the immune 
response through a pathway that involves the mediation of dendritic cells. However, 
research performed both in our group and in other groups has shown that this 
response is definitely mediated through Tregs. Our group’s later experiments [633] 
showed that immunisation with peptide P210 conjugated with an adjuvant (BSA) 
induced Tregs in apoE’^ ' mice. The adjuvant protects the antigen from degradation by 
forming a protective layer around it and ensures its gradual release, otherwise it 
would be cleared immediately by macrophages. So the adjuvant acts to increase the 
half-life of the peptide and it enhances the immune response by effectively 
increasing the size of the antigen to render it more easily detectable by B cells and 
DCs. Similar results on the atheroprotective role of P210 were provided by Wigren et 
al. [637]. The way that Tregs are believed to be activated in the lymph nodes through 
the activation of migrating DCs can be seen in Figure 7.2.
Another recent report on the subcutaneous immunisation of 
hypercholesterolemic mice with P210 demonstrated that a CD8  ^T cell response is 
induced following vaccination [638] . The authors suggested that the CD8  ^T cells 
that were generated could have a cytotoxic action to lyse DCs since the number of 
the latter was shown to be lower in the immunisation sites and in atherosclerotic 
plaques.
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Figure 7.2: Treg activation in the lymph nodes. DCs resident in tissues capture antigens and 
migrate to the lymph nodes to present them to Tregs.Tregs then travel back to the tissues to 
block the activity of effector T cells (reproduced from Mahnke J. et al. [639])
A recent study has shown that modified low density lipoprotein (MDA-LDL) 
administration with complete Freund’s adjuvant (CFA) leads to Treg induction and 
atheroprotection [584-586] but on the other hand, MDA-LDL delivered by DCs has a 
pro-atherogenic effect [584]. The researchers isolated draining inguinal lymph nodes 
following injection with DC or complete Freund’s adjuvant (CFA) and stimulation 
with or without MDA-LDL in apoE"' mice. It was demonstrated that cells taken 
from draining lymph nodes after treatment with MDA-LDL-CFA showed an increase 
in CD4 CD25^FoxP3^ cells after re-challenge with MDA-LDL. In addition, it was 
observed that after MDA-LDL stimulation, the number of CD4 CD25 FoxP3^ cells 
was slightly increased in contrast to no stimulation. This latter observation was
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accompanied by an increase in IL-10 secretion. On the other hand, Treg induction 
was not observed in cells from mice that had been treated with MDA-LDL-DCs 
[584].
Another study confirmed that the immune pathway through which 
atheroprotection is induced when apoB-100 peptides are administrated 
subcutaneously in low doses and without any adjuvant into apoE" ' mice involves a 
30% induction of CD4^CD25^ Tregs in the lymph nodes [640]. These antigen- 
specific Tregs were shown to inhibit the proliferation of effector T cells in vitro. In 
the same study, the levels of Thl-related (IL-12, IFN-y), Th2-related (IL-10) and 
Thl7-related (IL-17) cytokines were reduced. Furthermore, the subcutaneous 
infusion of a mix of apoB-100 peptides led to an increase in the collagen content in 
the plaques by 22% and a 45% reduction in lesional T cell infiltration. These results 
show that subcutaneous infusion of apoB-100 peptides can offer atheroprotection in 
both early and advanced atherosclerosis. The important role that P210 has in 
atheroprotection was again confirmed since subcutaneous infusion of P210 alone 
reduced the size of the plaques by 30%. The results also indicate that vaccinating 
with a combination of peptides, could also be very effective.
A study published after the completion of this experimental work showed that 
immunization of apoE~^ ~ mice with the apoB peptide vaccine aBp210 results in Treg 
activation whereas when mice were co-administered with anti-CD25 antibodies, a 
reduction of the Treg number was observed as well as the blockade of the vaccine’s 
atheroprotective effect [641].
In another study, intranasal immunisation of apoE-/- mice with P210 fused 
with the B subunit of the cholera toxin for 12 weeks caused a 35% reduction in aortic 
lesion size of apoE-/- mice. This effect was accompanied by induction of CD4+
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Tregs producing ILIO (Tri) that was able to suppress effector T cells when these 
were re-challenged with apolipoprotein B-100. A peptide-specific antibody response 
was also shown [329]. Intranasal (mucosal) vaccination is fi*equently used to induce 
tolerance [642]
This vaccine, in contrast to the oxLDL vaccines, can be manufactured readily 
under GMP conditions and therefore it was thought that it could be used in clinical 
trials. The effect of the vaccine was independent of lipid levels, in contrast with 
statins. In order to transfer these findings successfully into clinical trials, there is a 
need to identify the patients who are likely to benefit from therapy, and to select the 
most appropriate time-point within the natural course of the disease when 
immunization should take place (early vs late disease). Chuy et al. demonstrated that 
vaccination of apoE'^' mice with nLDL is only effective when administrated during 
early disease (6-7 weeks) in terms of reducing the plaque size. [643] Vaccination at a 
later stage (20weeks) did not have an effect on plaque size or collagen content and 
only provoked a small reduction in macrophage infiltration. Therefore, this study 
demonstrated that only early LDL immunization bears the athero-protective ability to 
reduce plaque size and increase collagen content [644].
Other factors to take into consideration in the design of a vaccine are the 
duration, the dose of the therapy and the frequency of vaccination regimens. 
Evaluating the efficacy of the vaccine is a crucial issue because morbidity and 
mortality trials will involve a large number of patients followed for a long period of 
time at a high cost. Therefore, imaging of the carotid arteries with MRI and FDG- 
PET/CT (18Fluoro-2-deoxyglucose positron emission tomography) can be used 
initially to establish efficacy of the vaccine before large scale trials are started.
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The vaccine was finally developed by the CardioVax company with the P210 
peptide bound to a carrier protein (recombinant human serum albumin) and 
formulated with aluminum hydroxide colloid gel as an adjuvant [645]. Aluminum 
hydroxide (Alum) has been shown to have atheroprotective effects itself by inducing 
Tregs and reducing atherosclerosis in apoE'^' mice [646] and therefore seems the 
appropriate adjuvant for this vaccine. Alum’s mechanism of action involves delayed 
clearance of the antigen fi*om the site of injection and stimulation of the immune 
response by the recruitment of APCs on site or by the facilitation of the uptake of 
antigens by APCs and it has been proven to be safe [647]. The proposed course of 
treatment with this vaccine is four injections, sub-cutaneously, with a time interval of 
three weeks between each booster [645]. Another booster could also be performed 
some time later, for example 5 years later. The vaccine has been shown to decrease 
plaques by 60 to 70% in mice and stabilize the remaining plaques. CardioVax 
therapy is intended to complement other therapies such as statins and reverse 
cholesterol transport agents [645]. The disadavantage for this vaccine is that its 
mechanism of action is poorly understood. Based on the information provided by 
Cardiovax [645], the vaccine is waiting FDA approval to be tested in Phase I clinical 
trials.
Another possible disadvantage with using the apoB-100 peptides as vaccines 
in atheroprotection is that they might need to be adapted to each individual according 
to their HLA type, which also means that HLA genotyping of the patient before 
therapy is also required. However, it has been demonstrated that the protective effect 
of oxLDL vaccinations in apoE'^' mice is not dependent on CD4^ cells [648], so this 
finding poses a new challenge in elucidating the role of the HLA antigen presentation 
pathway in the atheroprotection conferred by the peptides.
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Other studies on possible vaccinations for atherosclerosis include the 
vaccination of human apoB-100 transgenic mice with human oxLDL to generate 
CD4^ T cell hybridomas recognizing only native LDL or purified apoB-100. These 
hybridomas were all found to express the T cell receptor (TCR) variable p chain, 
TRVB3L When a peptide from the sequence of TRVB31 was used to immunise 
mice, anti-TRVB31 antibodies were produced and they inhibited the recognition of 
apoB-100 from T cells. This subsequently reduced atherosclerosis [649].
Passive immunisation has also been tested [650] when antibodies for P45 
were used to immunise apoE'^" mice. Atherosclerosis was reduced by 50% over a 5- 
week period and this was followed by a reduction in the accumulation of 
macrophages in the plaques. Recombinant antibodies for human apoB-100 were used 
to vaccinate LDL" ' mice overexpressing human apoB-100 and the plaque area was 
reduced [651, 652]. Further research showed that high levels of anti-MDA-p45 IgGl 
antibody are associated with decreased atherosclerosis in the carotid arteries in 
humans. Also, subjects that had not suffered any acute coronary events were found to 
have higher levels of these antibodies compared to subjects that had suffered an acute 
myocardial infarction or sudden death, indicating therefore that they might have an 
atheroprotective role [617]. However, similar studies using antibodies for MDA- 
oxidised peptides showed that high levels of antibodies against the peptides were 
linked with severe cardiovascular disease [653, 654]. It is possible, therefore, that the 
peptides can offer atheroprotection only when they are native or mildly oxidised. 
This paper’s findings matches well with my decision to use the peptides in a native 
state for my experiments.
The antibody binding p45 has been called BI-204 and it has been developed 
in a vaccine jointly by Biolnvent and Genentech. In a phase I trial in humans, it
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reduced plaques by half and was well-tolerated by the patients [655]. It is currently 
being tested in phase II trials and it is being delivered intranasally to patients with 
stable coronary disease in order to study any reduction in inflammation in the carotid 
artery quantified by FDG-PET imaging [656].
Another group generated B cell hybridomas that produce IgM antibodies 
against ox-LDL epitopes. One of them, the T(EPC)15 murine monoclonal IgA anti- 
PC Ab (referred to by the group as T15), recognises the phosphorylcholine head- 
groups on the surface of apoptotic cells, and inhibits uptake of oxidized LDL and 
apoptotic cells in macrophages [657] The same antibodies protect against infection 
from Streptococcus pneumoniae so active immunization of LDLR knockout mice 
with the bacteria induced high levels of IgM specific for oxLDL together with a 
modest reduction of atherosclerosis [201]. The challenge with targeting the 
production of natural antibodies to treat atherosclerosis is our poor knowledge of 
how these responses are regulated and the cross-reactivity of the antibodies with 
phospholipids in other structures apart from oxLDL, such as apoptotic cells and some 
microorganisms.
Other therapies against atherosclerosis are being developed, and include the 
use of anti-inflammatory agents that are being used in other autoimmune diseases. 
Methotrexate, a cytotoxic drug currently used in rheumatoid arthritis, has been 
shown to decrease vascular events and it is now being tested in clinical trials for its 
possible effect on atheroprotection [658]. Canakinumab is another anti-inflammatory 
drug used to treat 'cryopyrin-associated periodic syndrome' by inhibiting II-ip, that is 
now tested for its effect on cardiovascular disease and diabetes [659]. Darapladib is a 
drug that has been shown to reduce atherosclerotic plaque size and inflammation. 
Darapladib inhibits an enzyme lipoprotein associated phospholipase, which acts on
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the release of lysophosphatidylcholine molecules from oxLDL. 
Lysophosphatidylcholine are known to be pro-inflammatory molecules [660]. All 
three drugs, methotrexate, darapladib and canakinumab are currently being tested in 
Phase III trials [660]. The disadavantage of these treatments however, is the adverse 
effects that they present. The most serious ones are provoked by methotrexate and 
are mainly gastrointestinal disorders and central nervous system disorders [661]. 
Canakinumab has more mild adverse effects: nausea, headache and vomitting [662]. 
The adverse effects that could be potentially be provoked by darapladib to patients 
suffering from cardiovascular disease are currently being studied [663].
A supplementary approach would be to boost the immune response of the 
host to the peptides by using antibody-cytokine fusion proteins. These are compound 
molecules comprising a cytokine fused with an antibody at the carboxy- or amino- 
terminus that are able to bind to soluble antigens and therefore act as targeting 
vehicles for specific delivery of cytokines in the areas needed to stimulate an 
efficient immune response. Penichet et al. have used it to boost the inflammatory 
response against cancer cells [664]; we would use it to boost tolerance or anti­
inflammatory responses by using atheroprotective antibodies that recognise selected 
apoB-100-derived peptides (the most efficient in inducing atheroprotection have 
proven to be P45 and P210) fused with anti-inflammatory proteins.
None of these studies investigate the use of DCs in vaccines against 
atherosclerosis as in many other autoimmune diseases. The experiments described in 
this thesis on immunisation of apoE" '^ mice with tolDCs follow on from our group’s 
experiments where Dr Alexandra Bermudez-Fajardo used peptide-loaded DCs to 
vaccinate apoE'^' mice to investigate their possible role on atherosclerosis without, 
however, observing a significant effect. Boosters were given every two weeks
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following the vaccination protocols obtained from Nilsson and Shah [613]. In my 
experiments, the immunisation with tolDCs induced Tregs in the spleen of 
immunized animals. This is consistent with the finding by Dr Bermudez-Fajardo that 
when DCs are vaccinated into apoE'^' mice, most of them travel to the spleen of the 
animals [633]. More specifically, vaccination with tolDCs induced the number of 
CD8^CD25'FoxP3^ cells. CD25" cells are Tregs generated in the periphery in 
contrast to CD4^CD25^ which are generated in the thymus. While it is known that 
CD8^CD25^ cells act through direct contact, not much is known about the 
mechanism of action of CD8^CD25" cells. The anti-inflammatory cytokine IL-10 
increases both in the serum and the spleen of the animals. Cholesterol levels in the 
serum also go down. However, the plaque size is the same. There are some first 
indications, therefore, that vaccinations with tolDCs can promote tolerogenic 
responses in apoE'^' mice. The variation in my results could be explained partly 
because unfortunately there were differences in the age of the mice vaccinated. 
Although there was no difference in the size of the plaques, macrophage 
accumulation and collagen content in them should be studied as this could determine 
plaque stability. The timing of the vaccination and the route of delivery should also 
be optimised.
One problem with the tolDC vaccination experiment described in this thesis 
is the preexisting DC population in the immunised animal and the fact that a high 
percentage of it might be pro-inflammatory. Therefore, the effect of the vaccinated 
tolDCs might not be strong enough to counteract the existing inflammatory DCs. In 
future work it would be worth repeating the experiments in transgenic mice deficient 
in DCs. An initial idea for this would be to use M-CSF'^' mice, that would be crossed 
with apoE'^' mice. The M-CSF' ' mice have a mutation for the osteoclast cell line
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which affects monocytes, macrophages and bone remodelling. However they were 
shown to have similar numbers of DCs to non-transgenic mice and these DCs 
presented the same structures and the same immunoreactivity [665]. It was 
hypothesized therefore that a population of DCs descends from GM-SCF -forming 
cells or another haematopoetic progenitor. However, a more recent paper 
demonstrates that there are two types of DCs present in the aortic intima: the M- 
CSF-dependent DC-SIGN+CDl lb+ and the fms-like thyrosine kinase 3 ligand 
(Flt3L) -signalling dependent CD103+CDllb- [666]. The paper also demonstrates 
that the Flt3-Flt3L-dependent DCs offer atheroprotection, since Flt3-/-LDLR-/- mice 
are deficient in CD 103+ DC, have fewer Tregs, more inflammatory cytokines and 
increased atherosclerosis. This finding might suggest that M-CSF-/- mice could be 
used to check the effect of tolDC vaccinations since the existing DCs would be 
atheroprotective DCs. If this is the case however, another question rises on the 
phenotype of DCs used for the vaccinations, as they might need to belong to the 
CDl lb- subset
Studies that have investigated tolerogenic DCs in other autoimmune diseases, 
report that the first clinical trials are underway [667]. TolDCs are believed to act by 
inducing antigen-specific T cell anergy and/or apoptosis of autoreactive T cells 
and/or antigen-specific Tregs. They can therefore re-establish antigen-specific 
tolerance. There are many difficulties in applying this in vaccines, including the 
choice of antigen, the protocol for generating tolDCs ex vivo, the route for delivery 
and the timing of the vaccination [668] so that antigen-specific tolerance is induced 
without promoting general immune suppression.
The tolDCs generated in vitro for a vaccine against an autoimmune disease 
should be functionally locked and resistant to maturation so that there is no
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possibility of them obtaining inflammatory properties once in v/vo.[669]. Returning 
to the experiments by Raich-Regue et al who generated tolDCs using a pro- 
inflammatory cocktail of cytokines (CC: TNF-a, IL-lp, PGE2) and la,25- 
dihydroxyvitamin D(3), a tolerogenic agent that is believed to have potential in the 
treatment of multiple sclerosis [625]. These tolDCs were shown to be stable in vitro 
and did not mature or secrete inflammatory cytokines when re-challenged with LPS. 
The question remains as to what happens to DCs in vivo following injection in terms 
of function and longevity. IL-10 was secreted in high levels from tolDCs generated 
after treatment with VitD3 in combination with monophosphoryl lipid A (LA) but 
these tolDCs were not as stable as the CC-treated ones. Another tolerogenic agent 
that has been shown to induce tolDCs is dexamethasone [670]. dexamethasone- 
treated DCs induced even higher IL-10 secretion than CC-treated DCs in 
combination with VitD3 and also displayed higher viability and yield.
Similar results were provided by Harry et al. [671] who used DCs extracted 
from patients suffering from rheumatoid arthritis and rendered them tolerogenic 
using dexamethasone, VitD3 and LA. TolDCs were demonstrated to display a 
reduced expression of co-stimulatory molecules, a lower secretion of pro- 
inflammatory cytokines to suppress T cell proliferation induced by mature DCs and 
the secretion of IFN-y and IL-17. Their tolerogenicity was highly stable. Toll-like 
receptor 2 (TLR-2) was highly expressed by tolDCs but not mature DCs so it was 
thought that it could be a potential marker for tolDCs.
It must be noted that VitD3 has also been linked with atheroprotection. 
Takeda et al. showed that oral administration of calcitriol (the active form of Vitamin 
D3) decreased the number of CD80+CD86+ DCs in the mesenteric lymph nodes, 
spleen and lesions, increased IL-10 secretion and reduced IL-12 mRNA expression
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in them [672]. The group was also able to demonstrate that C D llc+  DCs reduced 
proliferation of T cells. These findings were followed by a reduction in the size of 
atherosclerotic plaques, the macrophage accumulation in them, the infiltration of 
CD4+ cells and an increase in FoxP3 expressing Tregs. These data are consistent 
with studies showing that deficiency of VitD3 is linked with a higher risk of 
cardiovascular disease [673]. however the dose of VitD3 needs to be adjusted 
carefully to prevent unwanted effects in calcium metabolism leading to 
hypercalcemia [674]
Rapamycin was also successful in generating tolDCs in terms of suppressive 
ability in allogeneic T cell reactions, reduced LFN-y secretion fi*om T cells and Treg 
(CD4+CD25+FoxP3+) induction [670]. However, rapamycin-treated DCs do not 
produce IL-10 and display the same phenotype as mature DCs.
Concerning the route of administration, it is crucial that DCs are able to 
migrate to the specific tissues affected by the disease in question. The chemokine 
receptor CCR7 seems to have a very important role in mediating the migration of 
DCs (as well as Tregs) into the lymph nodes[675]
A report that studied TNF-treated DCs showed that these DCs still express 
co-stimulatory molecules and antigen-presenting molecules but do not secrete any 
cytokines. When these tolDCs were injected intravenously in an experimental model 
for autoimmune encephalomyelitis (EAE), they induced tolerance. However, when 
they were injected subcutaneously, it was shown that they remained responsive to 
stimuli and converted from tolerogenic to immunogenic due to their encounter with 
pathogens or the route of injection [676]. Therefore the injection route for tolDCs 
can play a very important role in their effectiveness as vaccines in autoimmune 
diseases.
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A report from Christiakov et a l suggests that oral administration of anti­
inflammatory modulators and drugs is a very good route of inducing tolerance in 
atherosclerosis since the intestinal immune system is very efficient in protecting our 
body from pathogens and food antigens and therefore the immune responses 
elucidated in these tissues are very potent. The modulators have an effect on the 
intestine immunity by recruiting tolDCs and promoting Tregs in the mucosa [632].
An interesting idea combining the use of antigen-loaded DCs with tolDCs 
comes from the Raich-Regue group again, who have shown that human DCs 
generated in the presence of the CC (day 4) and VitD3 (day 0 and 4) and loaded with 
myelin peptides at day 6, can induce antigen-specific hypo-responsiveness in T cells 
extracted from patients suffering from relapsing-remitting multiple sclerosis [677]. 
This is something that could be performed in continuation of the experiments 
presented in this thesis: the generation of tolDCs using a pro-tolerogenic agent such 
as VitD3 that would render their functionality more stable, in addition to loading 
with P45 or P210, both of which have shown strong immunodulatory abilities of the 
atherosclerotic responses.
To summarize, DCs could be a very important tool in immunomodulating the 
immune response in autoimmune diseases, which include atherosclerosis. Through 
the work described in this thesis, I have shown that the ApoB-100-derived peptide- 
loaded DCs could possibly be effective, subject to further investigation in vitro and 
in vivo, in modulating a T cell immune response from pro-inflammatory to 
tolerogenic or anti-inflammatory. If confirmed, it would prove that DCs play a 
crucial role in the atheroprotective effect offered by the peptide vaccines developed 
by Nilsson’s group. Moreover, I have demonstrated that tolDCs generated in vitro 
though incubation with anti-inflammatory cytokines IL-10 and TGF-b, induce a
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suppressive immune response and reduce lipid levels when vaccinated in ApoE' ' 
mice. Further research on these could prove another beneficial tool in the fight for 
atheroprotection.
The protocol for DC generation, the use of the appropriate antigen, the route 
of administration of a vaccine that would consist of tolDCs, the timing and the 
elucidation of the cellular immune responses that are involved in a disease are 
important factors to take into consideration when deciding how best to transfer these 
ideas into clinical trials.
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APPENDIX II Publications arising from thesis 
Journal publications
Milioti N., Bermudez-Fajardo A. et al. (2008) Clinical and Developmental 
Immunology. Published online 09 June 2008
Conference abstracts
1) Milioti N., Bermudez-Fajardo A. et al. (2008) Immunomodulatory properties of 
apoB-100 derived peptides on dendritic cells and T-lymphocytes. (2008) 
Atherosclerosis supplements 9(1): 63.
2) “Immunomodulatory properties of apoB-100 derived peptides on dendritic cells 
and T-Lymphocytes” A. Bermudez-Fajardo, N. Milioti, G. Fredrickson, J. Nilsson 
and E. Oviedo-Orta. ISA 2006
Meetings attended
1. Biosciences Postgraduate Sumposium 2008, University of Brighton: oral 
presentation
2. Festival of Research, University of Surrey, July 2008 : poster presentation
3. International Symposium in Atherosclerosis, Istanbul, April 2008: poster 
presentation
4. 4^  ^European Meeting on Vascular biology and Medicine, Bristol, September 
2007
5. Festival of Research, University of Surrey, July 2007: poster presentation
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6. International Symposium in Atherosclerosis, Rome, June 2006: poster 
presentation
7. Festival of Research, University of Surrey, 2006: poster presentation
8. Advances in prevention of cardiovascular disease, St George Hospital 
symposium. Sept 2006: poster presentation
9. Annual Research Evening, Postgraduate Medical School, University of Surrey 
and Royal County Hospital, October 2006: poster presentation
10. Annual Research Evening, Postgraduate Medical School, University of Surrey 
and Royal Surrey County Hospital, September 2006
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